WO2012054721A1 - Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors - Google Patents

Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors Download PDF

Info

Publication number
WO2012054721A1
WO2012054721A1 PCT/US2011/057090 US2011057090W WO2012054721A1 WO 2012054721 A1 WO2012054721 A1 WO 2012054721A1 US 2011057090 W US2011057090 W US 2011057090W WO 2012054721 A1 WO2012054721 A1 WO 2012054721A1
Authority
WO
WIPO (PCT)
Prior art keywords
azetidin
pyrrolidin
amine
carbonyl
phenyl
Prior art date
Application number
PCT/US2011/057090
Other languages
French (fr)
Other versions
WO2012054721A8 (en
Inventor
Yue-Mei Zhang
Peter J. Connolly
Shu-Chen Lin
Mark J. Macielag
Original Assignee
Janssen Pharmaceutical Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutical Nv filed Critical Janssen Pharmaceutical Nv
Priority to JP2013535087A priority Critical patent/JP2013540160A/en
Priority to EP11778748.1A priority patent/EP2630139A1/en
Priority to RU2013123274/04A priority patent/RU2013123274A/en
Priority to BR112013009828A priority patent/BR112013009828A2/en
Priority to CA2815353A priority patent/CA2815353A1/en
Priority to CN201180061845.6A priority patent/CN103261189B/en
Priority to KR1020137012916A priority patent/KR20130140020A/en
Priority to AU2011316975A priority patent/AU2011316975A1/en
Publication of WO2012054721A1 publication Critical patent/WO2012054721A1/en
Priority to IL225815A priority patent/IL225815A0/en
Publication of WO2012054721A8 publication Critical patent/WO2012054721A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • Cannabis sativa has been used for the treatment of pain for many years.
  • ⁇ 9 - tetrahydrocannabinol is a major active ingredient from Cannabis sativa and an agonist of cannabinoid receptors (Pertwee, Brit J Pharmacol, 2008, 153, 199-215).
  • Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBi Matsuda et al, Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB 2 Munro et al, Nature, 1993, 365, 61-5).
  • CBi is expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al, Curr Opin Lipidol, 2007, 18, 129-140).
  • CB 2 is predominantly expressed in immune cells, such as monocytes (Pacher et al, Amer J Physiol, 2008, 294, HI 133-H1134), and under certain conditions, also in the brain (Benito et al, Brit J Pharmacol, 2008, 153, 277-285) and in skeletal (Cavuoto et al, Biochem Biophys Res Commun, 2007, 364, 105-110) and cardiac
  • AEA fatty acid amide hydrolase
  • MML monoacylglycerol lipase
  • FAAH knockout mice use of specific FAAH inhibitors transiently elevates AEA levels and results in antinociception in vivo (Kathuria et al, Nat Med, 2003, 9, 76-81). Further evidence for an endocannabinoid-mediated antinociceptive tone is demonstrated by the formation of AEA in the periaqueductal grey following noxious stimulation in the periphery (Walker et al, Proc Natl Acad Sci USA, 1999, 96, 12198-203) and, conversely, by the induction of hyperalgesia following antisense RNA-mediated inhibition of CBi in the spinal cord (Dogrul et al, Pain, 2002, 100, 203-9).
  • 2-AG intravenous delivery of 2-AG produces analgesia in the tail flick (Mechoulam et al, Biochem Pharmacol, 1995, 50, 83-90) and hot plate (Lichtman et al, J Pharmacol Exp Ther, 2002, 302, 73-9) assays.
  • MGL inhibitors are potentially useful for the treatment of pain, inflammation, and CNS disorders (Di Marzo et al.
  • Y is a C 6 -ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, isothiazolyl, pyrrolyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, C 1-4 alkyl, Ci -4 alkoxy, cyano, and trifluoromethyl;
  • R a is CH(F), CF 2 , or CH(OH);
  • a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, indolinyl, and indazolinyl;
  • benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substituent selected from the group consisting of bromo, chloro, fluoro, iodo, Ci -4 alkyl, C 2-4 alkenyl, Ci -4 alkoxy, trifluoromethyl, and trifluoromethoxy; or v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl; wherein the C 6 -ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, iodo, Ci -4 alkyl, C 2-4
  • Rb is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl; C 3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyridinyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyridinyl, pyrimidinyl, and phenyl of Rb are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, Ci -4 alkyl, chloro, and fluoro;
  • Ri is hydrogen, fluoro, hydroxy, or methoxy
  • R 2 is hydrogen, C 1-6 alkyl, hydroxy, or formyl
  • the present invention also provides, inter alia, a pharmaceutical composition
  • a pharmaceutical composition comprising, consisting of and/or consisting essentially of a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and/or a pharmaceutically acceptable diluent, and a compound of Formula (I), or a pharmaceutically acceptable salt form thereof.
  • a pharmaceutical composition comprising, consisting of, and/or consisting essentially of admixing a compound of Formula (I) or a pharmaceutically acceptable salt form thereof, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and/or a pharmaceutically acceptable diluent.
  • the present invention further provides, inter alia, methods for treating or ameliorating a MGL-modulated disorder in a subject, including a human or other mammal in which the disease, syndrome, or condition is affected by the modulation of the MGL enzyme, such as pain and the diseases that lead to such pain, inflammation and CNS disorders, using a compound of Formula (I) or a pharmaceutically acceptable salt form thereof.
  • the present invention also provides, inter alia, methods for producing the instant compounds and pharmaceutical compositions and medicaments thereof.
  • DETAILED DESCRIPTION OF THE INVENTION With reference to substituents, the term “independently” refers to the situation where when more than one substituent is possible, the substituents may be the same or different from each other.
  • alkyl refers to straight and branched carbon chains having 1 to 8 carbon atoms. Therefore, designated numbers of carbon atoms (e.g., C 1-8 ) refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyl-containing substituent. In substituent groups with multiple alkyl groups such as, the Ci-6alkyl groups of the dialkylamino may be the same or different.
  • alkoxy refers to an -O-alkyl group, wherein the term “alkyl” is as defined above.
  • alkenyl and alkynyl refer to straight and branched carbon chains having 2 to 8 carbon atoms, wherein an alkenyl chain contains at least one double bond and an alkynyl chain contains at least one triple bond.
  • cycloalkyl refers to saturated or partially saturated, monocyclic or polycyclic hydrocarbon rings of 3 to 14 carbon atoms. Examples of such rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.
  • benzo-fused cycloalkyl refers to a 5- to 8- membered monocyclic cycloalkyl ring fused to a benzene ring.
  • the carbon atom ring members that form the cycloalkyl ring may be fully saturated or partially saturated.
  • heterocyclyl refers to a nonaromatic monocyclic or bicyclic ring system having 3 to 10 ring members that include at least 1 carbon atom and from 1 to 4 heteroatoms independently selected from N, O, and S. Included within the term heterocyclyl is a nonaromatic cyclic ring of 5 to 7 members in which 1 to 2 members are N, or a nonaromatic cyclic ring of 5 to 7 members in which 0, 1 or 2 members are N and up to 2 members are O or S and at least one member must be either N, O, or S; wherein, optionally, the ring contains 0 to 1 unsaturated bonds, and, optionally, when the ring is of 6 or 7 members, it contains up to 2 unsaturated bonds.
  • the carbon atom ring members that form a heterocycle ring may be fully saturated or partially saturated.
  • heterocyclyl also includes two 5 membered monocyclic heterocycloalkyl groups bridged to form a bicyclic ring. Such groups are not considered to be fully aromatic and are not referred to as heteroaryl groups.
  • heterocycle is bicyclic, both rings of the heterocycle are non-aromatic and at least one of the rings contains a heteroatom ring member.
  • heterocycle groups include, and are not limited to, pyrrolinyl (including 2H-pyrrole, 2-pyrrolinyl or 3-pyrrolinyl), pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl. Unless otherwise noted, the heterocycle is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • benzo-fused heterocyclyl refers to a 5 to 7 membered monocyclic heterocycle ring fused to a benzene ring.
  • the heterocycle ring contains carbon atoms and from 1 to 4 heteroatoms independently selected from N, O, and S.
  • the carbon atom ring members that form the heterocycle ring may be fully saturated or partially saturated.
  • benzo-fused heterocycle ring is attached to its pendant group at a carbon atom of the benzene ring.
  • aryl refers to an unsaturated, aromatic monocyclic or bicyclic ring of 6 to 10 carbon members. Examples of aryl rings include phenyl and naphthalenyl.
  • heteroaryl refers to an aromatic monocyclic or bicyclic aromatic ring system having 5 to 10 ring members and which contains carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O, and S. Included within the term heteroaryl are aromatic rings of 5 or 6 members wherein the ring consists of carbon atoms and has at least one heteroatom member. Suitable heteroatoms include nitrogen, oxygen, and sulfur. In the case of 5 membered rings, the heteroaryl ring preferably contains one member of nitrogen, oxygen or sulfur and, in addition, up to 3 additional nitrogens. In the case of 6 membered rings, the heteroaryl ring preferably contains from 1 to 3 nitrogen atoms.
  • heteroaryl groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzothiadiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl and quinazolinyl. Unless otherwise noted, the heteroaryl is attached to its pendant group at
  • halogen refers to fluorine, chlorine, bromine and iodine atoms.
  • alkyl or aryl or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for "alkyl” and "aryl.”
  • Designated numbers of carbon atoms e.g., Ci-C 6
  • the designated number of carbon atoms includes all of the independent members included within a given range specified.
  • Ci -6 alkyl would include methyl, ethyl, propyl, butyl, pentyl and hexyl individually as well as sub-combinations thereof (e.g., C 1-2 , C 1-3 , C 1-4 , Ci -5j C 2- 6, C 3-6 , C 4-6 , C 5-6 , C 2-5j etc).
  • R at a stereocenter designates that the stereocenter is purely of the R- configuration as defined in the art; likewise, the term “S” means that the stereocenter is purely of the ⁇ -configuration.
  • S means that the stereocenter is purely of the ⁇ -configuration.
  • the terms “*R” or “*S” at a stereocenter are used to designate that the stereocenter is of pure but unknown configuration.
  • RS refers to a stereocenter that exists as a mixture of the R- and S- configurations.
  • R*RS or “*SR” refer to a stereocenter that exists as a mixture of the R- and ⁇ -configurations and is of unknown configuration relative to another stereocenter within the molecule.
  • Compounds containing one stereocenter drawn without a stereo bond designation are a mixture of 2 enantiomers.
  • Compounds containing 2 stereocenters both drawn without stereo bond designations are a mixture of 4 diastereomers.
  • Compounds with 2 stereocenters both labeled "RS" and drawn with stereo bond designations are a 2- component mixture with relative stereochemistry as drawn.
  • Compounds with 2 stereocenters both labeled "*RS" and drawn with stereo bond designations are a 2- component mixture with relative stereochemistry unknown.
  • Unlabeled stereocenters drawn without stereo bond designations are a mixture of the R- and ⁇ -configurations. For unlabeled stereocenters drawn with stereo bond designations, the absolute stereochemistry is as depicted.
  • subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
  • terapéuticaally effective amount refers to an amount of an active compound or pharmaceutical agent, including a compound of the present invention, which elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition, or disorder being treated.
  • composition refers to a product that includes the specified ingredients in therapeutically effective amounts, as well as any product that results, directly, or indirectly, from combinations of the specified ingredients in the specified amounts.
  • MGL inhibitor is intended to encompass a compound that interacts with MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s).
  • MGL-modulated is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme, such as, for example, pain and the diseases that lead to such pain, inflammation and CNS disorders.
  • the term "affect" or “affected” when referring to a disease, syndrome, condition or disorder that is affected by inhibition of MGL shall include a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, syndrome, condition or disorder; and / or include the prevention of the development of one or more symptoms or manifestations of said disease, syndrome, condition or disorder or the development of the disease, condition, syndrome or disorder.
  • the compounds of Formula (I) are useful in methods for treating, ameliorating and / or preventing a disease, a syndrome, a condition or a disorder that is affected by the inhibition of MGL. Such methods comprise, consist of and/or consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment, amelioration and / or prevention, a therapeutically effective amount of a compound of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
  • the compounds of Formula (I) are useful for treating, ameliorating and / or preventing pain; diseases, syndromes, conditions, or disorders causing such pain; inflammation and / or CNS disorders. More particularly, the
  • compounds of Formula (I) are useful for treating, ameliorating and / or preventing inflammatory pain, inflammatory hypersensitivity conditions and / or neuropathic pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) , as herein defined.
  • inflammatory pain examples include pain due to a disease, condition, syndrome, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
  • inflammatory hyperalgesia is inflammatory hyperalgesia / hypersensitivity.
  • inflammatory hyperalgesia include a disease, syndrome, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary
  • incontinence interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity and/or dermal allergy, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, benign prostatic hypertrophy, and nasal hypersensitivity.
  • the present invention is directed to a method for treating, ameliorating and / or preventing inflammatory visceral hyperalgesia in which a enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of Formula (I) .
  • the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
  • a further embodiment of the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic pain.
  • a neuropathic pain include pain due to a disease, syndrome, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre syndrome, meralgia pares
  • neuropathic cold allodynia which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists.
  • neuropathic cold allodynia include allodynia due to a disease, condition, syndrome, disorder or pain state including
  • neuropathic pain neuralgia
  • pain arising from spine and peripheral nerve surgery or trauma traumatic brain injury (TBI)
  • TBI traumatic brain injury
  • trigeminal neuralgia postherpetic neuralgia
  • causalgia peripheral neuropathy
  • diabetic neuropathy central pain
  • stroke peripheral neuritis
  • polyneuritis complex regional pain syndrome I and II (CRPS I/II) and
  • the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
  • the present invention is directed to a method for treating, ameliorating and / or preventing CNS disorders.
  • CNS disorders include anxieties, such as social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress disorder, separation anxiety disorder, and generalized anxiety disorder, as well as depression, such as major depression, bipolar disorder, seasonal affective disorder, post natal depression, manic depression, and bipolar depression.
  • Embodiments of the present invention include a compound of Formula (I)
  • Y is a C 6 -ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two fluoro substituents;
  • Y is an unsubstituted C 6 -ioaryl or an unsubstituted heteroaryl that is thienyl or
  • Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or
  • R a is CH(F), CF 2 , or CH(OH);
  • a benzo-fused heterocyclyl selected from the group consisting of 1 ,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl;
  • benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substituent selected from the group consisting of bromo, chloro, fluoro, methyl, methoxy, or trifluoromethyl; or
  • a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
  • C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C 2-4 alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,; R b is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl;
  • R a is CH(F), CF 2 , or CH(OH);
  • a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl; wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
  • a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
  • C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C 2-4 alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,;
  • Rb is selected from the group consisting of phenylmethyl; C 3-6 cycloalkyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of R b are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro;
  • R a is CF 2 or CH(OH); iv) indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
  • a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
  • C 6 -ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C 1-4 alkyl, C2- 4 alkenyl, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is and
  • R b is selected from the group consisting of phenylmethyl; thienyl;
  • pyrimidinyl and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of 3 ⁇ 4, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro; Z is
  • R a is CF 2 or CH(OH);
  • indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
  • a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
  • C 6 -ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C 1-4 alkyl, C 2-4 alkenyl, trifluoromethyl, trifluoromethoxy, and R b ; provided that no more than one substituent is R b ;
  • R b is selected from the group consisting of phenylmethyl; thienyl;
  • pyrimidinyl and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of 3 ⁇ 4, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro; h) Ri is hydrogen, fluoro, or hydroxy; i) Ri is hydrogen or fluoro; j) R 2 is hydrogen, C 1-2 alkyl, or hydroxy; k) R 2 is hydrogen, methyl, or hydroxy; 1) R 2 is hydrogen; and any combination of embodiments a) through 1) above, provided that it is understood that combinations in which different embodiments of the same substituent would be combined are excluded;
  • An embodiment of the present invention includes a compound of Formula (I)
  • Y is a C 6 -ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two fluoro substituents;
  • R a is CH(F), CF 2 , or CH(OH);
  • a benzo-fused heterocyclyl selected from the group consisting of 1 ,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl; wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substituent selected from the group consisting of bromo, chloro, fluoro, methyl, methoxy, or trifluoromethyl; or
  • a heteroaryl selected from the group consisting thiazolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
  • C 6 -ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C 1-4 alkyl, C 2-4 alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,;
  • R b is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl; C 3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyrimidinyl, and phenyl of R b are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro; Ri is hydrogen, fluoro or hydroxy;
  • P2 is hydrogen, methyl, or hydroxy
  • Another embodiment of the present invention includes a compound of Formula (I)
  • Y is an unsubstituted C6-ioaryl or an unsubstituted heteroaryl that is thienyl or thiazolyl;
  • R a is CH(F), CF 2 , or CH(OH);
  • a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl;
  • benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
  • C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C 1-4 alkyl, C 2-4 alkenyl, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is 3 ⁇ 4;
  • Rb is selected from the group consisting of phenylmethyl; C 3-6 cycloalkyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of 3 ⁇ 4, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl,
  • Ri is hydrogen or fluoro
  • R 2 is hydrogen, C 1-2 alkyl, or hydroxy
  • Another embodiment of the present invention includes a compound of Formula (I)
  • Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or thiazolyl; Z is
  • R a is CF 2 or CH(OH);
  • indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
  • a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
  • C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of bromo, chloro, fluoro, Ci -4 alkyl, C 2-4 alkenyl, trifluoromethyl, trifluoromethoxy, and R t ,; provided that no more than one substituent is Rt,; and
  • R b is selected from the group consisting of phenylmethyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of R b are unsubstituted or substituted with one or two substituents each of which is
  • Ri is hydrogen or fluoro
  • R 2 is hydrogen, C 1-2 alkyl, or hydroxy
  • Another embodiment of the present invention includes a compound of Formula (I)
  • Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or thiazolyl;
  • R a is CF 2 or CH(OH);
  • indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
  • a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
  • C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C 1-4 alkyl, C 2-4 alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,;
  • R b is selected from the group consisting of phenylmethyl wherein the phenyl is unsubstituted or substituted with one fluoro substituent; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and phenyl of R b are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro;
  • Ri is hydrogen or fluoro
  • R 2 is hydrogen
  • An embodiment of the present invention includes a compound of Formula (I)
  • salts of compounds of Formula (I) refer to non-toxic
  • Suitable pharmaceutically acceptable salts of compounds of Formula (I) include acid addition salts that can, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as, hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • a pharmaceutically acceptable acid such as, hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.
  • suitable pharmaceutically acceptable salts thereof may include alkali metal salts such as, sodium or potassium salts; alkaline earth metal salts such as, calcium or magnesium salts; and salts formed with suitable organic ligands such as, quaternary ammonium salts.
  • alkali metal salts such as, sodium or potassium salts
  • alkaline earth metal salts such as, calcium or magnesium salts
  • suitable organic ligands such as, quaternary ammonium salts.
  • representative pharmaceutically acceptable salts include acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate,
  • Embodiments of the present invention include prodrugs of compounds of Formula (I).
  • such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound.
  • the term “administering” encompasses the treatment or prevention of the various diseases, conditions, syndromes and disorders described with the compound specifically disclosed or with a compound that may not be specifically disclosed, but which converts to the specified compound in vivo after administration to a patient.
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
  • the compounds according to embodiments of this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. The skilled artisan will understand that the term compound as used herein, is meant to include solvated compounds of Formula (I).
  • the processes for the preparation of the compounds according to certain embodiments of the invention give rise to mixture of stereoisomers
  • these isomers may be separated by conventional techniques such as, preparative chromatography.
  • the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
  • the compounds may, for example, be resolved into their component enantiomers by standard techniques such as, the formation of diastereomeric pairs by salt formation with an optically active acid such as,
  • the compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
  • compositions including a pharmaceutical composition, comprising, consisting of, and/or consisting essentially of the (+)-enantiomer of a compound of Formula (I) wherein said composition is substantially free from the (-)-isomer of said compound.
  • substantially free means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (-)-isomer calculated as
  • compositions including a pharmaceutical composition, comprising, consisting of, and consisting essentially of the (- )-enantiomer of a compound of Formula (I) wherein said composition is substantially free from the (+)-isomer of said compound.
  • substantially free from means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (+)-isomer calculated as
  • any of the processes for preparation of the compounds of the various embodiments of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups such as those described in Protective Groups in Organic Chemistry, Second Edition, J.F.W. McOmie, Plenum Press, 1973; T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, 1999.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • compositions comprising compounds of Formula (I) and at least one pharmaceutically acceptable carrier, pharmaceutically acceptable excipient, and/or pharmaceutically acceptable diluent.
  • the compounds of Formula (I) may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s), and combinations thereof.
  • Solid oral dosage forms such as, tablets or capsules, containing the compounds of the present invention may be administered in at least one dosage form at a time, as appropriate. It is also possible to administer the compounds in sustained release formulations.
  • Additional oral forms in which the present inventive compounds may be administered include elixirs, solutions, syrups, and suspensions; each optionally containing flavoring agents and coloring agents.
  • compounds of Formula (I) can be administered by inhalation
  • a suppository or pessary or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder.
  • a cream comprising, consisting of, and/or consisting essentially of an aqueous emulsion of polyethylene glycols or liquid paraffin.
  • an ointment comprising, consisting of, and/or consisting essentially of a wax or soft paraffin base together with any stabilizers and preservatives as may be required.
  • An alternative means of administration includes transdermal
  • compositions of the present invention can also be injected parenterally, for example, intracavernosally, intravenously, intramuscularly, subcutaneously, intradermally, or intrathecally.
  • the compositions will also include at least one of a suitable carrier, a suitable excipient, and a suitable diluent.
  • compositions of the present invention are best used in the form of a sterile aqueous solution that may contain other substances, for example, enough salts and monosaccharides to make the solution isotonic with blood.
  • compositions of the present invention may be administered in the form of tablets or lozenges, which can be formulated in a conventional manner.
  • compositions containing at least one of the compounds of Formula (I) as the active ingredient can be prepared by mixing the compound(s) with a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, and/or a pharmaceutically acceptable excipient according to conventional pharmaceutical compounding techniques.
  • a pharmaceutically acceptable carrier e.g., benzyl alcohol, benzyl ether, benzyl ether, benzyl ether, benzyl, sulfonyl, sulfonyl, adiluent, and/or a pharmaceutically acceptable excipient according to conventional pharmaceutical compounding techniques.
  • the carrier, excipient, and diluent may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral, etc.).
  • suitable carriers, excipients and diluents include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like;
  • suitable carriers, excipients and diluents include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like.
  • Solid oral preparations also may be optionally coated with substances such as, sugars, or be enterically coated so as to modulate the major site of absorption and disintegration.
  • the carrier, excipient and diluent will usually include sterile water, and other ingredients may be added to increase solubility and preservation of the composition.
  • injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives such as, solubilizers and preservatives.
  • composition thereof includes a dose range from about 0.1 mg to about 3000 mg, or any particular amount or range therein, in particular from about 1 mg to about 1000 mg, or any particular amount or range therein, or, more particularly, from about 10 mg to about 500 mg, or any particular amount or range therein, of active ingredient in a regimen of about 1 to about 4 times per day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for a compound of Formula (I) will vary as will the diseases, syndromes, conditions, and disorders being treated.
  • a pharmaceutical composition is preferably provided in the form of tablets containing about 1.0, about 10, about 50, about 100, about 150, about 200, about 250, and about 500 milligrams of a compound of Formula (I).
  • a compound of Formula (I) may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three and four times daily.
  • Optimal dosages of a compound of Formula (I) to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation and the advancement of the disease, syndrome, condition or disorder.
  • factors associated with the particular subject being treated including subject gender, age, weight, diet and time of administration, will result in the need to adjust the dose to achieve an appropriate therapeutic level and desired therapeutic effect.
  • the above dosages are thus exemplary of the average case. There can be, of course, individual instances wherein higher or lower dosage ranges are merited, and such are within the scope of this invention.
  • Compounds of Formula (I) may be administered in any of the foregoing
  • the compounds of Formula (I) are useful in methods for treating and preventing a disease, a syndrome, a condition or a disorder in a subject, including an animal, a mammal and a human in which the disease, the syndrome, the condition or the disorder is affected by the modulation, including inhibition, of the MGL enzyme.
  • Such methods comprise, consist of and/or consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment or prevention a therapeutically effective amount of a compound, salt or solvate of Formula
  • Scheme A illustrates a route for the synthesis of compounds of Formula (I)-A, wherein Z is a benzo-fused heterocyclyl as defined herein.
  • a compound of formula Al (wherein P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like) is either commercially available or may be prepared by known methods described in the scientific literature.
  • the compound of formula Al may be treated with a carboxylic acid of formula A2 wherein Q is hydroxy, in the presence of an appropriate coupling agent such as, HATU, DCC, EDC, HBTU, PyBrOP, and the like; and optionally in the presence of a base such as, DIPEA, to afford a compound of Formula A3.
  • an acid chloride of formula A2 wherein Q is chloro may be used to effect the acylation of a compound of formula Al.
  • a non-nucleophilic base such as, pyridine
  • a compound of formula A4 may be alkylated with a compound of formula Ci_ 6 alkyl-X (wherein X is bromo, chloro, iodo, or triflate), followed by removal of the amino protecting group (P) by conventional methods to afford a compound of formula A4.
  • a compound of formula A4 may undergo a reductive amination with a compound of formula A5 (wherein P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like) in the presence of a hydride source such as, sodium triacetoxyborohydride to afford a compound of formula A6. Removal of amino protecting group P using conventional methods affords a compound of formula A7.
  • P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like
  • a hydride source such as, sodium triacetoxyborohydride
  • a compound of formula A8, wherein ring A is a 5- to 6-membered heterocycyl containing at least one nitrogen atom, is either commercially available or may be prepared by known methods described in the scientific literature.
  • the compound of formula A8 may be treated with CDI in the presence of an organic base such as triethylamine to afford a compound of formula A9.
  • Treatment with methyl iodide in an anhydrous organic solvent provides a compound of formula A10.
  • the compound of formula A7 may be coupled with a compound of formula A10 in the presence of an organic amine such as triethylamine in an organic solvent such as dichloromethane to afford a compound of Formula (I)-A.
  • Scheme B illustrates a route for the synthesis of compounds of Formula (I)-B, wherein Z is a benzo-fused heterocyclyl substituted with a phenyl substituent.
  • a compound of Formula (I)-A may be treated with a phenylboronic acid of formula Bl, wherein R B is selected from the group consisting of hydrogen, bromo, chloro, fluoro, iodo, C 1-4 alkyl, C2- 4 alkenyl, trifluoromethyl, and trifluoromethoxy, in the presence of a palladium catalyst and appropriate ligands, and in the presence of an inorganic base such as sodium carbonate and the like, to afford a compound of Formula (I)-B.
  • Scheme C illustrates a route for the synthesis of compounds of Formula (I)-C.
  • a compound of formula CI is either commercially available or may be prepared by known methods described in the scientific literature.
  • the compound of formula C2 may be treated with a carboxylic acid of formula CI wherein Q is hydroxy, in the presence of an appropriate coupling agent such as, HATU, DCC, EDC, HBTU, PyBrOP, and the like; and optionally in the presence of a base such as, DIPEA, to afford a compound of formula C3.
  • an acid chloride of formula CI wherein Q is chloro may be used to effect the acylation of a compound of formula C2.
  • a non-nucleophilic base such as, pyridine or triethylamine, may be added to afford a compound of formula C3.
  • a compound of formula C3 may undergo a reductive amination with a compound of formula C4 (wherein P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like) in the presence of a hydride source such as, sodium triacetoxyborohydride to afford a compound of formula C5. Removal of amino protecting group P using conventional methods affords a compound of formula C6. Coupling with a Y-substituted reagent of formula A2 using the methods described in Scheme A affords the desired compound of Formula (I)-C.
  • P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like
  • a hydride source such as, sodium triacetoxyborohydride
  • Scheme D illustrates an alternate route for the synthesis of compounds of Formula (I)-C.
  • a compound of formula Dl (wherein PI is a conventional amino protecting group) is either commercially available or may be prepared by known methods described in the scientific literature.
  • a compound of formula Dl may undergo a reductive amination with a compound of formula A5, as described in Scheme A, to afford a compound of formula D2.
  • Selective removal of amino protecting group PI using conventional methods affords a compound of formula D3.
  • Coupling with a Y-substituted reagent of formula A2 using the methods described in Scheme A affords the desired compound of formula D4.
  • Removal of amino protecting group P using conventional methods affords a compound of formula D5.
  • Coupling with a compound of formula CI affords a compound of Formula (I)-C.
  • Scheme E illustrates a route for the synthesis of compounds of Formula (I)-E, wherein R 2 is hydroxy.
  • a compound of Formula (I)-C may be treated with an oxidizing agent such as wCPBA, 3,3-dimethyldioxirane, or sodium tungstate/H 2 0 2 to afford a compound of Formula (I)-E.
  • an oxidizing agent such as wCPBA, 3,3-dimethyldioxirane, or sodium tungstate/H 2 0 2
  • Z-substituents may have functional groups sensitive to oxidation conditions. Such functional groups may require the introduction of an appropriate protecting group prior to the oxidation step, and subsequent removal of the protecting group after oxidation.
  • Scheme F illustrates a route for the synthesis of compounds of Formula (I), wherein Z is a heteroaryl such as benzothienyl, and Z is substituted with C 1-4 alkyl, C2- 4 alkenyl, or C 3-6 cycloalkyl.
  • G C-
  • a compound of formula Fl (wherein R F is chloro, fluoro, Ci_ 4 alkyl, Ci_ 4 alkoxy, trifluoromethyl, or wherein 3 ⁇ 4, is thienyl, pyridinyl, pyrimidinyl, or phenyl) is either commercially available or may be prepared by known methods described in the scientific literature.
  • a compound of formula Fl may be treated with a boronic acid of formula F2 in the presence of a palladium catalyst and appropriate ligands, and in the presence of an inorganic base such as potassium phosphate, to afford a compound of formula F3.
  • a compound of formula Gl is either commercially available or may be prepared by known methods described in the scientific literature.
  • the compound of formula Gl may be coupled with a compound of formula G2 in the presence of trans-N, N'- dimethylcyclohexane-l,2-diamine, copper (I) iodide, and an inorganic base such as potassium phosphate to afford a compound of formula G3.
  • Saponification affords a carboxylic acid of formula G4.
  • Coupling with a compound of formula D5 in the presence of an appropriate coupling agent such as, HATU, DCC, EDC, HBTU, PyBrOP, and the like; and optionally in the presence of a base such as, DIPEA, affords a compound of Formula (I)-G.
  • Scheme H illustrates a route for the synthesis of compounds of Formula (I)-H, wherein Z is a heteroaryl such as indolyl, and Z is substituted at a carbon atom with G H , wherein G H is or an unsubstituted or substituted phenyl ring as defined by 3 ⁇ 4.
  • a compound of formula HI is either commercially available or may be prepared by known methods described in the scientific literature.
  • the compound of formula HI may be coupled with a boronic acid of formula H2 in the presence of a palladium catalyst and appropriate ligands, and in the presence of an inorganic base such as potassium phosphate, to afford a compound of formula H3.
  • the amino protecting group P may be removed by conventional methods known to one of skill in the art to afford a compound of formula H4. Saponification in the presence of hydroxide ion affords a carboxylic acid of formula H5.
  • a compound of formula H5 may be coupled with a compound of formula D5 as previously described in Scheme G to afford a compound of Formula (I)-H.
  • Scheme I illustrates a route for the synthesis of compounds of Formula (I)-I, wherein Z is a heteroaryl such as indolyl, and Z is substituted at a carbon atom with 3 ⁇ 4, wherein 3 ⁇ 4 is an optionally substituted phenylmethyl as defined herein.
  • a compound of formula II is either commercially available or may be prepared by known methods described in the scientific literature.
  • the compound of formula II may be coupled with a benzyl chloride of formula 12 (wherein R 1 is defined as trifluoromethyl, trifluoromethoxy, C 1-4 alkyl, chloro, and fluoro) in the presence of a silver oxide, in an organic solvent such as dioxane, to afford a compound of formula 13.
  • Saponification in the presence of hydroxide ion affords a carboxylic acid of formula 14, which may be coupled with a compound of formula D5 as previously described in Scheme G to afford a compound of Formula (I)-I.
  • Scheme J illustrates a route for the synthesis of compounds of Formula (I)-J, wherein Z is a benzo-fused heterocyclyl attached through a benzo carbon atom.
  • a compound of formula Jl is either commercially available or may be prepared by known methods described in the scientific literature.
  • the compound of formula Jl may be coupled with a G H -substituted bromide of formula J2 in the presence of a palladium catalylst, appropriate ligands, and an organic base to afford a mixture of a compound of formula J3 and a carboxylic acid of formula J4.
  • the mixture may be subjected to saponification conditions to afford the compound of formula J4, which, subsequently, may be coupled with a compound of formula D5 to afford a compound of Formula (I)-J.
  • l-(5-Chloro-2-fluoro-phenyl)-2,2,2-trifluoro-ethanone, 11c To a solution of LDA (2.0 M in THF/heptane/ethylbenzene, 12.6 mL, 25.3 mmol) in dry THF was slowly added l-fluoro-4-chloro-benzene 11a (2.45 mL, 23.0 mmol) at -78 °C. The mixture was stirred for 1 h at -78 °C and ethyl trifluoroacetate lib (3.02 mL, 25.3 mmol) was added.
  • reaction mixture was allowed to warm to room temperature overnight and was quenched with saturated aqueous NH 4 C1 solution.
  • the mixture was extracted with EtOAc.
  • the organic extracts were concentrated and purified by flash column chromatography (silica gel, 15% EtOAc/hexanes) to give a mixture of the compound 11c along with a regio-isomeric by-product, l-(5-fluoro-2-chloro-phenyl)-2,2,2-trifluoro-ethanone, in a ratio of 5: 1 (11c is the major product).
  • Methyl 3-cyclopropyl-6-fluorobenzo[b]thiophene-2-carboxylate, 12c A mixture of methyl 3-chloro-6-fluorobenzo[b]thiophene-2-carboxylate 12a (150 mg, 0.613 mmol), cyclopropylboronic acid 12b (79 mg, 0.92 mmol), Pd(OAc) 2 (20 mg, 0.09 mmol), SPhos (88 mg, 0.215 mmol), and K 3 P0 4 (0.26 g, 1.23 mmol) in toluene (2 mL) was heated to 100 °C for 3 h in a sealed reaction vessel. The reaction was diluted with EtOAc and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 10% EtOAc/hexanes) to give compound 12c.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds, and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof, are represented by Formula (I) as follows: (I) wherein Y, Z, and R1 and R2 are defined herein.

Description

AMINO-PYRROLIDINE-AZETIDINE DI AMIDES AS
MONOACYLGLYCEROL LIPASE INHIBITORS
CROSS-REFERENCE TO RELATED APPLICATIONS
Not applicable.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT
The research and development of the invention described below was not federally sponsored.
BACKGROUND OF THE INVENTION Cannabis sativa has been used for the treatment of pain for many years. Δ9- tetrahydrocannabinol is a major active ingredient from Cannabis sativa and an agonist of cannabinoid receptors (Pertwee, Brit J Pharmacol, 2008, 153, 199-215). Two cannabinoid G protein-coupled receptors have been cloned, cannabinoid receptor type 1 (CBi Matsuda et al, Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2 Munro et al, Nature, 1993, 365, 61-5). CBi is expressed centrally in brain areas, such as the hypothalamus and nucleus accumbens as well as peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscle (Di Marzo et al, Curr Opin Lipidol, 2007, 18, 129-140). CB2 is predominantly expressed in immune cells, such as monocytes (Pacher et al, Amer J Physiol, 2008, 294, HI 133-H1134), and under certain conditions, also in the brain (Benito et al, Brit J Pharmacol, 2008, 153, 277-285) and in skeletal (Cavuoto et al, Biochem Biophys Res Commun, 2007, 364, 105-110) and cardiac
(Hajrasouliha et al, Eur J Pharmacol, 2008, 579, 246-252) muscle. An abundance of pharmacological, anatomical and electrophysiological data, using synthetic agonists, indicate that increased cannabinoid signaling through CBi/CB2 promotes analgesia in tests of acute nociception and suppresses hyperalgesia in models of chronic neuropathic and inflammatory pain (Cravatt et al, J Neurobiol, 2004, 61, 149-60; Guindon et al, Brit J Pharmacol, 2008, 153, 319-334).
Efficacy of synthetic cannabinoid receptor agonists is well documented. Moreover, studies using cannabinoid receptor antagonists and knockout mice have also implicated the endocannabinoid system as an important modulator of nociception. Anandamide (AEA) (Devane et al, Science, 1992, 258, 1946-9) and 2-arachidinoylglycerol (2 -AG)
(Mechoulam et al, Biochem Pharmacol, 1995, 50, 83-90; Sugiura et al, Biochem Biophys Res Commun, 1995, 215, 89-97) are two major endocannabinoids. AEA is hydrolyzed by fatty acid amide hydrolase (FAAH) and 2-AG is hydrolyzed by monoacylglycerol lipase (MGL) (Piomelli, Nat Rev Neurosci, 2003, 4, 873-884). Genetic ablation of FAAH elevates endogenous AEA and results in a CBi -dependent analgesia in models of acute and inflammatory pain (Lichtman et al, Pain, 2004, 109, 319-27), suggesting that the endocannabinoid system functions naturally to inhibit pain (Cravatt et al, J Neurobiol, 2004, 61, 149-60). Unlike the constitutive increase in endocannabinoid levels using
FAAH knockout mice, use of specific FAAH inhibitors transiently elevates AEA levels and results in antinociception in vivo (Kathuria et al, Nat Med, 2003, 9, 76-81). Further evidence for an endocannabinoid-mediated antinociceptive tone is demonstrated by the formation of AEA in the periaqueductal grey following noxious stimulation in the periphery (Walker et al, Proc Natl Acad Sci USA, 1999, 96, 12198-203) and, conversely, by the induction of hyperalgesia following antisense RNA-mediated inhibition of CBi in the spinal cord (Dogrul et al, Pain, 2002, 100, 203-9).
With respect to 2-AG, intravenous delivery of 2-AG produces analgesia in the tail flick (Mechoulam et al, Biochem Pharmacol, 1995, 50, 83-90) and hot plate (Lichtman et al, J Pharmacol Exp Ther, 2002, 302, 73-9) assays. In contrast, it was demonstrated that 2-AG given alone is not analgesic in the hot plate assay, but when combined with other 2- monoacylglycerols (i.e., 2-linoleoyl glycerol and 2-palmitoyl glycerol), significant analgesia is attained, a phenomenon termed the "entourage effect" (Ben-Shabat et al, Eur J Pharmacol, 1998, 353, 23-31). These "entourage" 2-monoacylglycerols are endogenous lipids that are co-released with 2-AG and potentiate endocannabinoid signaling, in part, by inhibiting 2-AG breakdown, most likely by competition for the active site on MGL. This suggests that synthetic MGL inhibitors will have a similar effect. Indeed, URB602, a relatively weak synthetic MGL inhibitor, showed an antinociceptive effect in a murine model of acute inflammation (Comelli et al., Brit J Pharmacol, 2007, 152, 787-794)..
Although the use of synthetic cannabinoid agonists has conclusively demonstrated that increased cannabinoid signaling produces analgesic and anti-inflammatory effects, it has been difficult to separate these beneficial effects from the unwanted side effects of these compounds. An alternative approach is to enhance the signaling of the
endocannabinoid system by elevating the level of 2-AG, the endocannabinoid of highest abundance in the central nervous system (CNS) and gastrointestinal tract, which may be achieved by inhibition of MGL. Therefore, MGL inhibitors are potentially useful for the treatment of pain, inflammation, and CNS disorders (Di Marzo et al. , Curr Pharm Des, 2000, 6, 1361-80; Jhaveri et al, Brit J Pharmacol, 2007, 152, 624-632; McCarberg Bill et al., Amer J Ther, 2007, 14, 475-83), as well as glaucoma and disease states arising from elevated intraocular pressure (Njie, Ya Fatou; He, Fang; Qiao, Zhuanhong; Song, Zhao- Hui, Exp. Eye Res., 2008, 57(2): 106-14).
SUMMARY OF THE INVENTION The present invention is directed to a compound of Formula (I)
Figure imgf000004_0001
Formula (I) wherein Y is a C6-ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, isothiazolyl, pyrrolyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, C1-4alkyl, Ci-4alkoxy, cyano, and trifluoromethyl;
Z is
i) a C6-10aryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)-is unsubstituted or
substituted with one substituent selected from the group consisting of trifluoromethyl, chloro, Ci-4alkyl, and fluoro;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, indolinyl, and indazolinyl;
wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substituent selected from the group consisting of bromo, chloro, fluoro, iodo, Ci-4alkyl, C2-4alkenyl, Ci-4alkoxy, trifluoromethyl, and trifluoromethoxy; or v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl; wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, iodo, Ci-4alkyl, C2-4alkenyl, Ci-4alkoxy, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,; and
Rb is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl; C3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyridinyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyridinyl, pyrimidinyl, and phenyl of Rb are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, Ci-4alkyl, chloro, and fluoro;
Ri is hydrogen, fluoro, hydroxy, or methoxy;
R2 is hydrogen, C1-6 alkyl, hydroxy, or formyl;
and enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof.
The present invention also provides, inter alia, a pharmaceutical composition comprising, consisting of and/or consisting essentially of a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and/or a pharmaceutically acceptable diluent, and a compound of Formula (I), or a pharmaceutically acceptable salt form thereof.
Also provided are processes for making a pharmaceutical composition comprising, consisting of, and/or consisting essentially of admixing a compound of Formula (I) or a pharmaceutically acceptable salt form thereof, and a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and/or a pharmaceutically acceptable diluent.
The present invention further provides, inter alia, methods for treating or ameliorating a MGL-modulated disorder in a subject, including a human or other mammal in which the disease, syndrome, or condition is affected by the modulation of the MGL enzyme, such as pain and the diseases that lead to such pain, inflammation and CNS disorders, using a compound of Formula (I) or a pharmaceutically acceptable salt form thereof.
The present invention also provides, inter alia, methods for producing the instant compounds and pharmaceutical compositions and medicaments thereof. DETAILED DESCRIPTION OF THE INVENTION With reference to substituents, the term "independently" refers to the situation where when more than one substituent is possible, the substituents may be the same or different from each other.
The term "alkyl" whether used alone or as part of a substituent group, refers to straight and branched carbon chains having 1 to 8 carbon atoms. Therefore, designated numbers of carbon atoms (e.g., C1-8) refer independently to the number of carbon atoms in an alkyl moiety or to the alkyl portion of a larger alkyl-containing substituent. In substituent groups with multiple alkyl groups such as,
Figure imgf000007_0001
the Ci-6alkyl groups of the dialkylamino may be the same or different.
The term "alkoxy" refers to an -O-alkyl group, wherein the term "alkyl" is as defined above.
The terms "alkenyl" and "alkynyl" refer to straight and branched carbon chains having 2 to 8 carbon atoms, wherein an alkenyl chain contains at least one double bond and an alkynyl chain contains at least one triple bond.
The term "cycloalkyl" refers to saturated or partially saturated, monocyclic or polycyclic hydrocarbon rings of 3 to 14 carbon atoms. Examples of such rings include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.
The term "benzo-fused cycloalkyl" refers to a 5- to 8- membered monocyclic cycloalkyl ring fused to a benzene ring. The carbon atom ring members that form the cycloalkyl ring may be fully saturated or partially saturated.
The term "heterocyclyl" refers to a nonaromatic monocyclic or bicyclic ring system having 3 to 10 ring members that include at least 1 carbon atom and from 1 to 4 heteroatoms independently selected from N, O, and S. Included within the term heterocyclyl is a nonaromatic cyclic ring of 5 to 7 members in which 1 to 2 members are N, or a nonaromatic cyclic ring of 5 to 7 members in which 0, 1 or 2 members are N and up to 2 members are O or S and at least one member must be either N, O, or S; wherein, optionally, the ring contains 0 to 1 unsaturated bonds, and, optionally, when the ring is of 6 or 7 members, it contains up to 2 unsaturated bonds. The carbon atom ring members that form a heterocycle ring may be fully saturated or partially saturated. The term
"heterocyclyl" also includes two 5 membered monocyclic heterocycloalkyl groups bridged to form a bicyclic ring. Such groups are not considered to be fully aromatic and are not referred to as heteroaryl groups. When a heterocycle is bicyclic, both rings of the heterocycle are non-aromatic and at least one of the rings contains a heteroatom ring member. Examples of heterocycle groups include, and are not limited to, pyrrolinyl (including 2H-pyrrole, 2-pyrrolinyl or 3-pyrrolinyl), pyrrolidinyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl, thiomorpholinyl, and piperazinyl. Unless otherwise noted, the heterocycle is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
The term "benzo-fused heterocyclyl" refers to a 5 to 7 membered monocyclic heterocycle ring fused to a benzene ring. The heterocycle ring contains carbon atoms and from 1 to 4 heteroatoms independently selected from N, O, and S. The carbon atom ring members that form the heterocycle ring may be fully saturated or partially saturated.
Unless otherwise noted, benzo-fused heterocycle ring is attached to its pendant group at a carbon atom of the benzene ring.
The term "aryl" refers to an unsaturated, aromatic monocyclic or bicyclic ring of 6 to 10 carbon members. Examples of aryl rings include phenyl and naphthalenyl.
The term "heteroaryl" refers to an aromatic monocyclic or bicyclic aromatic ring system having 5 to 10 ring members and which contains carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O, and S. Included within the term heteroaryl are aromatic rings of 5 or 6 members wherein the ring consists of carbon atoms and has at least one heteroatom member. Suitable heteroatoms include nitrogen, oxygen, and sulfur. In the case of 5 membered rings, the heteroaryl ring preferably contains one member of nitrogen, oxygen or sulfur and, in addition, up to 3 additional nitrogens. In the case of 6 membered rings, the heteroaryl ring preferably contains from 1 to 3 nitrogen atoms. For the case wherein the 6 membered ring has 3 nitrogens, at most 2 nitrogen atoms are adjacent. Examples of heteroaryl groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoindolyl, benzofuryl, benzothienyl, indazolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, benzisoxazolyl, benzothiadiazolyl, benzotriazolyl, quinolinyl, isoquinolinyl and quinazolinyl. Unless otherwise noted, the heteroaryl is attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
The term "halogen" or "halo" refers to fluorine, chlorine, bromine and iodine atoms.
The term "formyl" refers to the group -C(=0)H.
The term "oxo" refers to the group (=0).
Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., arylalkyl, alkylamino) the name is to be interpreted as including those limitations given above for "alkyl" and "aryl." Designated numbers of carbon atoms (e.g., Ci-C6) refer independently to the number of carbon atoms in an alkyl moiety, an aryl moiety, or in the alkyl portion of a larger substituent in which alkyl appears as its prefix root. For alkyl and alkoxy substituents, the designated number of carbon atoms includes all of the independent members included within a given range specified. For example Ci-6 alkyl would include methyl, ethyl, propyl, butyl, pentyl and hexyl individually as well as sub-combinations thereof (e.g., C1-2, C1-3, C1-4, Ci-5j C2-6, C3-6, C4-6, C5-6, C2-5j etc).
In general, under standard nomenclature rules used throughout this disclosure, the terminal portion of the designated side chain is described first followed by the adjacent functionality toward the point of attachment. Thus, for example, a "Ci-C6 alkylcarbonyl" substituent refers to a group of the formula: alkyl
Figure imgf000009_0001
The term "R" at a stereocenter designates that the stereocenter is purely of the R- configuration as defined in the art; likewise, the term "S" means that the stereocenter is purely of the ^-configuration. As used herein, the terms "*R" or "*S" at a stereocenter are used to designate that the stereocenter is of pure but unknown configuration. As used herein, the term "RS" refers to a stereocenter that exists as a mixture of the R- and S- configurations. Similarly, the terms "*RS" or "*SR" refer to a stereocenter that exists as a mixture of the R- and ^-configurations and is of unknown configuration relative to another stereocenter within the molecule.
Compounds containing one stereocenter drawn without a stereo bond designation are a mixture of 2 enantiomers. Compounds containing 2 stereocenters both drawn without stereo bond designations are a mixture of 4 diastereomers. Compounds with 2 stereocenters both labeled "RS" and drawn with stereo bond designations are a 2- component mixture with relative stereochemistry as drawn. Compounds with 2 stereocenters both labeled "*RS" and drawn with stereo bond designations are a 2- component mixture with relative stereochemistry unknown. Unlabeled stereocenters drawn without stereo bond designations are a mixture of the R- and ^-configurations. For unlabeled stereocenters drawn with stereo bond designations, the absolute stereochemistry is as depicted.
Unless otherwise noted, it is intended that the definition of any substituent or variable at a particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of Formula (I) can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth herein.
The term "subject" refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
The term "therapeutically effective amount" refers to an amount of an active compound or pharmaceutical agent, including a compound of the present invention, which elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation or partial alleviation of the symptoms of the disease, syndrome, condition, or disorder being treated.
The term "composition" refers to a product that includes the specified ingredients in therapeutically effective amounts, as well as any product that results, directly, or indirectly, from combinations of the specified ingredients in the specified amounts.
The term "MGL inhibitor" is intended to encompass a compound that interacts with MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s). The term "MGL-modulated" is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme, such as, for example, pain and the diseases that lead to such pain, inflammation and CNS disorders.
As used herein, unless otherwise noted, the term "affect" or "affected" (when referring to a disease, syndrome, condition or disorder that is affected by inhibition of MGL) shall include a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, syndrome, condition or disorder; and / or include the prevention of the development of one or more symptoms or manifestations of said disease, syndrome, condition or disorder or the development of the disease, condition, syndrome or disorder.
The compounds of Formula (I) are useful in methods for treating, ameliorating and / or preventing a disease, a syndrome, a condition or a disorder that is affected by the inhibition of MGL. Such methods comprise, consist of and/or consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment, amelioration and / or prevention, a therapeutically effective amount of a compound of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof. In particular, the compounds of Formula (I) are useful for treating, ameliorating and / or preventing pain; diseases, syndromes, conditions, or disorders causing such pain; inflammation and / or CNS disorders. More particularly, the
compounds of Formula (I) are useful for treating, ameliorating and / or preventing inflammatory pain, inflammatory hypersensitivity conditions and / or neuropathic pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) , as herein defined. Examples of inflammatory pain include pain due to a disease, condition, syndrome, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
One type of inflammatory pain is inflammatory hyperalgesia / hypersensitivity. Examples of inflammatory hyperalgesia include a disease, syndrome, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary
incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity and/or dermal allergy, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, benign prostatic hypertrophy, and nasal hypersensitivity.
In an embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing inflammatory visceral hyperalgesia in which a enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound, salt or solvate of Formula (I) . In a further embodiment, the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
A further embodiment of the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic pain. Examples of a neuropathic pain include pain due to a disease, syndrome, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, postherpetic neuralgia, causalgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, trigeminal neuralgia, vulvodynia, or vidian neuralgia.
One type of neuropathic pain is neuropathic cold allodynia, which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists. Examples of neuropathic cold allodynia include allodynia due to a disease, condition, syndrome, disorder or pain state including
neuropathic pain (neuralgia), pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS I/II) and
radiculopathy. In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing CNS disorders. Examples of CNS disorders include anxieties, such as social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress disorder, separation anxiety disorder, and generalized anxiety disorder, as well as depression, such as major depression, bipolar disorder, seasonal affective disorder, post natal depression, manic depression, and bipolar depression.
Embodiments of the present invention include a compound of Formula (I)
Figure imgf000014_0001
Formula (I) wherein a) Y is a C6-ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two fluoro substituents;
b) Y is an unsubstituted C6-ioaryl or an unsubstituted heteroaryl that is thienyl or
thiazolyl;
c) Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or
thiazolyl; Z is
i) a Ce-ioaryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1 ,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl;
wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substituent selected from the group consisting of bromo, chloro, fluoro, methyl, methoxy, or trifluoromethyl; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro,
Figure imgf000015_0001
C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,; Rb is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl;
C3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyrimidinyl, and phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro; Z is
i) a Ce-ioaryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl; wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro,
Figure imgf000016_0001
C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,;
Rb is selected from the group consisting of phenylmethyl; C3-6 cycloalkyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro;
Z is
i) a C6-ioaryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CF2 or CH(OH); iv) indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
v) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is and
Rb is selected from the group consisting of phenylmethyl; thienyl;
pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of ¾, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro; Z is
i) a C6-10aryl;
ii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CF2 or CH(OH);
iii) indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
iv) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rb; provided that no more than one substituent is Rb;
Rb is selected from the group consisting of phenylmethyl; thienyl;
pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of ¾, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro; h) Ri is hydrogen, fluoro, or hydroxy; i) Ri is hydrogen or fluoro; j) R2 is hydrogen, C1-2 alkyl, or hydroxy; k) R2 is hydrogen, methyl, or hydroxy; 1) R2 is hydrogen; and any combination of embodiments a) through 1) above, provided that it is understood that combinations in which different embodiments of the same substituent would be combined are excluded;
and enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof.
An embodiment of the present invention includes a compound of Formula (I)
Figure imgf000018_0001
Formula (I) wherein Y is a C6-ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two fluoro substituents;
Z is
i) a C6-10aryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or
substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1 ,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl; wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substituent selected from the group consisting of bromo, chloro, fluoro, methyl, methoxy, or trifluoromethyl; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,;
Rb is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl; C3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyrimidinyl, and phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro; Ri is hydrogen, fluoro or hydroxy;
P2 is hydrogen, methyl, or hydroxy;
and enantiomers, diastereomers, solvates, and pharmaceutically acceptable salt forms thereof.
Another embodiment of the present invention includes a compound of Formula (I)
Figure imgf000020_0001
Formula (I) wherein
Y is an unsubstituted C6-ioaryl or an unsubstituted heteroaryl that is thienyl or thiazolyl;
Z is
i) a C6-10aryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or
substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl;
wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl, benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is ¾;
Rb is selected from the group consisting of phenylmethyl; C3-6 cycloalkyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of ¾, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl,
trifluoromethoxy, chloro, and fluoro;
Ri is hydrogen or fluoro;
R2 is hydrogen, C1-2 alkyl, or hydroxy;
and enantiomers, diastereomers, solvates, and pharmaceutically acceptable salt forms thereof.
Another embodiment of the present invention includes a compound of Formula (I)
Figure imgf000021_0001
Formula (I) wherein
Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or thiazolyl; Z is
i) a C6-10aryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or
substituted with one substituent that is trifluoromethyl;
Ra is CF2 or CH(OH);
iv) indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
v) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of bromo, chloro, fluoro, Ci-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,; and
Rb is selected from the group consisting of phenylmethyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is
independently selected from the group consisting of trifluoromethyl, chloro, and fluoro;
Ri is hydrogen or fluoro;
R2 is hydrogen, C1-2 alkyl, or hydroxy;
and enantiomers, diastereomers, solvates, and pharmaceutically acceptable salt forms thereof.
Another embodiment of the present invention includes a compound of Formula (I)
Figure imgf000022_0001
Formula (I) wherein
Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or thiazolyl;
Z is
i) a C6-10aryl;
ii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or
substituted with one substituent that is trifluoromethyl;
Ra is CF2 or CH(OH);
iii) indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
iv) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,;
Rb is selected from the group consisting of phenylmethyl wherein the phenyl is unsubstituted or substituted with one fluoro substituent; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro;
Ri is hydrogen or fluoro;
R2 is hydrogen;
and enantiomers, diastereomers, solvates, and pharmaceutically acceptable salt forms thereof. An embodiment of the present invention includes a compound of Formula (I)
Figure imgf000024_0001
Formula (I)
selected from the group consisting of
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3- amine,
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine, (3S)-N-{l-[(4-Benzylphenyl)carbonyl]azetidin-3-yl}-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} - 1 -(phenylcarbonyl)pyrrolidin-3- amine,
(3S)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} - 1 -(thiophen-3-ylcarbonyl)pyrrolidin- 3 -amine,
(3R)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} - 1-(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3R)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} -1 -(phenylcarbonyl)pyrrolidin-3- amine,
(3S)-N-{l-[(6-Bromo-3,4-dihydroisoquinolin-2(lH)-yl)carbonyl]azetidin-3-yl}-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 - [(6-Phenyl-3 ,4-dihydroisoquinolin-2( 1 H)-yl)carbonyl]azetidin-3 -yl} - 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(5-Bromo-l,3-dihydro-2H-isoindol-2-yl)carbonyl]azetidin-3-yl}-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3 -amine, (3S)-N- { 1 -[(5-Phenyl- 1 ,3-dihydro-2H-isoindol-2-yl)carbonyl]azetidin-3-yl} -1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} -N-methyl- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-Methyl- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethyl)biphenyl-4-yl] carbonyl} azetidin-3 - yl)pyrrolidin-3 -amine,
(3S)-N-{l-[(3*,5*-Dichlorobiphenyl-4-yl)carbonyl]azetidin-3-yl}-l- (phenylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [5 -(trifluoromethoxy)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [5 -(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [6-(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(6-Bromo-3-chloro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Bromonaphthalen-2-yl)carbonyl]azetidin-3-yl} - 1 - (phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N- { 1 -[(5-phenylnaphthalen-2-yl)carbonyl]azetidin-3- yl} pyrrolidin-3 -amine,
(3 S)- 1 -(Phenylcarbonyl)-N- [ 1 -( {5 - [2-(trifluoromethyl)phenyl]naphthalen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N- [ 1 -( {5 - [3 -(trifluoromethyl)phenyl]naphthalen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[4-(trifluoromethoxy)phenyl]naphthalen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N-[l-(9H-Fluoren-2-ylcarbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine, (3 S)-N-( 1 - { [3 -Chloro-6-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(3'-Chlorobiphenyl-4-yl)carbonyl]azetidin-3-yl}-l-(phenylcarbonyl)pyrrolidin-
3-amine,
(3S)-N-{l-[(3*,4*-Dichlorobiphenyl-4-yl)carbonyl]azetidin-3-yl}-l- (phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl] azetidin-3 -yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[1 -( {3-Chloro-6-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl} carbonyl)azetidin-3-yl]-l -(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-[ 1 -( {3-Chloro-6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(5 -Bromonaphthalen-2-yl)carbonyl]azetidin-3-yl} -N-hydroxy- 1 - (phenylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [4'-(trifluoromethyl)biphenyl-4-yl]carbonyl} azetidin-3- yl)pyrrolidin-3 -amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [4'-(trifluoromethoxy)biphenyl-4-yl]carbonyl} azetidin-3- yl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 - (phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(3-Methyl-5-phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}-l- (phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 -( {3 -Methyl-5 - [4-(trifluoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 -( {3 -Methyl-5 - [3 -(trifluoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine, (3 S)-N- { 1 -[(6-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {6-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-[(4-fluorophenyl)carbonyl]pyrrolidin-
3-amine,
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-[(3-fluorophenyl)carbonyl]pyrrolidin- 3-amine,
(3 S)- 1 -( 1 -Benzofuran-2-ylcarbonyl)-N- [ 1 -(biphenyl-4-ylcarbonyl)azetidin-3 -yl]pyrrolidin- 3-amine,
(3 S)- 1 -( 1 -Benzothiophen-2-ylcarbonyl)-N-[ 1 -(biphenyl-4-ylcarbonyl)azetidin-3 - yl]pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(5-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5 -Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3 S)-N-Ethyl- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-N-Hydroxy-l-(phenylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(3-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine, (3S)-N- { 1 -[(3-Chloro-6-fluoro- l-benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N- { 1 -[(3 -phenyl- lH-indol-6-yl)carbonyl] azetidin-3 - yl} pyrrolidin-3 -amine,
N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-4-fluoro-l-(phenylcarbonyl)pyrrolidin-3- amine,
4-Fluoro- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethyl)biphenyl-4-yl] carbonyl} azetidin-
3 -yl)pyrrolidin-3 -amine,
(3R)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-4-fluoro-l-(phenylcarbonyl)pyrrolidin-3- amine,
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-4-fluoro-l-(phenylcarbonyl)pyrrolidin-3- amine,
(3R)-4-Fluoro-l-(phenylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)-4-Fluoro- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[( 1 -Methyl-3 -phenyl- 1 H-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3 -Phenyl- 1 -benzothiophen-2-yl)carbonyl] azetidin-3 -yl} - 1 - (phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(3-Cyclopropyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
{4-[(3-{[(3S)-l-(Phenylcarbonyl)pyrrolidin-3-yl]amino}azetidin-l-yl)carbonyl]phenyl} [4-
(trifluoromethyl)phenyl]methanol,
(3 S)-N- { 1 -[(3-Methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
N- { 1 -[(4- {Fluoro[4-(trifluoromethyl)phenyl]methyl}phenyl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine, (3S)-N-{l-[(3-Cyclopropyl-6-fluoro-l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3R,4R)-4-Methoxy-l-(phenylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3R,4R)-l-(Phenylcarbonyl)-4-[(l-{[3'-(trifluoromethyl)biphenyl-4-yl]carbonyl}azetidin-
3-yl)amino]pyrrolidin-3-ol,
(3S)-N-[1 -( {4-[Difluoro(phenyl)methyl]phenyl} carbonyl)azetidin-3-yl]- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [3 -phenyl-6-(trifluoromethyl)- 1 -benzothiophen-2- yljcarbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-Cyclopropyl-6-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-3- yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 - { [3 -(2-Methylprop- 1 -en- 1 -yl)-6-(trifluoromethyl)- 1 -benzothiophen-2- yljcarbonyl} azetidin-3 -yl)- 1 -(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {4-[4-(trifluoromethyl)benzyl]phenyl} carbonyl)azetidin-3- yl]pyrrolidin-3 -amine,
(3R,4R)-4- { [ 1 -(Biphenyl-4-ylcarbonyl)azetidin-3-yl]amino} - 1 -
(phenylcarbonyl)pyrrolidin-3-ol,
(3 S)-N- { 1 -[(3-Cyclobutyl-6-fluoro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 - (phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 -{ [3 -Methyl-6-(trifluoro methyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)- l-(phenylcarbonyl)pyrrolidin-3-amine,
N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -N-[(3S)- 1 -
(phenylcarbonyl)pyrrolidin-3-yl]formamide,
N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -N-[(3S)- 1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-yl]formamide,
N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -N-[(3S)- 1 -(1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-yl]formamide, (3S)-N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -(1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(6-Fluoro-3-methyl-l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Fluoro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Fluoro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(1 - {[3-Fluoro-6-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3-yl)- 1-
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 -( {3 -Methyl-5 - [3 -(trifluoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 -( {3 -Methyl-5 - [4-(trifluoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(3-Methyl-5-phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-(3-Fluorophenyl)-3-methyl-l-benzothiophen-2-yl]carbonyl}azetidin-3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-(4-Fluorophenyl)-3-methyl-l-benzothiophen-2-yl]carbonyl}azetidin-3-yl)- l-(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(5-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine, (3S)-N- { 1 -[(5-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3 S)- 1 -( 1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -( {6-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-
2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)- 1 -( 1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -( {6-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-
2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {3-[4-(trifluoromethyl)phenyl]- lH-indol-6- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3 S)- 1 -( 1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -( {6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen- 2-yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {3-[3-(trifluoromethyl)phenyl]- lH-indol-6- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -( {3-[4-(trifluoromethyl)phenyl]- lH-indol-6- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -( {3-[3-(trifluoromethyl)phenyl]- lH-indol-6- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)- 1 -(1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -( {3-[3-(trifluoromethyl)phenyl]- lH-indol-6- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)-N- { 1 -[(5-Bromo- 1 -benzofuran-2-yl)carbonyl]azetidin-3-yl} - 1- (phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N- { 1 -[(4-phenylquinazolin-7-yl)carbonyl]azetidin-3- yl} pyrrolidin-3 -amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {4-[4-(trifluoromethyl)phenyl]quinazolin-7- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)-N- { 1 -[(4-Phenylquinazolin-7-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -( {4-[4-(trifluoromethyl)phenyl]quinazolin-7- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine, (3S)-N- { 1 -[(4-Phenylquinazolin-7-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)- 1 -( 1 ,3 -Thiazol-2-ylcarbonyl)-N-( 1 - { [4*-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-Fluoro-3'-(trifluoromethyl)biphenyl-4-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 -{ [3 -Methyl-3 '-(trifluoromethyl)biphenyl-4-yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -( { 1 -[4-(trifluoromethyl)phenyl]- lH-indol-5- yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3 S)-N- { 1 -[( 1 -Pyrimidin-2-yl- 1 H-indol-5 -yl)carbonyl]azetidin-3 -yl} - 1 -( 1 ,3 -thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(1 -Phenyl- lH-indazol-5-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(5-Phenyl- 1 -benzofuran-2-yl)carbonyl]azetidin-3-yl} - 1 - (phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [5-(5-Chlorothiophen-2-yl)- 1 -benzofuran-2-yl]carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3 -Methyl-5 -phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1-(1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(6-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N- [ 1 -( {3 -Methyl-5 - [3 -(trifluoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)- 1 -(Phenylcarbonyl)-N-[ 1 -({4-[3-(trifluoromethyl)benzyl]phenyl} carbonyl)azetidin-3- yl]pyrrolidin-3 -amine,
(3 S)- 1 -( 1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -( {4-[3-
(trifluoromethyl)benzyl]phenyl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)- 1 -( 1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -( {6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-
2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)- 1 -(1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -({5-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen- 2-yl} carbonyl)azetidin-3-yl]pyrrolidin-3 -amine,
(3S)-N- { 1 -[(5-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -({5-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-
2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)-N- { 1 -[(2-Phenyl- 1 ,3-benzothiazol-6-yl)carbonyl]azetidin-3 -yl} - 1 -( 1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 - { [2-(2-Fluorophenyl)-4-methyl- 1 ,3 -thiazol-5 -yl]carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [2-(4-Fluorophenyl)-4-methyl- 1 ,3 -thiazol-5 -yl]carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[2-(3-Chlorophenyl)-4-methyl-l,3-thiazol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[2-(4-Chlorophenyl)-4-methyl-l,3-thiazol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -( 1 ,3 -Thiazol-2-ylcarbonyl)-N-( 1 - { [6-(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)- 1 -( 1 ,3 -Thiazol-4-ylcarbonyl)-N-( 1 - { [6-(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine, (3 S)-N- { 1 -[(6-Bromo-3-chloro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Bromo-3-chloro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -Fluoro- 1 -(4-fluorophenyl)- 1 H-indol-5 -yl]carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[3-Fluoro- 1 -(4-fluorophenyl)- lH-indol-5-yl]carbonyl} azetidin-3 -yl)- 1 -(1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -( 1 ,3 -Thiazol-4-ylcarbonyl)-N-[ 1 -( {4- [4- (trifluoromethyl)benzyl]phenyl} carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)- 1 -( 1 ,3 -Thiazol-4-ylcarbonyl)-N-( 1 - { [4,-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(3 -Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl] azetidin-3-yl} - 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(3 -Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl] azetidin-3-yl} - 1 -( 1 ,3 - thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[1 -( {3-Chloro-6-[3-(trifiuoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[1 -( {3-Chloro-6-[3-(trifiuoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N-[ 1 -( {3-Chloro-6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N-[ 1 -( {3-Chloro-6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-(l-{[3-Fluoro-3'-(trifluoromethyl)biphenyl-4-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 -{ [3 -Methyl-3 '-(trifluoromethyl)biphenyl-4-yl] carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine, (3S) - 1 -(Phenylcarbonyl)-N-[ 1 -( { 1 -[4-(trifluoromethyl)phenyl]- 1 H-indol-5 - yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N- { 1 - [( 1 -pyrimidin-2-yl- 1 H-indol-5 -yl)carbonyl] azetidin-3 - yl} pyrrolidin-3 -amine,
(3 S)-l-(Phenylcarbonyl)-N-{l-[(l -phenyl- lH-indazol-5-yl)carbonyl] azetidin-3 - yl} pyrrolidin-3 -amine,
(3S)-N-{l-[(2-Phenyl-l,3-benzothiazol-6-yl)carbonyl]azetidin-3-yl}-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -( { 1 -[4-(trifluoromethyl)phenyl]- lH-indol-5- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 - { [ 1 -(4-Fluorophenyl)- 1 H-indol-5 -yl] carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({l-Methyl-3-[3-(trifluoromethyl)phenyl]-lH-indol-6-yl}carbonyl)azetidin-3- yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({l-Methyl-3-[4-(trifluoromethyl)phenyl]-lH-indol-6-yl}carbonyl)azetidin-3- yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({l-Methyl-3-[3-(trifluoromethyl)phenyl]-lH-indol-6-yl}carbonyl)azetidin-3- yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({l-Methyl-3-[4-(trifluoromethyl)phenyl]-lH-indol-6-yl}carbonyl)azetidin-3- yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({l-Methyl-3-[3-(trifluoromethyl)phenyl]-lH-indol-6-yl}carbonyl)azetidin-3- yl] - 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 - { [3 -Chloro-6-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)- 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N-( 1 - { [3 -Chloro-6-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)- 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(l-Methyl-3-phenyl-lH-indol-6-yl)carbonyl]azetidin-3-yl}-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-{l-[(l-Methyl-3-phenyl-lH-indol-6-yl)carbonyl]azetidin-3-yl}-l-(l,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(3-Fluoro-5-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Fluoro-5-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(3-Fluoro-5-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 -( { 3 -Fluoro-5 - [4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[1 -( {3 -Fluoro-5 -[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[1 -( {3 -Fluoro-5 -[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[1 -( {3-Fluoro-6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({3-Fluoro-6-[4-(trifluoromethyl)phenyl]-l-benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({3-Fluoro-6-[4-(trifluoromethyl)phenyl]-l-benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-Chloro-3-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-Chloro-3-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-3-yl)-l-
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N-( 1 - { [6-Chloro-3 -(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [6-Chloro-3 -(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)- 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-Methyl-3-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-3-yl)-
1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 -{ [6-Methyl-3 -(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)-
1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[6-Methyl-3-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-3-yl)- 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Phenyl- lH-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(3-Phenyl- lH-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l- (phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-(l - { [3-(4-Fluorophenyl)- 1 -methyl- 1 H-indol-6-yl]carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(1 -Methyl-3 -phenyl- lH-indazol-5-yl)carbonyl]azetidin-3-yl} -1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine, (3S)-N-{l-[(l-Methyl-3-phenyl-lH-indazol-5-yl)carbonyl]azetidin-3-yl}-l-(l,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[( 1 -Methyl-3-phenyl- 1 H-indazol-5-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[4-Fluoro-l-(4-fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3-yl)-l-(l ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 - { [3 -(3 -Fluorophenyl)- 1 H-indol-6-yl] carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[3 -(3 -Fluorophenyl)- 1 -methyl- lH-indol-6-yl] carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[6-Phenyl-3-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-3 -yl)- 1 -
( 1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indazol-5 -yl]carbonyl } azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indazol-5 -yl]carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indazol-5 -yl]carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[6-Fluoro-l-(4-fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3R)-N-(l-{[l-(2,2-Difluoroethyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-4-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-4-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-( 1 - { [1 -(4-Fluorophenyl)-2,3-dihydro- 1 H-indol-4-yl]carbonyl} azetidin-3-yl)- 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-2,3-dihydro-lH-indol-4-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[l-(3-Fluorophenyl)-lH-indol-3-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-3-yl]carbonyl}azetidin-3-yl)-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-2,3-dihydro-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[3-(4-Fluorobenzyl)- 1 -methyl- lH-indol-6-yl] carbonyl} azetidin-3 -yl)-l -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
N-Methyl-N-phenyl-2- { 5 - [(3 - { [(3 S)- 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 - yl] amino } azeti din- 1 -yl)carbonyl]-l H-indol- 1 -yl } acetamide,
(3S)-N-(l-{[4-Chloro-l-(4-fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-(1 - {[ 1 -(4-Fluorophenyl)-6-methyl- lH-indol-5-yl]carbonyl} azetidin-3-yl)- 1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3 -amine, and
(3S)-N-(l-{[6-Chloro-l-(4-fiuorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
and pharmaceutically acceptable salt forms thereof.
For use in medicine, salts of compounds of Formula (I) refer to non-toxic
"pharmaceutically acceptable salts." Other salts may, however, be useful in the preparation of compounds of Formula (I) or of their pharmaceutically acceptable salts thereof. Suitable pharmaceutically acceptable salts of compounds of Formula (I) include acid addition salts that can, for example, be formed by mixing a solution of the compound with a solution of a pharmaceutically acceptable acid such as, hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Furthermore, where the compounds of Formula (I) carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include alkali metal salts such as, sodium or potassium salts; alkaline earth metal salts such as, calcium or magnesium salts; and salts formed with suitable organic ligands such as, quaternary ammonium salts. Thus, representative pharmaceutically acceptable salts include acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate,
dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide,
hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, N-methylglucamine ammonium salt, oleate, pamoate
(embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, sulfate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, and valerate.
Representative acids and bases that may be used in the preparation of pharmaceutically acceptable salts include acids including acetic acid, 2,2-dichloroacetic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+)-camphoric acid, camphorsulfonic acid, (+)-(lS)-camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane- 1,2- disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucoronic acid, L-glutamic acid, a-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+)-L-lactic acid, (±)-DL-lactic acid, lactobionic acid, maleic acid, (-)- L-malic acid, malonic acid, (±)-DL-mandelic acid, methanesulfonic acid, naphthalene-2- sulfonic acid, naphthalene- 1,5 -disulfonic acid, l-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebaic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+)-L-tartaric acid, thiocyanic acid, p- toluenesulfonic acid and undecylenic acid; and bases including ammonia, L-arginine, benethamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine,
diethylamine, 2-(diethylamino)-ethanol, ethanolamine, ethylenediamine, N-methyl- glucamine, hydrabamine, lH-imidazole, L-lysine, magnesium hydroxide, 4-(2- hydroxyethyl)-morpholine, piperazine, potassium hydroxide, 1 -(2-hydroxyethyl)- pyrrolidine, sodium hydroxide, triethanolamine, tromethamine, and zinc hydroxide.
Embodiments of the present invention include prodrugs of compounds of Formula (I). In general, such prodrugs will be functional derivatives of the compounds that are readily convertible in vivo into the required compound. Thus, in the methods of treating or preventing embodiments of the present invention, the term "administering" encompasses the treatment or prevention of the various diseases, conditions, syndromes and disorders described with the compound specifically disclosed or with a compound that may not be specifically disclosed, but which converts to the specified compound in vivo after administration to a patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.
Where the compounds according to embodiments of this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. The skilled artisan will understand that the term compound as used herein, is meant to include solvated compounds of Formula (I).
Where the processes for the preparation of the compounds according to certain embodiments of the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as, preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their component enantiomers by standard techniques such as, the formation of diastereomeric pairs by salt formation with an optically active acid such as,
(-)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
One embodiment of the present invention is directed to a composition, including a pharmaceutical composition, comprising, consisting of, and/or consisting essentially of the (+)-enantiomer of a compound of Formula (I) wherein said composition is substantially free from the (-)-isomer of said compound. In the present context, substantially free means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (-)-isomer calculated as
{mass (+) - enantiomer)
% (+) - enantiomer = x lOO
{mass {+) - enantiomer) + {mass{-) - enantiomer)
Another embodiment of the present invention is a composition, including a pharmaceutical composition, comprising, consisting of, and consisting essentially of the (- )-enantiomer of a compound of Formula (I) wherein said composition is substantially free from the (+)-isomer of said compound. In the present context, substantially free from means less than about 25 %, preferably less than about 10 %, more preferably less than about 5 %, even more preferably less than about 2 % and even more preferably less than about 1 % of the (+)-isomer calculated as
{mass {-) - enantiomer)
% (-) - enantiomer = x lOO
{mass {+) - enantiomer) + {mass{-) - enantiomer)
During any of the processes for preparation of the compounds of the various embodiments of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups such as those described in Protective Groups in Organic Chemistry, Second Edition, J.F.W. McOmie, Plenum Press, 1973; T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, Third Edition, John Wiley & Sons, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
Even though the compounds of embodiments of the present invention (including their pharmaceutically acceptable salts and pharmaceutically acceptable solvates) can be administered alone, they will generally be administered in admixture with a
pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient and/or a pharmaceutically acceptable diluent selected with regard to the intended route of administration and standard pharmaceutical or veterinary practice. Thus, particular embodiments of the present invention are directed to pharmaceutical and veterinary compositions comprising compounds of Formula (I) and at least one pharmaceutically acceptable carrier, pharmaceutically acceptable excipient, and/or pharmaceutically acceptable diluent.
By way of example, in the pharmaceutical compositions of embodiments of the present invention, the compounds of Formula (I) may be admixed with any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilizing agent(s), and combinations thereof.
Solid oral dosage forms such as, tablets or capsules, containing the compounds of the present invention may be administered in at least one dosage form at a time, as appropriate. It is also possible to administer the compounds in sustained release formulations.
Additional oral forms in which the present inventive compounds may be administered include elixirs, solutions, syrups, and suspensions; each optionally containing flavoring agents and coloring agents.
Alternatively, compounds of Formula (I) can be administered by inhalation
(intratracheal or intranasal) or in the form of a suppository or pessary, or they may be applied topically in the form of a lotion, solution, cream, ointment or dusting powder. For example, they can be incorporated into a cream comprising, consisting of, and/or consisting essentially of an aqueous emulsion of polyethylene glycols or liquid paraffin.
They can also be incorporated, at a concentration of between about 1 % and about 10 % by weight of the cream, into an ointment comprising, consisting of, and/or consisting essentially of a wax or soft paraffin base together with any stabilizers and preservatives as may be required. An alternative means of administration includes transdermal
administration by using a skin or transdermal patch.
The pharmaceutical compositions of the present invention (as well as the compounds of the present invention alone) can also be injected parenterally, for example, intracavernosally, intravenously, intramuscularly, subcutaneously, intradermally, or intrathecally. In this case, the compositions will also include at least one of a suitable carrier, a suitable excipient, and a suitable diluent.
For parenteral administration, the pharmaceutical compositions of the present invention are best used in the form of a sterile aqueous solution that may contain other substances, for example, enough salts and monosaccharides to make the solution isotonic with blood.
For buccal or sublingual administration, the pharmaceutical compositions of the present invention may be administered in the form of tablets or lozenges, which can be formulated in a conventional manner.
By way of further example, pharmaceutical compositions containing at least one of the compounds of Formula (I) as the active ingredient can be prepared by mixing the compound(s) with a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, and/or a pharmaceutically acceptable excipient according to conventional pharmaceutical compounding techniques. The carrier, excipient, and diluent may take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral, etc.). Thus, for liquid oral preparations such as, suspensions, syrups, elixirs and solutions, suitable carriers, excipients and diluents include water, glycols, oils, alcohols, flavoring agents, preservatives, stabilizers, coloring agents and the like; for solid oral preparations such as, powders, capsules, and tablets, suitable carriers, excipients and diluents include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Solid oral preparations also may be optionally coated with substances such as, sugars, or be enterically coated so as to modulate the major site of absorption and disintegration. For parenteral administration, the carrier, excipient and diluent will usually include sterile water, and other ingredients may be added to increase solubility and preservation of the composition. Injectable suspensions or solutions may also be prepared utilizing aqueous carriers along with appropriate additives such as, solubilizers and preservatives. A therapeutically effective amount of a compound of Formula (I) or a
pharmaceutical composition thereof includes a dose range from about 0.1 mg to about 3000 mg, or any particular amount or range therein, in particular from about 1 mg to about 1000 mg, or any particular amount or range therein, or, more particularly, from about 10 mg to about 500 mg, or any particular amount or range therein, of active ingredient in a regimen of about 1 to about 4 times per day for an average (70 kg) human; although, it is apparent to one skilled in the art that the therapeutically effective amount for a compound of Formula (I) will vary as will the diseases, syndromes, conditions, and disorders being treated.
For oral administration, a pharmaceutical composition is preferably provided in the form of tablets containing about 1.0, about 10, about 50, about 100, about 150, about 200, about 250, and about 500 milligrams of a compound of Formula (I).
Advantageously, a compound of Formula (I) may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three and four times daily.
Optimal dosages of a compound of Formula (I) to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation and the advancement of the disease, syndrome, condition or disorder. In addition, factors associated with the particular subject being treated, including subject gender, age, weight, diet and time of administration, will result in the need to adjust the dose to achieve an appropriate therapeutic level and desired therapeutic effect. The above dosages are thus exemplary of the average case. There can be, of course, individual instances wherein higher or lower dosage ranges are merited, and such are within the scope of this invention.
Compounds of Formula (I) may be administered in any of the foregoing
compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of a compound of Formula (I) is required for a subject in need thereof.
As MGL inhibitors, the compounds of Formula (I) are useful in methods for treating and preventing a disease, a syndrome, a condition or a disorder in a subject, including an animal, a mammal and a human in which the disease, the syndrome, the condition or the disorder is affected by the modulation, including inhibition, of the MGL enzyme. Such methods comprise, consist of and/or consist essentially of administering to a subject, including an animal, a mammal, and a human in need of such treatment or prevention a therapeutically effective amount of a compound, salt or solvate of Formula
CO-
GENERAL SYNTHETIC METHODS
Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and illustrated in the schemes and examples that follow. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions described in the schemes. The various starting materials used in the schemes and examples are commercially available or may be prepared by methods well within the skill of persons versed in the art. The variables are as defined herein.
Abbreviations used in the instant specification, particularly the schemes and examples, are as follows:
AcCl acetyl chloride
AcOH glacial acetic acid
aq. aqueous
Bn or Bzl benzyl
Boc tert-butyloxycarbonyl
cone. concentrated
dba dibenzylideneacetone
DCC Λ', /V'-dicyclohexy 1-carbodiirnide
DCE 1 ,2-dichloroethane DCM dichloromethane
DIPEA diisopropyl-ethyl amine
DMAP 4-N,N-dimethylaminopyridine
DMF N,N-dimethylformamide
DMSO dimethylsulfoxide
dppf 1 , 1 '-bis(diphenylphosphino)ferrocene
EDC N-(3 -dimethylaminopropyl)-N' -ethylcarbodiimide hydrochloride
ESI electrospray ionization
EtOAc ethyl acetate
EtOH ethanol
h hour(s)
HATU 0-(lH-7-azabenzotriazol- 1 -yl)- 1,1,3,3- tetramethyluronium hexafluorophosphate
HBTU O-(lH-benzotriazol-l-yl)-l,l,3,3-tetramethyluronium hexafluorophosphate
HEK human embryonic kidney
HEPES (4-(2-hydroxyethyl)- 1 -piperazineethane
sulfonic acid
HPLC high performance liquid chromatography
mCPBA weto-chloroperoxybenzoic acid
MeCN acetonitrile
MeOH methanol
MHz megahertz
min minutes
MS mass spectrometry
NMR nuclear magnetic resonance
PIPES piperazine-N,N'-bis(2-ethanesulfonic acid)
PyBrOP bromo-tris-pyrrolidinophosphonium
hexafluorophosphate RP reverse-phase
Rt retention time
SPhos 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl
TEA or Et3N triethylamine
TFA trifluoroacetic acid
THF tetrahydrofuran
TLC thin layer chromatography
TMS tetramethylsilane
XPhos 2-dicyclohexylphosphino-2',4',6'- triisopropylbiphenyl
Scheme A illustrates a route for the synthesis of compounds of Formula (I)-A, wherein Z is a benzo-fused heterocyclyl as defined herein.
Scheme A
o
1■ Optional alkylation O ¾
Reductive
Figure imgf000050_0001
Amination
Coupling
2. Amino deprotection
A1
or C^alkyl
Figure imgf000050_0002
Deprotection
A6 A7
Figure imgf000050_0003
A compound of formula Al (wherein P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like) is either commercially available or may be prepared by known methods described in the scientific literature. The compound of formula Al may be treated with a carboxylic acid of formula A2 wherein Q is hydroxy, in the presence of an appropriate coupling agent such as, HATU, DCC, EDC, HBTU, PyBrOP, and the like; and optionally in the presence of a base such as, DIPEA, to afford a compound of Formula A3. Similarly, an acid chloride of formula A2 wherein Q is chloro may be used to effect the acylation of a compound of formula Al. In such case a non-nucleophilic base such as, pyridine, may be added to afford a compound of Formula A3. At this stage, a compound of formula A4 may be alkylated with a compound of formula Ci_6alkyl-X (wherein X is bromo, chloro, iodo, or triflate), followed by removal of the amino protecting group (P) by conventional methods to afford a compound of formula A4. A compound of formula A4 may undergo a reductive amination with a compound of formula A5 (wherein P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like) in the presence of a hydride source such as, sodium triacetoxyborohydride to afford a compound of formula A6. Removal of amino protecting group P using conventional methods affords a compound of formula A7.
A compound of formula A8, wherein ring A is a 5- to 6-membered heterocycyl containing at least one nitrogen atom, is either commercially available or may be prepared by known methods described in the scientific literature. The compound of formula A8 may be treated with CDI in the presence of an organic base such as triethylamine to afford a compound of formula A9. Treatment with methyl iodide in an anhydrous organic solvent provides a compound of formula A10. The compound of formula A7 may be coupled with a compound of formula A10 in the presence of an organic amine such as triethylamine in an organic solvent such as dichloromethane to afford a compound of Formula (I)-A.
Scheme B illustrates a route for the synthesis of compounds of Formula (I)-B, wherein Z is a benzo-fused heterocyclyl substituted with a phenyl substituent.
Scheme B
Figure imgf000051_0001
A compound of Formula (I)-A may be treated with a phenylboronic acid of formula Bl, wherein RB is selected from the group consisting of hydrogen, bromo, chloro, fluoro, iodo, C1-4alkyl, C2-4alkenyl,
Figure imgf000051_0002
trifluoromethyl, and trifluoromethoxy, in the presence of a palladium catalyst and appropriate ligands, and in the presence of an inorganic base such as sodium carbonate and the like, to afford a compound of Formula (I)-B. Scheme C illustrates a route for the synthesis of compounds of Formula (I)-C.
Scheme
Figure imgf000052_0001
TEA, CH2CI2 Reductive
C1 C3 Amination C5
Amino
Deprotection
Figure imgf000052_0002
Formula (l)-C
A compound of formula CI is either commercially available or may be prepared by known methods described in the scientific literature. The compound of formula C2 may be treated with a carboxylic acid of formula CI wherein Q is hydroxy, in the presence of an appropriate coupling agent such as, HATU, DCC, EDC, HBTU, PyBrOP, and the like; and optionally in the presence of a base such as, DIPEA, to afford a compound of formula C3. Similarly, an acid chloride of formula CI wherein Q is chloro may be used to effect the acylation of a compound of formula C2. In such case a non-nucleophilic base such as, pyridine or triethylamine, may be added to afford a compound of formula C3. A compound of formula C3 may undergo a reductive amination with a compound of formula C4 (wherein P is a conventional amino protecting group such as, Boc, Fmoc, Cbz, and the like) in the presence of a hydride source such as, sodium triacetoxyborohydride to afford a compound of formula C5. Removal of amino protecting group P using conventional methods affords a compound of formula C6. Coupling with a Y-substituted reagent of formula A2 using the methods described in Scheme A affords the desired compound of Formula (I)-C.
Scheme D illustrates an alternate route for the synthesis of compounds of Formula (I)-C.
Scheme D
Figure imgf000053_0001
Formula (l)-C
A compound of formula Dl (wherein PI is a conventional amino protecting group) is either commercially available or may be prepared by known methods described in the scientific literature. A compound of formula Dl may undergo a reductive amination with a compound of formula A5, as described in Scheme A, to afford a compound of formula D2. Selective removal of amino protecting group PI using conventional methods affords a compound of formula D3. Coupling with a Y-substituted reagent of formula A2 using the methods described in Scheme A affords the desired compound of formula D4. Removal of amino protecting group P using conventional methods affords a compound of formula D5. Coupling with a compound of formula CI affords a compound of Formula (I)-C.
Scheme E illustrates a route for the synthesis of compounds of Formula (I)-E, wherein R2 is hydroxy.
Scheme E
Figure imgf000053_0002
A compound of Formula (I)-C may be treated with an oxidizing agent such as wCPBA, 3,3-dimethyldioxirane, or sodium tungstate/H202 to afford a compound of Formula (I)-E. One of skill in the art will recognize that some Z-substituents may have functional groups sensitive to oxidation conditions. Such functional groups may require the introduction of an appropriate protecting group prior to the oxidation step, and subsequent removal of the protecting group after oxidation.
Scheme F illustrates a route for the synthesis of compounds of Formula (I), wherein Z is a heteroaryl such as benzothienyl, and Z is substituted with C1-4alkyl, C2-4alkenyl, or C3-6cycloalkyl.
Scheme F
Figure imgf000054_0001
G = C-|_4alkyl, C2_4alkenyl, or C3_6cycloalkyl
A compound of formula Fl (wherein RF is chloro, fluoro, Ci_4alkyl, Ci_4alkoxy, trifluoromethyl, or wherein ¾, is thienyl, pyridinyl, pyrimidinyl, or phenyl) is either commercially available or may be prepared by known methods described in the scientific literature. A compound of formula Fl may be treated with a boronic acid of formula F2 in the presence of a palladium catalyst and appropriate ligands, and in the presence of an inorganic base such as potassium phosphate, to afford a compound of formula F3.
Saponification in the presence of hydroxide anion affords a compound of formula F4.
Treatment of a compound of formula F4 with oxalyl chloride in the presence of DMF in an organic solvent such as dichloromethane affords the corresponding acid chloride of formula F5. Coupling wtih a compound of formula D5 in the presence of a non- nucleophilic organic base such as triethylamine, pyridine, or the like, affords a compound of Formula (I)-F. Scheme G illustrates a route for the synthesis of compounds of Formula (I)-G, wherein Z is a heteroaryl such as, indolyl, and Z is substituted at the indolyl nitrogen atom with Rb. Substituent ¾ is an optionally substituted thienyl, pyridinyl, pyrimidinyl, or phenyl ring.
Figure imgf000055_0001
A compound of formula Gl is either commercially available or may be prepared by known methods described in the scientific literature. The compound of formula Gl may be coupled with a compound of formula G2 in the presence of trans-N, N'- dimethylcyclohexane-l,2-diamine, copper (I) iodide, and an inorganic base such as potassium phosphate to afford a compound of formula G3. Saponification affords a carboxylic acid of formula G4. Coupling with a compound of formula D5 in the presence of an appropriate coupling agent such as, HATU, DCC, EDC, HBTU, PyBrOP, and the like; and optionally in the presence of a base such as, DIPEA, affords a compound of Formula (I)-G.
Scheme H illustrates a route for the synthesis of compounds of Formula (I)-H, wherein Z is a heteroaryl such as indolyl, and Z is substituted at a carbon atom with GH, wherein GH is
Figure imgf000055_0002
or an unsubstituted or substituted phenyl ring as defined by ¾. Scheme H
Figure imgf000056_0001
A compound of formula HI is either commercially available or may be prepared by known methods described in the scientific literature. The compound of formula HI may be coupled with a boronic acid of formula H2 in the presence of a palladium catalyst and appropriate ligands, and in the presence of an inorganic base such as potassium phosphate, to afford a compound of formula H3. The amino protecting group P may be removed by conventional methods known to one of skill in the art to afford a compound of formula H4. Saponification in the presence of hydroxide ion affords a carboxylic acid of formula H5. A compound of formula H5 may be coupled with a compound of formula D5 as previously described in Scheme G to afford a compound of Formula (I)-H.
Scheme I illustrates a route for the synthesis of compounds of Formula (I)-I, wherein Z is a heteroaryl such as indolyl, and Z is substituted at a carbon atom with ¾, wherein ¾ is an optionally substituted phenylmethyl as defined herein.
Scheme I
Figure imgf000057_0001
A compound of formula II is either commercially available or may be prepared by known methods described in the scientific literature. The compound of formula II may be coupled with a benzyl chloride of formula 12 (wherein R1 is defined as trifluoromethyl, trifluoromethoxy, C1-4alkyl, chloro, and fluoro) in the presence of a silver oxide, in an organic solvent such as dioxane, to afford a compound of formula 13. Saponification in the presence of hydroxide ion affords a carboxylic acid of formula 14, which may be coupled with a compound of formula D5 as previously described in Scheme G to afford a compound of Formula (I)-I.
Scheme J illustrates a route for the synthesis of compounds of Formula (I)-J, wherein Z is a benzo-fused heterocyclyl attached through a benzo carbon atom.
Scheme J
Figure imgf000057_0002
A compound of formula Jl is either commercially available or may be prepared by known methods described in the scientific literature. The compound of formula Jl may be coupled with a GH-substituted bromide of formula J2 in the presence of a palladium catalylst, appropriate ligands, and an organic base to afford a mixture of a compound of formula J3 and a carboxylic acid of formula J4. The mixture may be subjected to saponification conditions to afford the compound of formula J4, which, subsequently, may be coupled with a compound of formula D5 to afford a compound of Formula (I)-J.
Example 1
Figure imgf000058_0001
A. (S)-tert-Buty\ (l-(thiazole-2-carbonyl)pyrrolidin-3-yl)carbamate, lc. To a solution of compound la (4.47 g, 24 mmol), 2-thiazole carboxylic acid lb (2.58 g, 20 mmol), and Et3N (1.4 mL, 100 mmol) in CH2C12 (50 mL) was added HATU (9.89 g, 26 mmol). The reaction mixture was stirred at room temperature for 18 h. The resultant mixture was diluted with CH2C12 and washed with aq. NaHC03. The organic phase was dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 50% EtOAc/hexanes) gave compound lc (5.5 g). JH NMR (300 MHz, CDC13): δ 7.89 (m, 1 H), 7.52 (m, 1 H), 4.65 (m, 1 H), 4.39-4.22 (m, 2.5H), 4.03 (m, 0.5 H), 3.91 (m, 0.5 H), 3.81-3.74 (m, 1H), 3.61 (m, 0.5 H), 2.28-2.19 (m, 1 H), 2.05-1.86 (m, 1 H), 1.44 (s, 9 H). B. (S)-(3-Aminopyrrolidin-l-yl)(thiazol-2-yl)methanone, Id. To a solution of compound lc (5.5 g, 18.52 mmol) in MeOH (30 mL) was added an HC1 solution in dioxane (4M, 50 mL) at room temperature. The mixture was stirred at room temperature for 4 h. The solvent was removed by evaporation. Ether (100 mL) was added to the residue. The resultant white solid was collected by filtration, washed with hexanes, and dried under reduced pressure. The crude compound Id was used in the next reaction without further purification. MS m/z (M+H+) 198.
C. (S)-tert-Butyl 3-((l-(thiazole-2-carbonyl)pyrrolidin-3-yl)amino)azetidine-l- carboxylate, If. To a solution of compound Id (diHCl salt, 2.7 g, 10 mmol) and N-Boc azetidinone le (2.4 g, 14 mmol) in 1,2-DCE (50 mL) was added slowly Et3N (20 mmol) followed by acetic acid (3.5 mL). To this mixture was added Na(OAc)3BH (3.39 g, 16 mmol). The reaction was stirred at room temperature for 5 h. To the reaction mixture was added aq. NaHC03, and the resultant mixture was extracted with CH2CI2. The organic layer was dried over Na2S04 and concentrated. Purification by flash column
chromatography (silica gel, 80% EtO Ac/heptane) gave compound If (2.96 g). 1H NMR (300 MHz, CDC13): δ 7.91 (m, 1 H), 7.53 (m, 1 H), 4.28 (m, 1 H), 4.22-4.11 (m, 2.5 H), 3.91 (m, 0.5 H), 3.83 (m, 1 H), 3.73-3.60 (m, 3.5 H), 3.49 (m, 0.5 H), 3.41 (m, 1 H), 2.11 (m, 1 H), 1.89-1.73 (m, 1 H), 1.44 (s, 9 H).
D. (S)-(3-(Azetidin-3-ylamino)pyrrolidin-l-yl)(thiazol-2-yl)methanone, lg. To a solution of compound If (3 g, 8.52 mmol) in MeOH (10 mL) was added an HC1 solution in dioxane (4M, 20 mL) at room temperature. The mixture was stirred at room temperature for 4 h. The solvent was removed by evaporation. Ether (50 mL) was added to the residue. The white solid was collected by filtration, washed with hexanes, and dried under vacuum. The crude compound lg was used in the next reaction without further
purification. MS m/z (M+H+) 253.
E. (6-bromo-3,4-dihydroisoquinolin-2(lH)-yl)(lH-imidazol-l-yl)methanone, li. To a suspension of compound lh (HC1 salt, 1.03g, 4.16 mmol) and CDI (0.74g, 4.57 mmol) in CH2C12 (8 mL) was added Et3N (0.665 mL, 4.78 mmol). The reaction was stirred at room temperature overnight. To the reaction mixture was added water, and the resultant mixture was extracted with CH2CI2. The organic layer was dried over Na2S04 and concentrated. The residue was triturated from EtOAc/hexanes to afford compound li (1.03 g). The crude compound li was used in the next reaction without further
purification. MS m/z (M+H+) 306. 1H NMR (300 MHz, CDCI3): δ 7.93 (s, 1 H), 7.36 (m, 2 H), 7.27 (m, 1 H), 7.14 (m, 1 H), 6.98 (d, 1H, J= 6.6 Hz), 4.69 (s, 2 H), 3.81 (m, 2 H), 2.99 (m, 2H).
F. l-(6-Bromo-l,2,3,4-tetrahydroisoquinoline-2-carbonyl)-3-methyl-lH- imidazol-3-ium iodide, lj. To a solution of compound li (1.03g, 3.37 mmol) in CH3CN (7 mL) was added Mel (0.84 mL, 13.46 mmol). The reaction was stirred at room temperature overnight. The reaction was concentrated and the residue was washed with Et20/hexanes to afford compound lj (1.48 g). JH NMR (300 MHz, CDC13): δ 10.44 (s, br, 1 H), 7.65 (s, 1 H), 7.31 (m, 3 H), 7.23 (m, 1 H), 5.02 (m, 2H), 4.31 (s, 3 H), 3.98 (m, 2 H), 3.04 (m, 2H).
G. (S)-(3-((l-(6-Bromo-l,2,3,4-tetrahydroisoquinoline-2-carbonyl)azetidin-3- yl)amino)pyrrolidin-l-yl)(thiazol-2-yl)methanone, Cpd 10. To a suspension of compound lg (di-HCl salt, 105 mg, 0.327 mmol) and compound lj (162 mg, 0.36 mmol) in CH2C12 (2 mL) was added Et3N (0.09 mL, 0.65 mmol). The reaction was stirred room temperature overnight. To the reaction mixture was added water, and the resultant mixture was extracted with CH2C12. The organic layer was dried over Na2S04 and concentrated. Purification by flash column chromatography (silica gel, 5% MeOH/ EtOAc + 0.5% TEA) gave compound 10 (136 m g). MS m/z (M+H+) 490, 492. JH NMR (300 MHz, CDC13): δ 7.90 (m, 1 H), 7.54 (m, 1 H), 7.31-7.28 (m, 2 H), 6.96 (m, 1 H), 4.42 (d, J= 3 Hz, 2 H), 4.31-4.16 (m, 3 H), 3.96-3.68 (m, 4 H), 3.53-3.40 (m, 3 H), 2.83 (m, 2 H), 2.12 (m, 1 H), 1.84 (m, 1 H).
Following the procedure described above for Example 1 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared. Cpd Cpd Name and Data
12 (3S)-N- { 1 -[(5-Bromo- 1 ,3-dihydro-2H-isoindol-2-yl)carbonyl]azetidin-3-yl} - l-(l ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine MS m/z (M+H+) 476, 478
Example 2
Figure imgf000061_0001
A. (S)-(3-((l-(6-Phenyl-l,2,3,4-tetrahydroisoquinoline-2-carbonyl)azetidin-3- yl)amino)pyrrolidin-l-yl)(thiazol-2-yl)methanone, Cpd 11. A mixture of compound 10 (82 mg, 0.167 mmol), phenyl boronic acid 2a (35 mg, 0.284 mmol), Pd(dppf)Cl2.CH2Cl2 (14 mg, 0.0167 mmol) and Na2C03 (35 mg, 0.334 mmol) in dioxane (0.8 mL) and water (0.2 mL) in a capped vial was heated at 80 °C for 6 h. The reaction mixture was diluted with EtOAc and water. The organic layer was concentrated and purified by
chromatography (silica gel, 5%MeOH/EtOAc) to give compound 11 (70 mg). MS m/z (M+H+) 488.
Following the procedure described above for Example 2 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared. Cpd Cpd Name and Data
13 (3S)-N- { 1 -[(5-Phenyl-l ,3-dihydro-2H-isoindol-2-yl)carbonyl]azetidin-3-yl} - l-(l ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine MS m/z (M+H+) 474
Example 3
Figure imgf000062_0001
A. l-([l,l'-Biphenyl]-4-carbonyl)azetidin-3-one, 3c. To a suspension of compound 3b (HC1 salt, 0.31 g, 2.88 mmol) in CH2C12 (10 mL) was dropwise added Et3N (0.87 g, 8.65 mmol) at 0 °C under argon gas followed by a solution of compound 3a (0.685 g, 3.17 mmol) in CH2C12 (3 mL). The reaction was stirred at 0 °C for 1 h and then quenched with water. The aqueous layer was extracted with CH2C12 and the combined organic extracts were concentrated and purified by column chromatography (silica gel, 35% EtOAc/hexanes) to give compound 3c as a white solid (0.6 g). MS m/z (M+H+) 252.
B. (Sytert-Butyl 3-((l-([l,l'-biphenyl]-4-carbonyl)azetidin-3- yl)amino)pyrrolidine-l-carboxylate, 3e. To a solution of compound 3c (0.223 g, 0.89 mmol) and compound 3d (0.25 g, 1.33 mmol) in 1 ,2-DCE (4 mL) was added acetic acid (0.4 mL). To this mixture was added Na(OAc)3BH (0.244 g, 1.15 mmol). The reaction was stirred at room temperature for 4 h. To the reaction mixture was added aq. NaHC03, and the resultant mixture was extracted with CH2CI2. The organic layer was dried over Na2S04 and concentrated. Purification by flash column chromatography (silica gel, 65% EtO Ac/heptane) gave compound 3e (0.3 g). MS m/z (M+H+) 422.2; (M+Na+) 444. 1H NMR (300 MHz, CDCI3) δ: 7.70 (m, 2 H), Ί .62-1.59 (m, 4 H), 7.46 (m, 2 H), 7.37 (m, 1 H), 4.48 (m, 2 H), 4.15-4.03 (m, 2 H), 3.77 (m, 1 H), 3.53-3.31 (m, 4 H), 3.08 (m, 1 H), 2.04 (m, 2 H), 1.46 (s, 9 H).
C. (S)-[l,l'-Biphenyl]-4-yl(3-(pyrrolidin-3-ylamino)azetidin-l-yl)methanone, 3f. To a solution of compound 3e (2.5 g, 5.92 mmol) in MeOH (7 mL) was added an HC1 solution in dioxane (4M, 12 mL) at room temperature. The mixture was stirred at room temperature for 4 h. The solvent was removed by evaporation. Ether (30 mL) was added to the residue. The off-white solid was collected by filtration, washed with hexanes, and dried under vacuum. The crude compound 3f was used in the next reaction without further purification. MS m/z (M+H+) 322.
D. (3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-[(3- fluorophenyl)carbonyl] pyrrolidin-3-amine, Cpd 46. To a solution of compound 3f (di- HC1 salt, 40 mg, 0.1 mmol), compound 3g (17 mg, 0.12 mmol), and Et3N (0.07 mL, 0.5 mmol) in CH2C12 (1 mL) was added HATU (61 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 18 h. The resultant mixture was diluted with CH2C12 and washed with aq. NaHC03. The organic phase was dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 50% EtOAc/hexanes) gave compound 46 (41 mg). MS m/z (M+H+) 444.5.
Following the procedure described above for Example 3 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared.
Figure imgf000064_0001
Cpd Cpd Name and Data
47 ( 3S)- 1 -( 1 -Benzofuran-2-ylcarbonyl)-N-[ 1 -(biphenyl-4-ylcarbonyl)azetidin-3- yl]pyrrolidin-3 -amine
MS m/z (M+H+) 466
48 (3 S)- 1 -( 1 -Benzothiophen-2-ylcarbonyl)-N-[ 1 -(biphenyl-4-ylcarbonyl)azetidin- 3 -yl]pyrrolidin-3 -amine
MS m/z (M+H+) 482
71 trans— 4-Met oxy- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine
MS m/z (M+H+) 524
72 trans- 1 -(Phenylcarbonyl)-4- [( 1 -{ [3 '-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)amino]pyrrolidin-3-ol
MS m/z (M+H+) 510
78 trans-4- { [ 1 -(Biphenyl-4-ylcarbonyl)azetidin-3 -yl] amino } - 1 - (phenylcarbonyl)pyrrolidin-3 -ol
MS m/z (M+H+) 442
Example 4
Figure imgf000066_0001
A. (S)-tert-Buty\ (l-benzoylpyrrolidin-3-yl)carbamate, 4b. To a solution of compound la (2.53 g, 13.58 mmol), benzoic acid 4a (1.66 g, 13.58 mmol), and Et3N (3.78 mL, 27.2 mmol) in CH2C12 (50 mL) was added HATU (6.72 g, 17.65 mmol). The reaction mixture was stirred at room temperature for 18 h. The resultant mixture was diluted with CH2C12 and washed with aq. NaHC03. The organic phase was dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 50% EtOAc/hexanes) gave compound 4b (3.5 g). MS m/z (M- Boc+) 190.2.
B. (S)-tert-Butyl (l-benzoylpyrrolidin-3-yl)(methyl)carbamate, 4c. To a solution of compound 4b (0.15 g, 0.517mmol) in DMF (2 mL) was added NaH (60% in mineral, 31 mg, 0.775 mmol) at 0 °C under nitrogen. The reaction was stirred at 0 °C for 30 min and then Mel (0.065 mL, 1.034 mmol) was added. The reaction was allowed to warm to room temperature with continuous stirring for 2 h. To the reaction mixture was added water and EtOAc. The aqueous layer was extracted with EtOAc twice. The organic phase was dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 35 %
EtOAc/hexanes) gave compound 4c (0.12 g). MS m/z (M-Boc+) 204.2.
C. (S)-(3-(Methylamino)pyrrolidin-l-yl)(phenyl)methanone, 4d. To a solution of compound 4c (0.12 g, 0.394 mmol) in CH2CI2 (3 mL) was added trifluoroacetic acid (1 mL) at room temperature. The mixture was stirred at room temperature for 5 h. The solvent was removed by evaporation. Ether (10 mL) was added to the residue. The crude product was collected by filtration, washed with ether, and dried under vacuum. MS m/z (M+ H+) 205.2.
D. (S)-tert-Butyl-3-((l-benzoylpyrrolidin-3-yl)(methyl)amino)azetidine-l- carboxylate, 4e. To a solution of compound 4d (TFA salt, 124 mg, 0.39 mmol) and compound le (94 mg, 0.55 mmol) in 1,2-DCE (2 mL) was added acetic acid (0.1 mL). To this mixture was added Na(OAc)3BH (132 mg, 0.624 mmol). The reaction was stirred at room temperature for 4 h. To the reaction mixture was added aq. NaHC03, and the resultant mixture was extracted with CH2CI2. The organic layer was dried over Na2S04 and concentrated. Purification by flash column chromatography (silica gel, 5%
MeOH/EtOAc +0.5% TEA) gave compound 4e (0.1 lg). MS m/z (M+H+) 360.5.
E. (S)-(3-(azetidin-3-yl(methyl)amino)pyrrolidin-l-yl)(phenyl)methanone, 4f. To a solution of compound 4e (0.11 g, 0.31 mmol) in MeOH (1 mL) was added HC1 solution in dioxane (4M, 1.5 mL) at room temperature. The mixture was stirred at room temperature for 4 h. The solvent was removed by evaporation. Ether (10 mL) was added to the residue. The off-white solid was collected by filtration, washed with hexanes, and dried under vacuum. The crude compound 4f was used in the next reaction without further purification. MS m/z (M+H+) 260.2.
F . (3S)-N-Methyl- l-(phenylcarbonyl)-N-(l- { [3 '-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine, Cpd 15. To a solution of compound 4f
(di-HCl salt, 38 mg, 0.114 mmol), compound 4g (36 mg, 0.137 mmol), and Et3N (0.08 mL, 0.57 mmol) in CH2C12 (1 mL) was added HATU (74 mg, 0.194 mmol). The reaction mixture was stirred at room temperature for 18 h. The resultant mixture was diluted with CH2CI2 and washed with aq. NaHC03. The organic phase was dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 5% MeOH/EtOAc+ 0.5 TEA%) gave compound 15 (36 mg). MS m/z (M+H+) 508.0.
Following the procedure described above for Example 4 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared.
Figure imgf000068_0002
Example 5
Figure imgf000068_0001
CH2CI2 A. (S)-Benzyl 3-((l-(tert-butoxycarbonyl)azetidin-3-yl)amino)pyrrolidine-l- carboxylate, 5b. To a solution of compound 5a (4.25 g, 19.3 mmol) and compound le (4.29 g, 25.08 mmol) in DCE (60 mL) was added acetic acid (3 mL). To this mixture was added Na(OAc)3BH (5.73 g, 27 mmol). The reaction was stirred at room temperature for 4 h. To the reaction mixture was added aq. NaHC03, and the resultant mixture was extracted with CH2CI2. The organic layer was dried over Na2S04 and concentrated. Purification by flash column chromatography (silica gel, 2 % MeOH/EtOAc +0.5% TEA) gave compound 5b (6.5 g). 1H NMR (300 MHz, CDC13): δ 7.37-7.30 (m, 5 H), 5.13 (s, 2 H), 4.11 (m, 2 H), 3.61 (m, 5H), 3.42 (m, 1 H), 3.31 (m, 1 H), 3.15 (m, 1 H), 2.05 (m, 1 H), 1.71 (m, 1 H), 1.43 (s, 9 H).
B. (S)-tert-Butyl-3-(pyrrolidin-3-ylamino)azetidine-l-carboxylate, 5c. A solution of compound 5b (1.3 g, 3.46 mmol), 10% Pd/C (200 mg) in EtOH (50 mL) was hydrogenated under 40 psi hydrogen pressure in a Parr apparatus for 4.5 h. The reaction was filtered through a pad of diatomaceous earth and the organic solution was concentrated and dried under vacuum to give compound 5c as a thick oil (0.825 g). H NMR (300 MHz, CDC13): δ 4.10 (m, 2 H), 3.64-3.55 (m, 3 H), 3.23 (m, 1 H), 3.05 (m, 1 H), 2.97-2.85 (m, 2 H), 2.68 (m, 1 H), 1.97 (m, 1 H), 1.51 (m, 1 H), 1.43 (s, 9 H).
C. (S)-tert-Butyl-3-((l-benzoylpyrrolidin-3-yl)amino)azetidine-l-carboxylate, 5d. To a solution of compound 5c (1 g, 4.14 mmol), compound 4a (0.557 g, 4.56 mmol), and Et3N (1.27 mL, 8.28 mmol) in CH2C12 (20 mL) was added HATU (2.05 g, 5.38 mmol). The reaction mixture was stirred at room temperature for 18 h. The resultant mixture was diluted with CH2C12 and washed with aq. NaHC03. The organic phase was dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 5% MeOH/EtOAc+ 0.5 TEA%) gave compound 5d (0.96 g). MS m/z (M+Na+) 368.0.
D. (S)-(3-(Azetidin-3-ylamino)pyrrolidin-l-yl)(phenyl)methanone, 5e. To a solution of compound 5d (0.96 g, 2.78 mmol) in MeOH (5 mL) was added HC1 solution in dioxane (4M, 10 mL) at room temperature. The mixture was stirred at room temperature for 4 h. The solvent was removed by evaporation. Ether (50 mL) was added to the residue. The off-white solid was collected by filtration, washed with hexanes, and dried under vacuum. The crude compound 5e was used in the next reaction without further purification. MS m/z (M+H+) 246.0.
E. (3S)-l-(Phenylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine, Cpd 16. To a solution of compound 5e (di-HCl salt, 300 mg, 0.934 mmol), compound 4g (0.262 g, 0.98' mmol), and Et3N (0.78 mL, 5.58 mmol) in CH2C12 (5 mL) was added HATU (74 mg, 0.194 mmol). The reaction mixture was stirred at room temperature for 18 h. The resultant mixture was diluted with CH2C12 and washed with aq. NaHC03. The organic phase was dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 5% MeOH/EtOAc+ 0.5 TEA%) gave compound 16 (400 mg). MS m/z (M+H+) 494.0. 1H NMR (400 MHz, CDC13): δ 7.84 (m, 1 H), 7.79-7.76 (m, 3 H), 7.66-7.57 (m, 4 H), 7.52-7.48 (m, 2 H), 7.43-7.40 (m, 3 H), 4.53-4.38 (m, 2 H), 4.08-3.83 (m, 3 H), 3.71-3.60 (m, 2 H), 3.46 (m, 2 H), 3.33 (m, 0.5 H), 3.22 (m, 0.5 H), 2.16-2.04 (m, 1 H), 1.83 (m, 1 H).
Following the procedure described above for Example 5 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000070_0001
Cpd Cpd Name and Data
19 ( 3S)- 1 -(Phenylcarbonyl)-N-( 1 - { [5 -(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
MS m/z (M+H+) 474
20 ( 3S)- 1 -(Phenylcarbonyl)-N-( 1 - { [6-(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
MS m/z (M+H+) 474
21 (3S)-N- { 1 -[(6-Bromo-3-chloro- 1 -benzothiophen-2 -yl)carbonyl]azetidin-3- yl} - 1 -(phenylcarbonyl)pyrrolidin-3-amine
MS w/z (M+H+) 518, 520
22 (3S)-N- { 1 -[(5 -Bromonaphthalen-2-yl)carbonyl] azetidin-3 -yl} -1 -
(phenylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 478, 480
27 ( 3S)-N-[ 1 -(9H-Fluoren-2-ylcarbonyl)azetidin-3-yl]- 1 -
(phenylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 438
28 ( 3S)-N-( 1 - { [3 -Chloro-6-(trif uoromethyl)- 1 -benzothiophen-2- yljcarbonyl} azetidin-3 -yl)- 1 -(phenylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 508
29 (3S)-N- { 1 -[(3*-Chlorobiphenyl-4-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 460
30 (3S)-N- { 1 -[(3',4*-Dichlorobiphenyl-4-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 495
35 ( 3S)- 1 -(Phenylcarbonyl)-N-( 1 - { [4'-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
MS m/z (M+H+) 494 Cpd Cpd Name and Data
36 (3S)- 1 -(Phenylcarbonyl)-N-( 1 - { [4'-(trifluoromethoxy)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
MS m/z (M+H+) 510
38 (3 S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 484, 486
(3S)-N- { 1 - [(5-Bromo- 1 -benzothiophen-2-yl)carbonyl] azetidin-3 -yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine
49 MS m/z (M+H+) 484, 486
(3S)-N- { 1 -[(3 -Bromo-1 -benzothiophen-2-yl)carbonyl] azetidin-3 -yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine
55 MS m/z (M+H+) 484, 486
(3S)-N- { 1 -[(3 -Chloro-6-f uoro- 1 -benzothiophen-2-yl)carbonyl] azetidin-3 - yl} - 1 -(phenylcarbonyl)pyrrolidin-3-amine
56 MS m/z (M+H+) 458
(J5)-N- { 1 -[(3-Methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine
68 MS m/z (M+H+) 420
(3 S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3 -yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
95 MS m/z (M+H+) 491, 493
(3 S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3 -yl} - 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
96 MS m/z (M+H+) 491, 493
(3S)-N- { 1 - [(5-Bromo- 1 -benzothiophen-2-yl)carbonyl] azetidin-3 -yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
97 MS m/z (M+H+) 491, 493 Cpd Cpd Name and Data
(3S)-N- { 1 - [(5-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
98 MS m/z (M+H+) 491, 493
(3S)-N- { 1 - [(5-Bromo- 1 -benzofuran-2-yl)carbonyl]azetidin-3-yl} - 1-
(phenylcarbonyl)pyrrolidin-3-amine
107 MS m/z (M+H+) 468, 470
(3S)-l-(l ,3-Thiazol-2-ylcarbonyl)-N-(l-{[3'-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
113 MS m/z (M+H+) 501
(3S)-l-(l ,3-Thiazol-4-ylcarbonyl)-N-(l-{[3'-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
114 MS m/z (M+H+) 501
(3S)-l-(l ,3-Thiazol-2-ylcarbonyl)-N-(l-{[4*-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
115 MS m/z (M+H+) 501
(3 S)-N-( 1 - { [3 -Fluoro-3 '-(trif uoromethyl)biphenyl-4-yl] carbonyl} azetidin-
3-yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
116 MS m/z (M+H+) 519
(3 S)-N-( 1 -{ [3 -Methyl-3 '-(trif uoromethyl)biphenyl-4-yl] carbonyl} azetidin-
3-yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
117 MS m/z (M+H+) 515
(3 S)-N-( 1 - { [2-(2-Fluorophenyl)-4-methyl- 1 ,3 -thiazol-5 - yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 -amine
134 MS m/z (M+H+) 472
(3 S)-N-( 1 - { [2-(4-Fluorophenyl)-4-methyl- 1 ,3 -thiazol-5 - yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 -amine
135 MS m/z (M+H+) 472 Cpd Cpd Name and Data
(3 S)-N-( 1 - { [2-(3 -Chlorophenyl)-4-methyl- 1 ,3 -thiazol-5- yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 -amine
136 MS m/z (M+H+) 489
(3 S)-N-( 1 - { [2-(4-Chlorophenyl)-4-methyl- 1 ,3 -thiazol-5- yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 -amine
137 MS m/z (M+H+) 489
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-(l - {[6-(trifluoromethyl)- 1 - benzothiophen-2-yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
138 MS m/z (M+H+) 481
(3S)- 1 -(1 ,3-Thiazol-4-ylcarbonyl)-N-(l - {[6-(trifluoromethyl)- 1 - benzothiophen-2-yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
139 MS m/z (M+H+) 481
(3S)-N-{l-[(6-Bromo-3-chloro-l-benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
140 MS m/z (M+H+)
(3S)-N-{l-[(6-Bromo-3-chloro-l-benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
141 MS m/z (M+H+) 525, 527
(3S)-l-(l ,3-Thiazol-4-ylcarbonyl)-N-(l-{[4*-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine
145 MS m/z (M+H+) 501
(3S)-N-(l-{[3-Chloro-6-(trifluoromethyl)-l-benzothiophen-2- yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 -amine
167 MS m/z (M+H+) 515
(3S)-N-(l-{[3-Chloro-6-(trifluoromethyl)-l-benzothiophen-2- yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-4-ylcarbonyl)pyrrolidin-3 -amine
168 MS m/z (M+H+) 515 Example 6
Figure imgf000075_0001
A. (3S)-N-Ethyl-l-(phenylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine, Cpd 53. To a solution of Compound 16 (50 mg, 0.101 mmol) in dry DMF (1 mL) was added NaH (6 mg, 0.152 mmol) and the resulting mixture was stirred at room temperature for 20 min. EtBr (0.012 mL, 0.12 mmol) was added and the reaction mixture was heated to 130 ° C overnight. The resultant mixture was diluted with EtOAc and water. The organic layer was washed with water and aq. NaHC03, dried over Na2S04, filtered, and concentrated under reduced pressure.
Purification of the residue by flash column chromatography (silica gel, 5% MeOH/EtOAc+ 0.5 TEA%) gave compound 53 (9 mg). MS m/z (M+H+) 522.0. Example 7
Figure imgf000075_0002
A. (3S)-N-Hydroxy-l-(phenylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine, Cpd 54. To a solution of Compound 16 (60 mg, 0.12 mmol) in dry CH2C12 (1 mL) was added mCPBA (77%, 33 mg, 0.146 mmol) at 0 °C and the resulting mixture was stirred at this temperature for 30 min. The reaction mixture was diluted with CH2C12 and water. The organic layer was washed with water and brine, dried over Na2S04, filtered, and concentrated under reduced pressure. Purification of the residue by flash column chromatography (silica gel, 5% MeOH/EtOAc) gave compound 54 (7 mg). MS m/z (M+Na+) 510.0, MS m/z (M+Na+) 532.0. Following the procedure described above for Example 7 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000076_0002
Example 8
Figure imgf000076_0001
A. (3S)-l-(Phenylcarbonyl)-N-{l-[(5-phenylnaphthalen-2-yl)carbonyl]azetidin- 3-yl}pyrrolidin-3-amine, Cpd 23. A mixture of cpd 22 (50 mg, 0.105 mmol), phenylboronic acid (19 mg, 0.158 mmol), Pd(dppf)Cl2.CH2Cl2 (9 mg, 0.011 mmol), Na C03 (22 mg, 0.22 mmol) in dioxane (0.8 mL) and water (0.2 mL) in a capped vial was heated at 80 °C for 6 h. The reaction mixture was diluted with EtOAc and water. The organic layer was concentrated and purified by chromatography (silica gel,
5%MeOH/EtOAc) to give compound 23 (37 mg). MS m/z (M+H+) 476.
Following the procedure described above for Example 8 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000077_0001
Cpd Cpd Name and Data
(3 S) - 1 -(Phenylcarbonyl)-N-[ 1 -( {6- [3 -(trifluoromethyl)phenyl] - 1 - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
44 MS m/z (M+H+) 550
(3S)-N- { 1 -[(5 -Phenyl- l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -
(phenylcarbonyl)pyrrolidin-3-amine
50 MS m/z (M+H+) 519
(3S)-l-(Phenylcarbonyl)-N-[l-({5-[3-(trifluoromethyl)phenyl]-l- benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
51 MS m/z (M+H+) 550
(3 S) - 1 -(Phenylcarbonyl)-N-[ 1 -( {5 - [4-(trifluoromethyl)phenyl] - 1 - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
52 MS m/z (M+H+) 550
(3S)-N- { 1 -[(3 -Phenyl- l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}- 1 -
(phenylcarbonyl)pyrrolidin-3-amine
65 MS m/z (M+H+) 482
(3 S) - 1 - ( 1 ,3 -Thiazol-2-ylcarbonyl)-N- [ 1 -( {6-[3 -(trifluoromethyl)phenyl]- 1 - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
99 MS m/z (M+H+) 557
(3 S) - 1 - ( 1 ,3 -Thiazol-4-ylcarbonyl)-N- [ 1 -( {6-[3 -(trifluoromethyl)phenyl]- 1 - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
100 MS m/z (M+H+) 557
(3 S) - 1 - ( 1 ,3 -Thiazol-2-ylcarbonyl)-N- [ 1 -( {6-[4-(trifluoromethyl)phenyl]- 1 - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
102 MS m/z (M+H+) 533
(3 S)- 1 -(Phenylcarbonyl)-N- { 1 - [(4-phenylquinazolin-7- yl)carbonyl] azetidin-3-yl} pyrrolidin-3 -amine
108 MS m/z (M+H+) 478 Cpd Cpd Name and Data
(3 S)- 1 -(Phenylcarbonyl)-N- [ 1 -( {4-[4-(trifluoromethyl)phenyl] quinazolin-7- yl} carbonyl)azetidin-3 -yl]pyrrolidin-3 -amine
109 MS m/z (M+H+) 546
(3S)-N-{l-[(4-Phenylquinazolin-7-yl)carbonyl]azetidin-3-yl}-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine
110 MS m/z (M+H+) 485
(3 S) - 1 - ( 1 ,3 -Thiazol-2-ylcarbonyl)-N- [ 1 -( {4-[4-
(trifluoromethyl)phenyl]quinazolin-7-yl}carbonyl)azetidin-3-yl]pyrrolidin- 3 -amine
111 MS m/z (M+H+) 553
(3S)-N-{l-[(4-Phenylquinazolin-7-yl)carbonyl]azetidin-3-yl}-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine
112 MS m/z (M+H+) 485
(3S)-N- { 1 -[(5 -Phenyl- l-benzofuran-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine
121 MS m/z (M+H+) 466
(3 S)-N-( 1 - { [5 -(5 -Chlorothiophen-2-yl)- 1 -benzofuran-2- yljcarbonyl} azetidin-3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3-amine
122 MS m/z (M+H+) 507
(3 S)-N- { 1 - [(6-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3 -yl} - 1 -( 1 ,3 - thiazol-4-ylcarbonyl)pyrrolidin-3-amine
124 MS m/z (M+H+) 489
(3 S) - 1 - ( 1 ,3 -Thiazol-4-ylcarbonyl)-N- [ 1 -( {6-[4-(trifluoromethyl)phenyl]- 1 - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
128 MS m/z (M+H+) 557
(3 S)-N- { 1 -[(5-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine
129 MS m/z (M+H+) 489 Cpd Cpd Name and Data
(3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-[l-({5-[3-(trifluoromethyl)phenyl]-l- benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
130 MS m/z (M+H+) 557
(3 S)-N- { 1 -[(5-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine
131 MS m/z (M+H+) 489
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-[l-({5-[3-(trifluoromethyl)phenyl]-l- benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3 -amine
132 MS m/z (M+H+) 557
(3S)-N- { 1 -[(3-Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
146 MS m/z (M+H+) 524
(3S)-N- { 1 -[(3-Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
147 MS m/z (M+H+) 524
(3S)-N-[ 1 -( {3-Chloro-6-[3-(trifluoromethyl)phenyl]-l -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
148 MS m/z (M+H+) 592
(3S)-N-[ 1 -( {3-Chloro-6-[3-(trifluoromethyl)phenyl]-l -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
149 MS m/z (M+H+) 592
(3S)-N-[ 1 -( {3-Chloro-6-[4-(trifluoromethyl)phenyl]-l -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
150 MS m/z (M+H+) 592
(3S)-N-[ 1 -( {3-Chloro-6-[4-(trifluoromethyl)phenyl]-l -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
151 MS m/z (M+H+) 592 Exam le 9
Figure imgf000081_0001
A. 5-Chloro-3-methylbenzo[b]thiophene-2-carbonyl chloride, 9b. To compound 9a (0.651 g, 2.87 mmol) in CH2C12 (15 mL) at room temperature was added (C0C1)2 (0.267 mL, 3.16 mmol), followed by DMF (0.0556 mL, 0.718 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was then concentrated to give compound 9b, which was used in the next reaction without further purification.
B . (3 S)-N- { 1- [(5-Chloro-3-methyl- l-benzothiophen-2-yl)carbonyl] azetidin-3- yl}-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 37 and N-{l-[(5-Chloro-3-methyl-l- benzothiophen-2-yl)carbonyl]azetidin-3-yl}-N-[(3S)-l-(phenylcarbonyl)pyrrolidin-3- yljformamide, Cpd 81. To a solution of compound 5e (320 mg, 1.006 mmol) and Et3N (0.56 mL, 4.02 mmol) in CH2C12 (10 mL) at 0 °C was added a solution of compound 9b (271 mg, 1.106 mmol) in CH2C12 (1 mL). The reaction was slowly warmed up to room temperature over 4.5 h, diluted with CH2C12, and washed with aq. NaHC03. The organic layer was dried over Na S04 and concentrated. Purification by flash column
chromatography (silica gel, 3% MeOH/CH2Cl2) afforded cpd 37 (135 mg), MS m/z (M+H+) 454 and cpd 81 (70 mg). MS m/z (M+H+) 483. Following the procedure described above for Example 9 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000082_0002
Example 10
Figure imgf000082_0001
A. (3S)-N-(l-{[5-(3-Fluorophenyl)-3-methyl-l-benzothiophen-2- yl]carbonyl}azetidin-3-yl)-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 93. A mixture of cpd 37 (44 mg, 0.0991 mmol), 3 -fluorophenyl boronic acid 10a (27 mg, 0.19 mmol), Tris(dibenzylideneacetone)dipalladium (Pd2(dba)3)(8.8 mg), 2-Dicyclohexylphosphino- 2',4',6'-triisopropylbiphenyl (XPhos) (11 mg) and K3P04 (41 mg) in t-BuOH (0.8 mL) in a capped vial under a N2 atmosphere was heated at 100 °C for 3 h. The reaction was cooled to room temperature and diluted with water and EtOAc. The organic phase was washed with aq. NaHC03. The organic layer was dried over Na2S04 and concentrated.
Purification by flash column chromatography (silica gel, 3% MeOH/CH2Cl2) afforded cpd 93 (40 mg). MS m/z (M+H+) 514
Following the procedure described above for Example 10 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000083_0001
Cpd Cpd Name and Data
(3S)-N-[1 - ( {3-Methyl-5-[4-(trifiuoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
91 MS m/z (M+H+) 571.3
(3S)-N-{l-[(3-Methyl-5-phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
92 MS m/z (M+H+) 503
(3 S)-N-( 1 - { [5 -(4-Fluorophenyl)-3 -methyl- 1 -benzothiophen-2- yljcarbonyl} azetidin-3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3-amine
94 MS m/z (M+H+) 514
(3S)-N-{l-[(3-Methyl-5-phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
123 MS m/z (M+H+) 503
(3S)-N-[1 - ( {3-Methyl-5-[3-(trifiuoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
125 MS m/z (M+H+) 571
Exam le 10a
Figure imgf000084_0001
A. (3S)-N-(l-{[3-Methyl-6-(trifluoromethyl)-l-benzothiophen-2- yl]carbonyl}azetidin-3-yl)-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 80. A mixture of compound 28 (60 mg, 0.118 mmol), methylboronic acid (14 mg, 0.236 mmol), Pd(OAc)2 (2.65 mg, 0.012 mmol), 2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) (12 mg, 0.0295 mmol), and K3P04 (50 mg, 0.236 mmol) in toluene (0.8 mL) was heated to 100 °C for 3 h in a sealed reaction vessel. The reaction was diluted with EtOAc and water. The organic layer was concentrated and purified by flash column
chromatography (silica gel, 10% EtOAc/hexanes) to give cpd 80. MS m/z (M+H+) 488.
Following the procedure described above for Example 10a and substituting the appropriate reagents, starting materials and purification methods known to those skilled the art, the following compounds of the present invention were prepared:
Figure imgf000085_0001
Example 11
Figure imgf000086_0001
A. l-(5-Chloro-2-fluoro-phenyl)-2,2,2-trifluoro-ethanone, 11c. To a solution of LDA (2.0 M in THF/heptane/ethylbenzene, 12.6 mL, 25.3 mmol) in dry THF was slowly added l-fluoro-4-chloro-benzene 11a (2.45 mL, 23.0 mmol) at -78 °C. The mixture was stirred for 1 h at -78 °C and ethyl trifluoroacetate lib (3.02 mL, 25.3 mmol) was added. The reaction mixture was allowed to warm to room temperature overnight and was quenched with saturated aqueous NH4C1 solution. The mixture was extracted with EtOAc. The organic extracts were concentrated and purified by flash column chromatography (silica gel, 15% EtOAc/hexanes) to give a mixture of the compound 11c along with a regio-isomeric by-product, l-(5-fluoro-2-chloro-phenyl)-2,2,2-trifluoro-ethanone, in a ratio of 5: 1 (11c is the major product).
B. Methyl 5-chloro-3-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, lie. A solution of compound 11c (1.5 g, 6.62 mmol), methyl 2-mercaptoacetate lid (0.6 mL, 6.62 mmol), and Et3N (1.2 mL, 8.6 mmol) in acetonitrile (12 mL) was heated at 75 °C for 4 h. The reaction was diluted with EtOAc and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 10% EtOAc/hexanes) to provide compound lie.
C. 5-Chloro-3-trifluoromethyl-benzo[b]thiophene-2-carboxylic acid, llf. A mixture of compound lie (390 mg, 1.33 mmol) and LiOH (159 mg, 6.65 mmol) in THF/MeOH/]¾0 (4/4/4mL) was stirred for 4 h. The reaction was concentrated under reduced pressure and then water was added to the residue. The aqueous mixture was acidified with IN HC1 to pH ~ 4. A white precipitate was filtered and washed with water and Et20. The crude product was dried under vacuum to give compound llf which was used without purification.
D. 5-Chloro-3-trifluoromethyl-benzo[b]thiophene-2-carbonyl chloride, llg. The title compound llg was prepared using the method described in Example 9, substituting compound llf for compound 9a in Step A.
E. (3S)-N-(l-{[5-Chloro-3-(trifluoromethyl)-l-benzothiophen-2- yl]carbonyl}azetidin-3-yl)-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 180. The title compound Cpd 180 was prepared using the method described in Example 9, substituting compound llg for compound 9b in Step B. MS m/z (M+H+) 508.
Following the procedure described above for Example 11 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000087_0002
Example 11a
Figure imgf000087_0001
1 1 b
F. l-(4-Chloro-2-fluoro-phenyl)-2,2,2-trifluoro-ethanone, Hi. To a solution of n-BuLi (1.6 M in hexanes, 2.93 mL, 4.68 mmol) in dry THF was slowly added 4-chloro-2- f uoro-l-iodo-benzene llh (31.0 g, .9 mmol) at -78 °C under N2. The mixture was stirred for 1 h at -78 °C and ethyl trifluoroacetate lib (0.51 mL, 4.29 mmol) was added. The reaction was allowed to warm to room temperature overnight and was quenched with saturated aqueous NH4C1 solution. The mixture was extracted with EtOAc. The organic extracts were concentrated and purified by flash column chromatography (silica gel, 15% EtOAc/hexanes) to give compound Hi.
G. Methyl 6-chloro-3-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, llj. The title compound llj was prepared using a similar method to that described in Example 11, substituting compound Hi for compound 11c in Step B.
Following the procedure described above for Example 11, Steps C - E, and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000088_0002
Example 1 lb
Figure imgf000088_0001
H. Methyl 6-phenyl-3-(trifluoromethyl)benzo[b]thiophene-2-carboxylate, Ilk.
The title compound Ilk was prepared using a similar method to that described in Example 10a, substituting compound llj for compound 28 and phenyl boronic acid 2a for methyl boronic acid in Step A.
Following the procedure described above for Example 11, Steps C - E, and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000089_0002
Example 12
Figure imgf000089_0001
A. Methyl 3-cyclopropyl-6-fluorobenzo[b]thiophene-2-carboxylate, 12c. A mixture of methyl 3-chloro-6-fluorobenzo[b]thiophene-2-carboxylate 12a (150 mg, 0.613 mmol), cyclopropylboronic acid 12b (79 mg, 0.92 mmol), Pd(OAc)2 (20 mg, 0.09 mmol), SPhos (88 mg, 0.215 mmol), and K3P04 (0.26 g, 1.23 mmol) in toluene (2 mL) was heated to 100 °C for 3 h in a sealed reaction vessel. The reaction was diluted with EtOAc and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 10% EtOAc/hexanes) to give compound 12c.
B. 3-Cyclopropyl-6-fluoro-benzo[b]thiophene-2-carboxylic acid, 12d. The title compound 12d was prepared using the method described in Example 11, substituting compound 12c for compound_llf in Step C.
C. 3-Cyclopropyl-6-fluoro-benzo[b]thiophene-2-carbonyl chloride, 12e. The title compound 12e was prepared using the method described in Example 9, substituting compound 12d for compound 9a in Step A.
D. l-{l-[(3-Cyclopropyl-6-fluoro-l-benzothiophen-2-yl)carbonyl]azetidin-3- yl}-4-(l,3-thiazol-2-ylcarbonyl)piperazine, Cpd 70. The title compound Cpd 70 was prepared using the method described in Example 9, substituting compound 12e for compound 9b in Step B. MS m/z (M+H+) 464.
Following the procedure described above for Example 12 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following intermediate compounds were prepared:
Figure imgf000090_0001
Following the procedure described above for Example 12 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Cpd Cpd Name and Data Cpd Cpd Name and Data
(3S)-N- { 1 -[(3-Cyclobutyl-6-fluoro- 1 -benzothiophen-2-yl)carbonyl] azetidin-3 - yl} - 1 -(phenylcarbonyl)pyrrolidin-3-amine
79 MS m/z (M+H+) 478
(3S)-N- { 1 -[(6-Fluoro-3 -methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(phenylcarbonyl)pyrrolidin-3-amine
86 MS m/z (M+H+) 438
(3S)-N- { 1 -[(6-Fluoro-3 -methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
87 MS m/z (M+H+) 445
(3S)-N- { 1 -[(6-Fluoro-3 -methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
88 MS m/z (M+H+) 445
(3S)-N-(l-{[5-Methyl-3-(trifluoromethyl)-l-benzothiophen-2- yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-4-ylcarbonyl)pyrrolidin-3 -amine
184 MS m/z (M+H+) 495
(3S)-N-(l-{[6-Methyl-3-(trifluoromethyl)-l-benzothiophen-2- yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-4-ylcarbonyl)pyrrolidin-3 -amine
185 MS m/z (M+H+) 495
(3S)-N-(l-{[6-Methyl-3-(trif uoromethyl)-l-benzothiophen-2- yl] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 -amine
186 MS m/z (M+H+) 495
Example 13
Figure imgf000092_0001
A. Methyl 5-Phenyl-benzo[b]thiophene-2-carboxylate, 13b. A mixture of compound 13a (542.3 mg, 2 mmol), phenyl boronic acid (2a, 268.2 mg, 2.2 mmol), Pd(dppf)Cl2.CH2Cl2 (98 mg, 0.12 mmol), and K2C03 (414.6 mg, 3 mmol), in a dioxane (4 mL) / water (1 mL) mixture, was placed in a capped vial and heated at 80 °C overnight. The reaction mixture was then diluted with EtOAc and water. The organic layer was concentrated under reduced pressure and purified by flash column chromatography (silica gel, 2-10% EtO Ac/heptane) to give compound 13b (510 mg). MS m/z (M+H+) 269.1.
B. 5-Phenyl-benzo[b]thiophene-2-carboxylic acid, 13c. A solution of compound 13b (510 mg, 1.9 mmol) and LiOH.H20 (319 mg, 7.6 mmol) in THF/H20 (10/10 mL) was stirred at room temperature overnight. The resulting mixture was concentrated and diluted with water. The water layer was acidified with IN aqueous HC1 to pH~4 and extracted with CH2C12. The organic solution was dried over Na2S04 and concentrated to give compound 13c (479 mg), which was used in the next reaction without further purification. MS w/z (M+H+) 255.0.
C. 3-Fluoro-5-phenyl-benzo[b]thiophene-2-carboxylic acid, 13d. To a solution of compound 13c (507 mg, 1.99 mmol) in THF (8 mL) at -70 °C was added n- nU (1.6 M in hexane, 2.62 mL, 4.19 mmol). The mixture was stirred at -70 °C for 1 h, then a solution of N-fluorobenzenesulfonimide (817.3 mg, 2.59 mmol) in THF (2 mL) was slowly added. The reaction mixture was allowed to warm to room temperature and was stirred overnight. The resulting mixture was partitioned between dilute aqueous HC1 and EtOAc. The organic solution was washed with water and brine, dried over Na2S04, and concentrated. The residue was tritrated from CH2C12, filtered and dried the solid to give compound 13d (391.9 mg). MS m/z (M+H+) 273.0.
D. 3-Fluoro-5-phenyl-benzo[b]thiophene-2-carbonyl chloride, 13e. To a solution of compound 13d (136.2 mg, 0.5 mmol) in CH2C12 (5 mL) at room temperature was added (COCl)2 (0.064 mL, 0.75 mmol), followed by DMF (0.01 mL, 0.125 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was then concentrated to give compound 13e as a light pink powder, which was used in the next reaction without further purification.
E . (3S)-N- { 1- [(3-Fluor o-5-phenyl-l -benzothiophen-2-yl)carbonyl] azetidin-3- yl}-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 173. To a solution of compound 5e (42.7 mg, 0.131 mmol) and Et3N (0.07 mL, 0.5 mmol) in CH2C12 (2 mL) at 0 °C was slowly added a solution of compound 13e (36.3 mg, 0.125 mmol) in CH2C12 (1 mL). The reaction was stirred at 0 °C for 2 h, diluted with CH2C12, and washed with aqueous NaHC03. The organic layer was dried over Na2S04 and concentrated. The residue was purified by flash column chromatography (silica gel, % MeOH/EtOAc) to give compound Cpd 173 (16.7 mg). MS m/z (M+H+) 500.
Following the procedure described above for Example 13 and substituting the appropriate reagents, starting materials and purification methods known to those skilled the art, the following compounds of the present invention were prepared:
Figure imgf000093_0001
Cpd Cpd Name and Data
(3S)-N-{l-[(3-Fluoro-5-phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
172 MS m/z (M+H+) 507
(3 S)-N- [ 1 -( {3 -Fluoro-5 - [4-(trifluoromethyl)phenyl] - 1 -benzothiophen-2- yl} carbonyl)azetidin-3 -yl] - 1 -( 1 ,3 -thiazol-2-ylcarbonyl)pyrrolidin-3 -amine
174 MS m/z (M+H+) 575
(3 S)-N- [ 1 -( {3 -Fluoro-5 - [4-(trif uoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
175 MS m/z (M+H+) 575
(3 S)-N- [ 1 -( {3 -Fluoro-5 - [4-(trif uoromethyl)phenyl] - 1 -benzothiophen-2- yl} carbonyl)azetidin-3-yl]- 1 -(phenylcarbonyl)pyrrolidin-3 -amine
176 MS m/z (M+H+) 568
(3S)-N-[l-({3-Fluoro-6-[4-(trif uoromethyl)phenyl]-l-benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
177 MS m/z (M+H+) 575
(3S)-N-[l-({3-Fluoro-6-[4-(trif uoromethyl)phenyl]-l-benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
178 MS m/z (M+H+) 575
(3S)-N-[l-({3-Fluoro-6-[4-(trif uoromethyl)phenyl]-l-benzothiophen-2- yl} carbonyl)azetidin-3-yl]- 1 -(phenylcarbonyl)pyrrolidin-3 -amine
179 MS m/z (M+H+) 568
Example 14
Figure imgf000095_0001
14c
A. 3-Fluoro-6-trifluoromethyl-benzo[b]thiophene-2-carboxylic acid, 14b. A solution of 6-trifluoromethyl-benzo[b]thiophene-2-carboxylic acid 14a (2.031 mmol, 0.50 g) in THF (8 mL) at -70 °C was treated with a 1.6 M solution of n-BuLi in hexanes (2.66 mL, 4.26 mmol). After 1 h at -70 °C, N-fluorobenzenesulfonimide (0.833 g, 2.64 mmol) in THF (2 mL) was slowly added and the reaction was warmed to room temperature. After 1 h the mixture was partitioned between dilute aqueous HC1 and EtOAc. The organic layer was washed with water and brine and then concentrated. The residue was triturated with CH2CI2. The off-white precipitate was collected by filtration to provide compound 14b.
B. 3-Fluoro-6-trifluoromethyl-benzo[b]thiophene-2-carbonyl chloride, 14c. The title compound 14c was prepared using the method described in Example 11, substituting compound 14b for compound lie in Step C.
C. (3S)-N-(l-{[3-Fluoro-6-(trifluoromethyl)-l-benzothiophen-2- yl]carbonyl}azetidin-3-yl)-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 89. The title compound Cpd 89 was prepared using the method described in Example 13, substituting compound 14c for compound 13e in Step E. MS m/z (M+H+) 492. Example 15
Figure imgf000096_0001
A. 1-fert-Butyl 6-methyl 3-(3-trifluoromethylphenyl)-lH-indole-l,6- dicarboxylate, 15c. A mixture of compound 15a (1.00 g, 2.49 mmol), 3- trifluoromethylphenyl boronic acid 15b (710 mg, 3.74 mmol), Pd(OAc)2 (44.8 mg, 0.2 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos, 204.7 mg, 0.5 mmol), and K3PO4 (1.06 g, 4.99 mmol), in toluene (5 mL) was placed in a capped vial and heated at 90 °C under N2 for 3 h. The reaction mixture was then diluted with EtO Ac and water. The organic layer was washed with brine, concentrated under reduced pressure, and purified by flash column chromatography (silica gel, 2-10% EtO Ac/heptane) to give compound 15c as a light yellow solid, which was further recrystallized from heptane to obtain a white solid (900 mg). MS m/z (M+H+) 420.0.
B. Methyl 3-(3-trifluoromethylphenyl)-lH-indole-6-carboxylate, 15d. To a solution of compound 15c (900 mg, 2.14 mmol) in CH2C12 (5 mL) was added
trifluoroacetic acid (2 mL) at room temperature. The mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated to give compound 15d (840 mg) as a white solid. MS m/z (M+H+) 320.0. C. 3-(3-Trifluoromethyl-phenyl)-lH-indole-6-carboxylic acid, 15e. A solution of compound 15d (TFA salt, 500 mg, 1.15 mmol), and LiOH.H20 (132.7 mg, 3.16 mmol) in THF/H20 (10 mL/10 mL) was stirred at 45 °C overnight. The resulting mixture was concentrated and diluted with water. The aqueous layer was acidified with IN aqueous HC1 to pH~4 and extracted with CH2C12. The organic solution was dried over Na2S04 and concentrated to give compound 15e (330 mg), which was used in the next reaction without further purification. MS m/z (M+H+) 306.0.
D . (3S)- l-(Phenylcarbonyl)-N- [ l-({3- [3-(trifluoromethyl)phenyl] -1 H-indol-6- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine, Cpd 103. The titled compound 103 was prepared using the method described in Example 5, substituting compound 15d for compound 4g in Step F. MS m/z (M+H+) 533.
Following the procedure described above for Example 15 Step A-C, and substituting the appropriate reagents, starting materials and purification methods known to those killed in the art, the following intermediate compounds were prepared:
Figure imgf000097_0001
Following the procedure described above for Example 15 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000097_0002
Cpd Cpd Name and Data
(3 S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {3-[4-(trifluoromethyl)phenyl]- 1 H-indol-6- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine
101 MS m/z (M+H+) 533
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-[l-({3-[4-(trifluoromethyl)phenyl]-lH- indol-6-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine
104 MS m/z (M+H+) 540
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-[l-({3-[3-(trifluoromethyl)phenyl]-lH- indol-6-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine
105 MS m/z (M+H+) 540
(3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-[l-({3-[3-(trifluoromethyl)phenyl]-lH- indol-6-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine
106 MS m/z (M+H+) 540
(3S)-N- { 1 -[(3-Phenyl- lH-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3 -amine
187 MS m/z (M+H+) 472
(3S)-N- { 1 -[(3-Phenyl- lH-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3 -amine
188 MS m/z (M+H+) 472
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine
189 MS m/z (M+H+) 490
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine
190 MS m/z (M+H+) 490
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine
191 MS m/z (M+H+) 483 Cpd Cpd Name and Data
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine
202 MS m/z (M+H+) 490
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine
203 MS m/z (M+H+) 490
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine
204 MS m/z (M+H+) 483
Example 15a
Figure imgf000099_0001
E. Methyl 3-(3-trifluoromethyl-phenyl)-l-methyl-lH-indole-6-carboxylate,
15f. To a solution of compound 15d (300 mg, 0.78 mmol) in DMF (3 mL) was added NaH (60% in mineral oil, 68.9 mg, 1.72 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min, then CH3I (0.053 mL, 0.86 mmol) was added and stirring continued at 0 °C for another 1 h. The resulting mixture was diluted with EtOAc and water. The organic layer was washed with brine and concentrated. The residue was recrystallized from heptane, filtered and the solid dried to give compound 15f (265 mg) as a light yellow solid. MS m/z (M+H+) 284.1.
F. 3-(3-Trifluoromethyl-phenyl)-l-methyl-lH-indole-6-carboxylic acid, 15g. A solution of compound 15f (264 mg, 0.93 mmol), and LiOH.H20 (156.4 mg, 3.73 mmol) in THF/H20 (lOmL/10 mL) was stirred at 45 °C for 5 h. The resulting mixture was concentrated and diluted with water. The aqueous layer was acidified with IN aqueous HC1 to pH~4 and extracted with CH2C12. The organic solution was dried over Na2S04 and concentrated to give compound 15g (252 mg), which was used in the next reaction without further purification. MS m/z (M+H+) 270.1.
Following the procedure described above for Example 15a and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following intermediate compounds were prepared:
Figure imgf000100_0001
Following the procedure described above for Example 15a and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000100_0002
Cpd Cpd Name and Data
(3S)-N-[l-({l-Methyl-3-[4-(trifluoromethyl)phenyl]-lH-indol-6- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
165 MS m/z (M+H+) 554
(3S)-N-[l-({l-Methyl-3-[3-(trifluoromethyl)phenyl]-lH-indol-6- yl} carbonyl)azetidin-3-yl]- 1 -(phenylcarbonyl)pyrrolidin-3 -amine
166 MS m/z (M+H+) 547
(3 S)-N- { 1 - [( 1 -Methyl-3 -phenyl- 1 H-indol-6-yl)carbonyl]azetidin-3 -yl} - 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine
169 MS m/z (M+H+) 486
(3 S)-N- { 1 - [( 1 -Methyl-3 -phenyl- 1 H-indol-6-yl)carbonyl]azetidin-3 -yl} - 1 -( 1 ,3 - thiazol-4-ylcarbonyl)pyrrolidin-3-amine
170 MS m/z (M+H+) 486
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3- yl)-l -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
192 MS m/z (M+H+) 504
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3- yl)-l -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
193 MS m/z (M+H+) 504
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3- yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine
194 MS m/z (M+H+) 497
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3- yl)-l -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
205 MS m/z (M+H+) 504
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3- yl)-l -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
206 MS m/z (M+H+) 504 Cpd Cpd Name and Data
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3- y 1)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine
207 MS m/z (M+H+) 497
Example 16
Figure imgf000102_0001
A. tert-Butyl (l-(4-bromobenzoyl)azetidin-3-yl)carbamate, Cpd 16c. To a solution of compound 16a (1.02 g, 5.92 mmol) and Et3N (1.24 mL, 8.88 mmol) in CH2CI2 (25 mL) at 0 °C was slowly added a solution of compound 16b (1.36 g, 6.22 mmol) in CH2CI2 (5 mL). The reaction was stirred at 0 °C for 2 h, diluted with CH2CI2, and washed with aqueous NaHC03. The organic layer was dried over Na2S04 and concentrated. The residue was purified by flash column chromatography (silica gel, 35% EtOAc/hexanes) to give compound 16c (810 mg). MS m/z (M+H+) 356.0.
B. (3-Aminoazetidin-l-yl)(4-bromophenyl)methanone, Cpd 16d. To a solution of compound 16c (810 mg, 2.28 mmol) in CH2C12 (10 mL) was added trifluoroacetic acid (7 mL) at room temperature. The mixture was stirred at room temperature for 2 h. The resulting mixture was concentrated. To the residue was added CH2C12 and IN aqueous NaOH solution until the the pH of the aqueous layer was approximately 8. The organic phase was washed with brine, dried over anhydrous Na2S04 and concentrated under reduced pressure to give compound 16d (570 mg). MS m/z (M+H+) 254, 256.
C. tert-Butyl 3-((l-(4-bromobenzoyl)azetidin-3-yl)amino)-4-fluoropyrrolidine- 1-carboxylate, 16f. The title compound 16f was prepared using the method described in Example 5, substituting compound 16d for compound 5a and compound 16e for compound le in Step A. MS m/z (M+H+) 441, 443.
D. (4-Bromophenyl)(3-((4-fluoropyrrolidin-3-yl)amino)azetidin-l- yl)methanone, 16g. The title compound 16g was prepared using the method described in Example 5, substituting compound 16f for compound 5d in Step E. MS m/z (M+H+).
E. (3-((l-Benzoyl-4-fluoropyrrolidin-3-yl)amino)azetidin-l-yl)(4-bromophenyl) methanone, 16h. The title compound was prepared using the method described in Example 5, substituting compound 16g for compound 5e and compound 4a for compound 4g in Step F. MS m/z (M+H+) 341, 343.
F. (3-((l-Benzoyl-4-fluoropyrrolidin-3-yl)amino)azetidin-l-yl)(3'- (trifluoromethyl)-[l,l'-biphenyl]-4-yl)methanone, Cpd 59, (3-(((3R)-l-benzoyl-4- fluor opyr rolidin-3-yl)amino)azetidin- l-yl)(3 '-(trifluoromethyl)- [1 , 1 '-biphenyl] -4- yl)methanone, Cpd 62 and (3-(((3S)-l-benzoyl-4-fluoropyrrolidin-3-yl)amino)azetidin- l-yl)(3'-(trifluoromethyl)-[l,l'-biphenyl]-4-yl)methanone, Cpd 63. The title compounds were prepared using the method described in Example 8, substituting compound 16h for compound 22 and compound 15b for phenyl boronic acid. The crude products were purified by column chromatography (silica gel, 10% MeOH/EtOAc + 0.5% TEA) to give compound 59. Compound 59 was further separated by a chiral column
(Chiralpak AD-H, 50% IPA/hexanes, 0.65 mL/min) to give the first fraction as compound 62 MS m/z (M+H+) 548 and the second fraction as compound 63 MS m/z (M+H+) 512. Following the procedure described above for Example 16 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000104_0002
Example 17
Figure imgf000104_0001
A. Methyl 4-(hydroxy(4-(trifluoromethyl)phenyl)methyl)benzoate, 17c. To a solution of methyl 4-iodobenzoate 17a (2.1 g, 8 mmol) in 10 mL of dry THF was added i- propyl magnesium chloride (2M in THF, 4.2 mL, 8.4 mmol) dropwise under N2 at -20 °C. The solution was stirred for 30 min. The THF solution was then added slowly to a solution of 4-trifluoromethylbenzaldehyde 17b (1.1 mL, 8 mmol) in THF (20 mL) at -40 °C. After 20 min, the reaction mixture was allowed to warm up slowly to room temperature. The reaction was quenched with saturated aqueous NH4C1 and extracted with EtOAc. The organic layer was concentrated and purified by flash column chromatography (silica gel, 15% EtOAc/hexanes) to give compound 17c as a white solid.
B. 4-(Hydroxy(4-(trifluoromethyl)phenyl)methyl)benzoic acid, 17d. The title compound 17d was prepared using the method described in Example 13, substituting compound 17c for compound 13b in Step B.
C. ((3-(((S)-l-Benzoylpyrrolidin-3-yl)amino)azetidin-l-yl)(4-(hydroxy(4- (trifluoromethyl)phenyl)methyl)phenyl)methanone, Cpd 67. The title compound 67 was prepared using the method described in Example 5, substituting compound 16g for compound 5e and compound 4a for compound 4g in Step F. MS m/z (M+H+) 526.
Example 17a
Figure imgf000105_0001
A. 4 Methyl 4-(fluoro(4-(trifluoromethyl)phenyl)methyl)benzoate, 17d. To a solution of compound 63c (300 mg, 0.97 mmol) in CH2C12 was added DAST (0.133 mL, 1.015 mmol) dropwise at -78 °C under N2. The reaction was kept at -78 °C for 30 min and then quenched with aqueous NaHC03 solution at 0 °C. The reaction was diluted with CH2CI2 and the organic solution was concentrated. The crude material was purified flash column chromatography (silica gel, 10% EtOAc/hexanes) to give compoundl7d.
B. 4-(Fluoro(4-(trifluoromethyl)phenyl)methyl)benzoic acid, 17e. The titlecompound 17e was prepared using the method described in Example 13, substituting compound 17d for compound 13b in Step B.
C. N-{l-[(4-{Fluoro[4- (trifluoromethyl)phenyl]methyl}phenyl)carbonyl]azetidin-3-yl}-l- (phenylcarbonyl)pyrrolidin-3-amine, Cpd 69. The title compound 69 was prepared using the method described in Example 5, substituting compound 17e for compound 4g in Step F. MS m/z (M+H+) 526.
Example 17b
Figure imgf000106_0001
A. Methyl 4-(4-(trifluoromethyl)benzyl)benzoate , Cpd 17d. A solution of compound 17c (250 g, 0.806 mmol), 10% Pd/C (50 mg) in EtOH (18 mL) and AcOH (2 mL) was hydrogenated under 40 psi hydrogen pressure in a Parr apparatus overnight. The reaction was filtered through a pad of diatomaceous earth and the organic solution was concentrated. The crude product was purified by flash column chromatography (silica gel, 10% EtOAc/hexanes) to give compound 17d (120 mg) and unreacted starting material compound 17c (100 mg). B. 4-(4-(trifluoromethyl)benzyl)benzoic acid , Cpd 17f. The title compound 17f was prepared using the method described in Example 13, substituting compoundl7d for compound 13b in Step B.
C. (S)-(3-((l-Benzoylpyrrolidin-3-yl)amino)azetidin-l-yl)(4-(4- (trifluoromethyl) benzyl)phenyl)methanone, Cpd 77. The title compound 77 was prepared using the method described in Example 5, substituting compound 17f for compound 4g in Step F. MS m/z (M+H+) 508.
Following the procedure described above for Example 17b and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000107_0002
Exam le 17c
Figure imgf000107_0001
dioxane
A. Methyl 4-(3-(trifluoromethyl)benzyl)benzoate, Cpd 17i. A mixture of 4- bromomethyl-benzoic acid methyl ester 17h (1 g, 4.37 mmol), 3- trifluoromethylphenylboronic acid 15b (1 g, 5.25 mmol) and Pd(PPh3)4 (50 mg, 0.044 mmol) in dioxane (15 mL) was stirred at room temperature for 1 min. An aqueous solution of Na2C03 (2M, 4 mL) was added. The resulting solution was heated at 90 °C for 5 h and was then cooled to room temperature. The reaction was partitioned between EtOAc and water. The organic phase was concentrated and purified by flash column chromatography (silica gel, 5% EtOAc/hexanes) to give compound 17i. Following the procedure described above for Example 17b, Step B and Step C and substituting compound 17i for compound 17d, the following compounds of the present invention were prepared:
Figure imgf000108_0002
Example 18
A. Methyl 4-(2-phenyl-l,3-dithiolan-2-yl)benzoate, 18b. Methyl 4- benzoylbenzoate 18a (0.50 g, 2.08 mmol) and BF3.(OAc)2 (0.73 mL, 5.2 mmol) dissolved in dry CH2C12 under a N2 atmosphere. Ethane- 1,2-dithiol (0.333 mL, 3.95 mmol) was added and the solution was stirred overnight. The reaction mixture was partitioned between CH2CI2 and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 10% EtOAc/hexanes) to afford compound 18b.
B. Methyl 4-(difluoro(phenyl)methyl)benzoate, 18c. l-Chloromethyl-4-fluoro- l,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (Selectfluor) (381 mg, 1.07 mmol) and HF-pyridine reagent (1.5 mL, HF: Pyridine = 70:30 wt%) were dissolved in CH2C12 (4 mL) in a polyethylene bottle and cooled to 0 °C. A solution of compound 18b (162 mg, 0.512 mmol) in CH2CI2 (2 mL) was slowly added and the mixture was stirred for 45 min at room temperature. The solution was extracted with CH2CI2, and the combined organics were dried over anhydrous Na2S04 and concentrated. A crude product was purified by flash column chromatography (silica gel, 5% EtOAc/hexanes) to afford compound 18c as aclear oil.
C. 4-(Difluoro(phenyl)methyl)benzoic acid, 18d. The title compound 18d was prepared using the method described in Example 13, substituting compound 17c for compound 13b in Step B.
D. (3S)-N- [l-({4- [Difluoro(phenyl)methyl] phenyl} carbonyl)azetidin-3-yl] -1- (phenylcarbonyl)pyrrolidin-3-amine, Cpd 73. The title compound 73 was prepared using the method described in Example 5, substituting compound 18d for compound 4g in Step F. MS m/z (M+H+) 476.
Example 19
Figure imgf000110_0001
A. Methyl l-(4-trifluoromethylphenyl)-indole-5-carboxylate, 19c. A mixture of methyl indole-5-carboxylate 19a (2 g, 11.4 mmol), l-bromo-4-trifluoromethyl-benzene 19b (2.8 g, 12.5 mmol), Cul (0.22 g, 1.14 mmol), trans-N, N'-dimethylcyclohexane-l,2- diamine (0.54 mL, 3.43 mmol), and K3PO4 (6.06 g, 28.5 mmol) in toluene (12 mL) was heated at 110 °C for 7 h. The reaction mixture was diluted with CH2CI2 and filtered. The solution was concentrated and the residue was purified by flash column chromatography (silica gel, 20% EtO Ac/heptane) to give compound 19c (3.0 g).
B. (4-Trifluoromethylphenyl)-indole-5-carboxylate acid, 19d. The title compound 19d was prepared using the method described in Example 15, substituting compound 19c for compound 15d in Step C.
C. (3S)-l-(Phenylcarbonyl)-N-[l-({l-[4-(trifluoromethyl)phenyl]-lH-indol-5- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine, Cpd 154. The title compound 154 was prepared using the method described in Example 5, substituting compound 19d for compound 4g in Step F. MS m/z (M+H+) 533.
Following the procedure described above for Example 19, Steps A and B, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following intermediate compounds were prepared:
Figure imgf000111_0001
Following the procedure described above for Example 19 and substituting the appropriate reagents, starting materials and purification methods known to those skilled the art, the following compounds of the present invention were prepared:
Figure imgf000111_0002
Cpd Cpd Name and Data
159 (3 S)-N-(l - { [ 1 -(4-Fluorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3-yl)- 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 490
160 (3 S)-N-(l - { [ 1 -(4-Fluorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3-yl)- 1 -( 1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 490
161 (3 S)-N-(l - { [ 1 -(4-Fluorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3-yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 483
214 (3 S)-N-( 1 - { [ 1 -(4-Fluorophenyl)- 1 H-indol-4-yl]carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 490
215 (3 S)-N-( 1 - { [ 1 -(4-Fluorophenyl)- 1 H-indol-4-yl]carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-4-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 490
218 (3S)-N-(1 - {[ 1 -(3-Fluorophenyl)- lH-indol-3-yl]carbonyl} azetidin-3 -yl)- 1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 490
219 (3 S)-N-(l - { [ 1 -(4-Fluorophenyl)- 1 H-indol-3-yl]carbonyl} azetidin-3 -yl)- 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 490
Example 20
Figure imgf000113_0001
A. Ethyl l-Methyl-3-phenyl-lH-indazole-5-carboxylate, 20b. A mixture of compound 20a (300 mg, 0.91 mmol), phenyl boronic acid 2a (133 mg, 1.09 mmol), Pd(dppf)Cl2.CH2Cl2 (40 mg, 0.055 mmol), and K2C03 (251.2 mg, 1.82 mmol), in a toluene (2 mL) / water (0.4 mL) mixture, was placed in a capped vial and heated at 90 °C overnight. The reaction mixture was then partitioned between EtO Ac and water. The organic layer was concentrated under reduced pressure and purified by flash column chromatography (silica gel, 2-10% EtO Ac/Heptanes) to give compound 20b (231 mg). MS m/z (M+H+) 281.1.
B. l-Methyl-3-phenyl-lH-indazole-5-carboxylic acid, 20c. A solution compound 20b (230 mg, 0.58 mmol), and LiOH.H20 (98 mg, 2.33 mmol) in THF/H20 (10/10 mL) was stirred at 45 °C for 8 h. The resulting mixture was concentrated and diluted with water. The water layer was acidified with IN aqueous HCl to pH~4 and extracted with CH2C12. The organic solution was dried over Na2S04 and concentrated to give compound 20c (206 mg), which was used in the next reaction without further purification. MS m/z (M+H+) 253.1.
C. (3S)-N-{l-[(l-Methyl-3-phenyl-lH-indazol-5-yl)carbonyl]azetidin-3-yl}-l- (phenylcarbonyl)pyrrolidin-3-amine, Cpd 197. The title compound 197 was prepared using the method described in Example 5, substituting compound 20c for compound 4g in Step F. MS m/z (M+H+) 480. Following the procedure described above for Example 20, steps A and B, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following intermediate compounds were prepared:
Figure imgf000114_0001
Following the procedure described above for Example 20 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000114_0002
Cpd Cpd Name and Data
209 (3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indazol-5 -yljcarbony 1} azetidin-
3-yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 505
210 (3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indazol-5 -yljcarbony 1} azetidin-
3-yl)-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine
MS m/z (M+H+) 505
211 (3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indazol-5 -yljcarbony 1} azetidin- 3 -y 1)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine
MS m/z (M+H+) 498
Example 20a
Figure imgf000115_0001
20d 20e
D. Ethyl 2-phenyl-benzothiazole-6-carboxylate, 20e. A mixture of ethyl 2- bromo-benzothiazole-6-carboxylate 20d (300 mg, 1.05 mmol), phenylboronic acid (192 mg, 1.57 mmol), K2C03 (188 mg, 1.36 mmol) and Pd(dppf)Cl2.CH2Cl2 (43 mg, 0.05 mmol) in dioxane (2 mL) and H 0 (0.4 mL) was heated at 120 °C for 25 min in a microwave reactor. The reaction mixture was diluted with CH2C12, washed with H20, dried over Na2S04, and concentrated. Purification by flash column chromatography (silica gel, 15% EtO Ac/heptane) gave compound 20e (220 mg).
Following the procedure described above for Example 20 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000116_0002
Example 21
Figure imgf000116_0001
A. Methyl 3-fluoro-lH-indole-6-carboxylate, 21a. A solution of methyl 1H- indole-6-carboxylate 19a (2.0 g, 11.4 mmol) and N-fluoro-2,4,6-trimethylpyridinium triflate (4.3 g, 14.8 mmol) in MeOH (100 mL) was heated at reflux for 18 h. The reaction mixture was concentrated and purified by flash column chromatography (silica gel, 15- 20% EtOAc/hexanes) to give compound 21a as an off- white solid.
B. Methyl 3-fluoro-l-(4-fluorophenyl)-lH-indole-6-carboxylate, 21c.
Compound 21a (51 mg, 0.264 mmol), Cul (5 mg, 0.0264 mmol) and K3P04 (40 mg, 0.66 mmol) were combined in a sealed reaction tube and the vial was back- flushed with N2. 4- Fluoro-iodobenzene 21b (0.0394 mL, 0.264 mmol) and N,N'-dimethylcyclohexane-l,2- diamine (0.0125 mL, 0.0792 mmol) were added via syringe, followed by toluene. The reaction mixture was heated at 95 °C for 6 h. The reaction was partitioned between EtOAc and water. The organic phase was concentrated and purified by flash column
chromatography (silica gel, 20% EtOAc/hexanes) to give compound 21c.
C. 3-Fluoro-l-(4-fluorophenyl)-lH-indole-6-carboxylic acid, 21d. The title compound 21d was prepared using the method described in Example 13, substituting compound 21c for compound_13b in Step B.
D. (3S)-N-(l-{[3-Fluoro-l-(4-fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3- yl)-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 142. The title compound 142 was prepared using the method described in Example 5, substituting compound 21d for compound 4g in Step F. MS m/z (M+H+) 501.
Following the procedure described above for Example 21 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000117_0001
Example 22
Figure imgf000118_0001
A. (S)-tert-Butyl 3-((l-(thiazole-2-carbonyl)pyrrolidin-3-yl)amino)azetidine-l- carboxylate, 22b. The title compound 22b was prepared using the method described in Example 5, substituting compound la for compound 4a in Step C.
B. (S)-(3-(Azetidin-3-ylamino)pyrrolidin-l-yl)(thiazol-2-yl)methanone, 22c.
The title compound 22c was prepared using the method described in Example 5, substituting compound 22b for compound 5d in Step D.
C. Methyl 4-fluoro-l-triisopropylsilanyl-lH-indole-5-carboxylate, 22e. To a solution of 4-fluoro-l-triisopropylsilanyl-lH-indole-5-carboxylic acid 22d (prepared using the procedure described in Eur. J. Org. Chem. 2006, 2956) (2.71 g, 8.08 mmol) in dry CH2C12 (20 mL) was added oxalyl chloride (0.82 mL, 9.69 mmol) followed by DMF (0.063 mL, 0.81 mmol). The reaction was stirred at rt for 30 min and then concentrated. The residue was dissolved in CH2C12 (20 mL) and cooled to 0 °C. Et3N (5.6 mL, 40.4 mmol) was added, followed by slow addition of MeOH. The reaction mixture was stirred at 0 °C for 30 min and concentrated. The residue was partitioned between EtOAc and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 5% EtOAc/hexanes) to give compound 22e.
D. Methyl 4-fluoro-lH-indole-5-carboxylate, 22f. TBAF (1M solution in THF, 15.8 mL, 15.8 mmol) was added to a solution of compound 22e (2.76 g, 7.9 mmol) in THF at 0 °C. After 10 min at room temperature, the reaction was diluted with EtOAc and washed sequentially with brine, saturated NaHC03, and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 35%
EtOAc/hexanes) to afford compound 22f.
E. Methyl 4-fluoro-l-(4-fluorophenyl)-lH-indole-5-carboxylate, 22g. The title compound 22g was prepared using the method described in Example 21, substituting compound 22f for compound 21b in Step B.
D. 4-Fluoro-l-(4-fluoro-phenyl)-lH-indole-5-carboxylic acid, 22h. The title compound 22h was prepared using the method described in Example 15, substituting compound 22g for compound 15d in Step C.
E. (3S)-N-(l-{[4-Fluoro-l-(4-fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3- yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, Cpd 198. The title compound Cpd 198 was prepared using the method described in Example 5, substituting compound 22h for compound 4g and compound 22c for compound 5e in Step F. MS m/z (M+H+) 508.2.
Following the procedure described above for Example 22, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following intermediate compound was prepared:
Figure imgf000119_0001
Following the procedure described above for Example 22, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000120_0002
Example 22a
Figure imgf000120_0001
F. Methyl 4-amino-2-chloro-benzoate, 22j. Acetyl chloride (2.5 mL, 35.2 mmol) was added dropwise to a stirring solution of 4-amino-2-chloro-benzoic acid 22i (2.22 g, 12.9 mmol) in methanol (50 mL). The mixture was heated at reflux for 18 h, cooled, and concentrated under reduced pressure. The residue was dissolved in EtOAc, washed sequentially with saturated aqueous NaHC03 and brine, dried, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 30% EtOAc/hexanes) to give compound 22j.
I. Methyl 4-amino-2-chloro-5-iodo-benzoate, 22k. To a suspension of compound 22j (1.18 g, 6.38 mmol) and CaC03 (1.28 g, 12.8 mmol) in MeOH (13 mL) was added a solution of iodine monochloride (1.09 g, 6.70 mmol) in CH2CI2 (6 mL) dropwise at room temperature. The resulting reaction mixture was stirred at room temperature for 1.5 h. The reaction mixture was concentrated and then partitioned between EtOAc and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 20-25% EtOAc/hexanes) to provide methyl 4-amino-2-chloro-5-iodo-benzoate 22k as the major product and methyl 4-amino-2-chloro-3-iodo-benzoate 221 as the minor product.
J. Methyl 4-amino-2-chloro-5-((trimethylsilyl)ethynyl)benzoate, 22m. To a mixture of compound 22k (200 mg, 0.642 mmol), Cul (12.2 mg, 0.064 mmol) and
Pd(PPh3)2Cl2 (45 mg, 0.064 mmol) in THF (2 mL) was added ethynyltrimethylsilane (95 mg, 0.963 mmol) followed by Et3N (1 mL, 7.19 mmol) under N2. The reaction mixture was stirred at room temperature for 1.5 h and then partitioned between EtOAc and water. The organic layer was concentrated and purified by flash column chromatography (silica gel, 15%) EtOAc/hexanes) to give compound 22m.
K. Methyl 6-chloro-lH-indole-5-carboxylate, 22n. A mixture of compound 22m (150 mg, 0.532 mmol) and Cul (60 mg, 0.32 mmol) in DMF (1.5 mL) was heated at 110 °C for 5 h and them cooled to room temperature. The reaction was quenched with water and extracted with EtOAc. The organic layer was concentrated and purified by flash column chromatography (silica gel, 15% EtOAc/hexanes) to give compound 22n. Following the procedure described above for Example 22a and Example 22, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following intermediate compounds were prepared:
Figure imgf000122_0001
Following the procedure described above for Example 22, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000122_0002
Example 23
Figure imgf000123_0001
A. Methyl l-(2,2-difluoroethyl)-lH-indole-5-carboxylate, 23b. To a suspension of NaH (60% dispersion in mineral oil, 59 mg, 1.48 mmol) in DMF (2 mL) was slowly added a solution of lH-indole-5-carboxylic acid methyl ester 19a (200 mg, 1.14 mmol) in DMF (1 mL)at 0 °C. The resulting solution was stirred at 0 °C for 20 min and 1,1- difluoro-2-iodoethane 23a (263 mg, 1.37 mmol) was added. The reaction was warmed to room temperature and stirred for 2 h. The reaction was quenched with water and extracted with EtOAc. The organic layer was concentrated and purified by flash column
chromatography (silica gel, 20 % EtOAc/hexanes) to afford compound 23b.
B. l-(2,2-Difluoroethyl)-lH-indole-5-carboxylic acid, 23c. The title compound 23c was prepared using the method described in Example 15, substituting compound 23b for compound 15d in Step C.
C. (3S)-N-(l-{[l-(2,2-Difluoroethyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l- (l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, Cpd 213. The title compound 213 was prepared using the method described in Example 5, substituting compound 22h for compound 4g and compound 22c for compound 5e in Step F. MS m/z (M+H+) 460.
Following the procedure described above for Example 23, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following compounds of the present invention were prepared: Cpd Cpd Name and Data
222 N-Methyl-N-phenyl-2-{5-[(3-{[(3S)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3- yl] amino } azetidin- 1 -yl)carbonyl] - 1 H-indol- 1 -y 1} acetamide
MS m/z (M+H+) 543
Example 24
Figure imgf000124_0001
A. Methyl 2,3-dihydro-lH-indole-5-carboxylate, 24a. To a solution of methyl lH-indole-5-carboxylate 19a (2 g, 11.4 mmol) in glacial acetic acid (15 mL) at 0 °C was slowly added sodium cyanoborohydride (1.08 g, 17.2 mmol). The mixture was allowed to warm up and stirred at room temperature for 2 h. Water was added to the resulting mixture at 0 °C, and the solution was adjusted to pH~12 with IN aqueous NaOH. The mixture was extracted with CH2CI2 and the organic layer was washed with brine and dried over Na2S04. The solution was concentrated and purified by flash column chromatography (silica gel, 15% EtO Ac/heptane) to give compound 24a (1.79 g). MS m/z (M+H+) 178.1.
B. Methyl l-(4-fluoro-phenyl)-2,3-dihydro-lH-indole-5-carboxylate, 24c, and l-(4-fluoro-phenyl)-2,3-dihydro-lH-indole-5-carboxylic acid, 24d. A mixture of compound 24a (500 mg, 2.82 mmol), l-bromo-4-fluoro-benzene 24b (0.31 mL, 2.82 mmol), Pd2(dba)3 (129 mg, 0.14 mmol), ΒΓΝΑΡ (132 mg, 0.21 mmol), and sodium t- butoxide (325 mg, 3.39 mmol) in toluene (25 mL) was placed in a capped vial and heated at 80 °C overnight. The reaction mixture was then diluted with EtOAc and water, and the water layer was basified to pH~8 with IN aqueous NaOH. The organic layer was concentrated under reduced pressure and purified by flash column chromatography (silica gel, 5-30% EtO Ac/heptane) to give a mixture of compound 24c (145 mg), MS m/z (M+H+) 272.1 , and compound 24d (232 mg), MS m/z (M+H+) 258.0.
C. l-(4-Fluoro-phenyl)-2,3-dihydro-lH-indole-5-carboxylic acid, 24d. The title compound 24d was prepared using the method described in Example 15, substituting compound 24c for compound 15d in Step C.
D. (3S)-N-(l-{[l-(2,2-Difluoroethyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l- (l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, Cpd 220. The title compound Cpd 220 was prepared using the method described in Example 5, substituting compound 24d for compound 4g and compound 22c for compound 5e in Step F. MS m/z (M+H+) 492.
Following the procedure described above for Example 24 and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following intermediate compound was prepared:
Figure imgf000125_0001
Following the procedure described above for Example 24, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled in the art, the following compounds of the present invention were prepared:
Figure imgf000125_0002
Example 25
Figure imgf000126_0001
A. Methyl 3-(4-fluorobenzyl)-l-methyl-lH-indole-6-carboxylate, 25c. To a solution of compound 25a (500 mg), 2.64 mmol) and compound 25b (0.35 mL, 2.91 mmol) in dioxane (5 mL) was added silver oxide (683.6 mg, 2.91 mmol). The mixture was stirred at 80 °C overnight. The resultant mixture was filtered through diatomaceous earth and washed with EtOAc. The filtrate was concentrated and the residue was purified by flash column chromatography (silica gel, 20-60% CH2Cl2/heptanes) to give compound 25c (175 mg). MS m/z (M+H+) 298.2.
B. 3-Benzyl-l-methyl-lH-indole-6-carboxylic acid, 25d. A solution of compound 25c (175 mg, 0.59 mmol), and LiOH.H20 (101 mg, 2.41 mmol) in THF/H20 (3/3 mL) was stirred at room temperature for 6 h. The resultant mixture was concentrated and partitioned between CH2Cl2and water. The aqueous layer was acidified with IN HCl(aq) to pH~4. The organic layer was dried over Na S04 and concentrated to give compound 25d (163 mg), which was used in the next reaction without further purification.
C. (3S)-N-(l-{[3-(4-Fluorobenzyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3- yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, Cpd 221. The title compound Cpd 221 was prepared using the method described in Example 5, substituting compound 25d for compound 4g and compound 22c for compound 5e in Step F. MS m/z (M+H+) 518.
Example 26
Figure imgf000127_0001
A. 3-Fluoro-3'-(trifluoromethyl)-[l,l'-biphenyl]-4-carboxylic acid, 26b. To a suspension of compound 26a (75 mg, 0.345 mmol), compound 15b (80 mg, 0.42 mmol), and CS2CO3 (282 mg, 0.864 mmol) in dioxane (9 mL) and EtOH (3 mL) was added Pd(dppf)Cl2 (0.0252 g, 0.0345 mmol). The reaction mixture was stirred at 80 °C for 3 h. After cooling, the solid was removed by filtration and washed with CH3OH. The filtrate was concentrated. The crude compound 26b was purified by reverse phase
chromatography.
B . (3S)-N-(1- { [3-Fluoro-3 '-(trifluoromethyl)biphenyl-4-yl] carbonyl} azetidin-3- yl)-l-(phenylcarbonyl)pyrrolidin-3-amine, Cpd 152. The title compound Cpd 152 was prepared using the method described in Example 5, substituting compound 26b for compound 4g in Step F. MS m/z (M+H+) 512.
Following the procedure described above for Example 26, Step A and substituting the appropriate reagents, starting materials and purification methods known to those skilled in the art, the following intermediate compounds were prepared:
Figure imgf000127_0002
26-11
Following the procedure described above for Example 26, and substituting the appropriate reagents, starting materials, and purification methods known to those skilled the art, the following compounds of the present invention were prepared:
Cpd Cpd Name and Data Cpd Cpd Name and Data
153 (3 S)-N-( 1 - { [3 -Methyl-3 '-(trifluoromethyl)biphenyl-4-yl] carbonyl} azetidin-3 - y 1)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine
MS m/z (M+H+) 508.
Biological Examples
In Vitro Methods
Example 1
MGL Enzyme Activity Assay
All rate-based assays were performed in black 384-well polypropylene PCR microplates (Abgene) in a total volume of 30 μί. Substrate 4-methylumbelliferyl butyrate (4MU-B; Sigma) and either purified mutant MGL (mut-MGLL 11-313 L179S L186S) or purified wild type MGL (wt-MGLL 6H-11-313) were diluted separately into 20 mM PIPES buffer (pH = 7.0), containing 150 mM NaCl and 0.001% Tween 20. Compounds of Formula (I) were pre-dispensed (50 nL) into the assay plate using a Cartesian
Hummingbird prior to adding 4 of 1.2X solution to a final concentration of 10 μΜ) followed by enzyme (5
Figure imgf000128_0001
lution to a final concentration of 5 nM) to initiate the reaction. Final compound concentrations ranged from 17 to 0.0003 μΜ. The fluorescence change due to 4MU-B cleavage was monitored with excitation and emission wavelengths of 335 and 440 nm, respectively, and a bandwidth of 10 nm (Satire2, Tecan) at 37°C for 5 min.
The IC50 values for the following compounds were determined using Microsoft Office Excel from a fit of the equation to the concentration-response plot of the fractional activity as a function of inhibitor concentration. Biological Data Table 1
Figure imgf000129_0001
MGL mutant MGL wild type
Cpd inh lCso (μΜ ) inh lCso (μΜ )
40 0.0189 0.0160
41 0.0063 <0.005
42 0.0075 0.0100
43 0.267
44 0.0317 0.0090
45 1.63
46 0.336
47 10.9
48 8.97
49 0.357 0.480
50 0.0060 0.0087
51 0.229 <0.005
52 0.226 0.0066
53 0.0100 0.286
54 <0.005 0.0588
55 <0.005 0.0202
56 <0.005 0.0684
57 0.0443 0.179
58 0.0330 0.464
59 <0.005 0.0414
60 >16.7
61 0.0133 0.856
62 5.86 >16.6686
63 0.0063 0.0666
64 0.0395 0.0709
65 0.103
66 0.214
67 0.0097
68 0.0845
69 0.198
70 0.0255
71 5.58
72 0.757
73 0.0158
74 0.277
75 0.210
76 0.0618
77 <0.005
78 13.4
79 0.281 MGL mutant MGL wild type
Cpd inh lCso (μΜ ) inh lCso (μΜ )
80 0.0226
81 4.88
82 0.231
83 2.44
84 <0.005
85 0.0482
86 0.298
87 0.0341
88 0.152
89 0.154
90 <0.005
91 <0.005
92 <0.005
93 <0.005
94 <0.005
95 0.410
96 1.05
97 0.133
98 3.10
99 <0.005
100 <0.005
101 0.0440
102 <0.005
103 0.0150
104 0.0222
105 0.0180
106 <0.005
107 >16.6686
108 1.03
109 0.857
110 0.311
111 0.179
112 1.66
113 <0.005
114 0.0167
115 0.0100
116 <0.005
117 <0.005
118 <0.005
119 0.0488 MGL mutant MGL wild type
Cpd inh lCso (μΜ ) inh lCso (μΜ )
120 0.372
121 1.75
122 0.0597
123 <0.005
124 0.0060
125 <0.005
126 <0.005
127 <0.005
128 0.0050
129 <0.005
130 <0.005
131 <0.005
132 <0.005
133 0.145
134 2.93
135 1.13
136 0.165
137 0.446
138 0.0160
139 0.311
140 0.0124
141 0.0190
142 0.0565
143 0.0465
144 <0.005
145 0.0964
146 <0.005
147 <0.005
148 <0.005
149 <0.005
150 <0.005
151 <0.005
152 0.0352
153 0.176
154 0.0134
155 1.28
156 0.482
157 0.211
158 0.0160
159 0.0060 MGL mutant MGL wild type
Cpd inh lCso (μΜ ) inh lCso (μΜ )
160 0.0124
161 0.0550
162 0.0063
163 0.0107
164 0.0251
165 0.0445
166 0.0498
167 0.0110
168 0.0322
169 0.0139
170 0.350
171 <0.005
172 <0.005
173 <0.005
174 0.0100
175 <0.005
176 0.0060
177 0.0160
178 <0.005
179 0.0120
180 0.0427
181 0.0396
182 0.217
183 0.0231
184 0.205
185 0.488
186 0.0905
187 <0.005
188 0.0749
189 0.0125
190 0.114
191 0.297
192 <0.005
193 0.0190
194 0.0449
195 0.0224
196 0.298
197 0.199
198 <0.005
199 0.107 MGL mutant MGL wild type
Cpd inh lCso (μΜ ) inh lCso (μΜ )
200 0.843
201 0.459
202 0.0110
203 0.0504
204 0.344
205 <0.005
206 0.0810
207 0.0639
208 0.0134
209 0.279
210 2.04
211 0.943
212 <0.005
213 1.39
214 0.106
215 0.668
216 0.0945
217 0.723
218 1.89
219 4.98
220 0.0120
221 <0.005
222 1.68
223 0.0140
224 0.224
225 0.0392
Example 2
2-AG Accumulation assay
To measure the accumulation of 2-AG due to inhibition of MGL, one g rat brain was homogenized using a Polytron homogenizer (Brinkmann, PT300) in 10 mL of 20 mM HEPES buffer (pH = 7.4), containing 125 mM NaCl, 1 mM EDTA, 5 mM KC1 and 20 mM glucose. Compounds of Formula (I) (10 μΜ) were pre-incubated with rat brain homogenate (50 mg). After a 15-min incubation time at 37°C, CaCl2 (final concentration = 10 mM) was added and then incubated for 15 min at 37°C in a total volume of 5 mL. The reactions were stopped with 6 mL organic solvent extraction solution of 2: 1 chloroform/methanol. Accumulated 2-AG in the organic phase was measured by a HPLC/MS method, according to the following equation:
percent vehicle = (2-AG accumulation in the presence of compound/2-AG accumulation in vehicle) x 100.
Biological Data Table 2
Figure imgf000135_0001
Figure imgf000136_0001
Figure imgf000137_0001
Figure imgf000138_0001
Example 3
MGL ThermoFluor® Assay - mutant The ThermoFluor (TF) assay is a 384-well plate-based binding assay that measures thermal stability of proteins1'2. The experiments were carried out using instruments available from Johnson & Johnson Pharmaceutical Research & Development, LLC. TF dye used in all experiments was 1,8-ANS (Invitrogen: A-47). Final TF assay conditions used for MGL studies were 0.07 mg/ml of mutant MGL, 100 μΜ ANS, 200 mM NaCl, 0.001% Tween-20 in 50 mM PIPES (pH = 7.0).
Screening compound plates contained 100% DMSO compound solutions at a single concentration. For follow-up concentration-response studies, compounds were arranged in a pre-dispensed plate (Greiner Bio-one: 781280), wherein compounds were serially diluted in 100% DMSO across 11 columns within a series. Columns 12 and 24 were used as DMSO reference and contained no compound. For both single and multiple compound concentration-repsonse experiments, the compound aliquots (46 nL) were robotically predispensed directly into 384-well black assay plates (Abgene: TF-0384/k) using the Hummingbird liquid handler. Following compound dispension, protein and dye solutions were added to achieve the final assay volume of 3 μί. The assay solutions were overlayed with 1 of silicone oil (Fluka, type DC 200: 8541 1) to prevent evaporation.
Bar-coded assay plates were robotically loaded onto a thermostatically controlled PCR-type thermal block and then heated from 40 to 90 °C degrees at a ramp-rate of 1 °C/min for all experiments. Fluorescence was measured by continuous illumination with UV light (Hamamatsu LC6), supplied via fiber optics and filtered through a band-pass filter (380-400 nm; > 6 OD cutoff). Fluorescence emission of the entire 384-well plate was detected by measuring light intensity using a CCD camera (Sensys, Roper Scientific) filtered to detect 500 ± 25 nm, resulting in simultaneous and independent readings of all 384 wells. A single image with 20-sec exposure time was collected at each temperature, and the sum of the pixel intensity in a given area of the assay plate was recorded vs temperature and fit to standard equations to yield the Τ„. 1. Pantoliano, M. W., Petrella, E. C, Kwasnoski, J. D., Lobanov, V. S., Myslik, J., Graf, E., Carver, T., Asel, E., Springer, B. A., Lane, P., and Salemme, F. R. (2001) JBiomol Screen 6, 429-40.
2. Matulis, D., Kranz, J. K., Salemme, F. R., and Todd, M. J. (2005) Biochemistry 44,
5258-66.
The Ka values for certain compounds of Formula (I) were determined from a fit of the equation to the concentration-response plot of the fractional activity as a function of Tm. For some experiments, quantitative NMR spectroscopy (qNMR) was used to measure concentration of the initial 100% DMSO compound solutions and, using the same fitting method, qlQ values were determined.
Biological Data Table 3
Figure imgf000140_0001
In Vitro Methods
Example 4
CFA-Induced Paw Radiant Heat Hypersensitivity
Each rat was placed in a test chamber on a warm glass surface and allowed to acclimate for approximately 10 min. A radiant thermal stimulus (beam of light) was focused through the glass onto the plantar surface of each hind paw in turn. The thermal stimulus was automatically shut off by a photoelectric relay when the paw was moved or when the cut-off time was reached (20 sec for radiant heat at ~5 amps). An initial
(baseline) response latency to the thermal stimulus was recorded for each animal prior to the injection of complete Freund's adjuvant (CFA). Twenty-four hours following intraplantar CFA injection, the response latency of the animal to the thermal stimulus was re-evaluated and compared to the animal's baseline response time. Only rats that exhibited at least a 25% reduction in response latency (i.e., are hyperalgesic) were included in further analysis. Immediately following the post-CFA latency assessment, the indicated test compound or vehicle was administered orally. Post-compound treatment withdrawal latency was assessed at fixed time intervals, typically 30, 60, 120, 180, and 300 min.
The percent reversal (%R) of hypersensitivity was calculated in one of two different ways: 1) using group mean values or 2) using individual animal values. More specifically:
Method 1. For all compounds, the %R of hypersensitivity was calculated using the mean value for groups of animals at each time point according to the following formula:
% reversal = [(group treatment response - group CFA response)/(group
baseline response - group CFA response)] x 100
Results are given for the maximum % reversal observed for each compound at any time point tested. Method 2. For some compounds, the %R of hypersensitivity was calculated separately for each animal according to the following formula:
% reversal = [(individual treatment response - individual CFA response)/(individual baseline response - individual CFA response)] x 100.
Results are given as a mean of the maximum % reversal values calculated for each individual animal.
Biological Data Table ##: CFA thermal hypersensitivity
Figure imgf000142_0001
While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

Claims

We claim:
1. A compound of Formula (I)
Figure imgf000143_0001
Formula (I) wherein
Y is a C6-ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, isothiazolyl, pyrrolyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, Ci-4alkyl, Ci-4alkoxy, cyano, and trifluoromethyl;
Z is
Figure imgf000143_0002
ii) 9H-fluorenyl;
iii) phenyl (Ra)-phenyl wherein the phenyl ring on phenyl (Ra)-is unsubstituted or substituted with one substituent selected from the group consisting of trifluoromethyl, chloro, C1-4 alkyl, and fluoro;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, indolinyl, and indazolinyl;
wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substitutent selected from the group consisting of bromo, chloro, fluoro, iodo, Ci_4alkyl, C2-4alkenyl, Ci_4alkoxy, trifluoromethyl, and trifluoromethoxy; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl; wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, iodo, C1-4alkyl, C2- 4alkenyl, Ci-4alkoxy, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is ¾; and
Rb is selected from the group consisting of 2,2-difluoroethyl;
phenylmethyl; C3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyridinyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyridinyl, pyrimidinyl, and phenyl of ¾ are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, Ci-4alkyl, chloro, and fluoro;
Ri is hydrogen, fluoro, hydroxy, or methoxy;
R2 is hydrogen, C1-6 alkyl, hydroxy, formyl; or acetyl;
and enantiomers, diastereomers, and pharmaceutically acceptable salts thereof.
2. The compound of claim 1 wherein Y is a C6-ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two fluoro substituents.
3. The compound of claim 2 wherein Y is an unsubstituted C6-ioaryl or an
unsubstituted heteroaryl that is thienyl or thiazolyl. 4. The compound of claim 3 wherein Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or thiazolyl.
5. The compound of claim 1 wherein Z is
i) a C6-10aryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl;
wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substitutent selected from the group consisting of bromo, chloro, fluoro, iodo, C1-4alkyl, C2-4alkenyl,
Figure imgf000145_0001
trifluoromethyl, and trifluoromethoxy; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,; and
Rb is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl; C3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyrimidinyl, and phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro. 6. The compound of claim 5 wherein Z is
Figure imgf000146_0001
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl;
wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro,
Figure imgf000146_0002
C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,; and
Rb is selected from the group consisting of phenylmethyl; C3-6 cycloalkyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro.
7. The compound of claim 6 wherein
Z is
i) a C6-ioaryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CF2 or CH(OH); iv) indolinyl and said indolinyl is unsubstituted or substituted on the benzo portion of the ring with one substituent that is phenyl or bromo; or
v) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is and
Rb is selected from the group consisting of phenylmethyl; thienyl;
pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of ¾, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro.
8. The compound of claim 7 wherein Z is
i) a C6-10aryl;
ii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CF2 or CH(OH);
iii) indolinyl and said indolinyl is unsubstituted or substituted on the benzo portion of the ring with one substituent that is phenyl or bromo; or
iv) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rb; provided that no more than one substituent is Rb; and
Rb is selected from the group consisting of phenylmethyl; thienyl;
pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of ¾, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro.
9. The compound of claim 1 wherein Ri is hydrogen, fluoro, or hydroxy.
10. The compound of claim 9 wherein Ri is hydrogen or fluoro.
11. The compound of claim 1 wherein R2 is hydrogen, C1-2 alkyl, or hydroxy.
12. The compound of claim 11 wherein R2 is hydrogen, methyl, or hydroxy.
13. The compound of claim 12 wherein R2 is hydrogen.
14. A compound of Formula (I
Figure imgf000148_0001
Formula (I) wherein
Y is a C6-ioaryl or a heteroaryl selected from the group consisting of thiazolyl, thienyl, benzofuranyl, and benzothienyl; wherein Y is unsubstituted or substituted with one or two fluoro substituents;
Z is
i) a C6-10aryl; ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl;
wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo, wherein said phenyl is unsubstituted or substituted with one substituent selected from the group consisting of bromo, chloro, fluoro, methyl, methoxy, or trifluoromethyl; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,; and
Rb is selected from the group consisting of 2,2-difluoroethyl; phenylmethyl; C3-6 cycloalkyl; N-methyl-N-phenylaminocarbonyl-methyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl, pyrimidinyl, and phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro;
Ri is hydrogen, fluoro or hydroxy;
R2 is hydrogen, methyl, or hydroxy;
and enantiomers, diastereomers, and pharmaceutically acceptable salt forms thereof.
A compound of Formula (I) Formula (I) wherein
Y is an unsubstituted C6-ioaryl or an unsubstituted heteroaryl that is thienyl or thiazolyl;
Z is
i) a C6-10aryl;
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CH(F), CF2, or CH(OH);
iv) a benzo-fused heterocyclyl selected from the group consisting of 1 ,2,3,4- tetrahydroisoquinolinyl, isoindolinyl, and indolinyl; wherein the benzo-fused heterocyclyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
v) a heteroaryl selected from the group consisting thiazolyl, benzothienyl,
benzofuranyl, benzothiazolyl, quinazolinyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and Rt,; provided that no more than one substituent is Rt,;
Rb is selected from the group consisting of phenylmethyl ; C3-6 cycloalkyl; thienyl; pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, chloro, and fluoro;
Ri is hydrogen or fluoro;
P2 is hydrogen, C1-2 alkyl, or hydroxy;
and enantiomers, diastereomers, and pharmaceutically acceptable salt forms thereof.
A compound of Formula (I)
Figure imgf000151_0001
Formula (I)
wherein
Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or thiazolyl;
Z is
Figure imgf000151_0002
ii) 9H-fluorenyl;
iii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl;
Ra is CF2 or CH(OH);
iv) indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
v) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl; wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is and
Rb is selected from the group consisting of phenylmethyl; thienyl;
pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of ¾, are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro;
Ri is hydrogen or fluoro;
R2 is hydrogen, C1-2 alkyl, or hydroxy;
and enantiomers, diastereomers, and pharmaceutically acceptable salt forms thereof.
A compound of Formula (I)
Figure imgf000152_0001
Formula (I)
wherein
Y is an unsubstituted phenyl or an unsubstituted heteroaryl that is thienyl or thiazolyl;
Z is
i) a C6-10aryl;
ii) phenyl-(Ra)-phenyl wherein the phenyl ring on phenyl-(Ra)- is unsubstituted or substituted with one substituent that is trifluoromethyl; Ra is CF2 or CH(OH);
iii) indolinyl and said indolinyl is unsubstituted or substituted with one substituent that is phenyl or bromo; or
iv) a heteroaryl selected from the group consisting benzothienyl, benzofuranyl, indolyl, and indazolyl;
wherein the C6-ioaryl and the heteroaryl of Z are unsubstituted or substituted with one or two substitutents each of which is independently selected from the group consisting of bromo, chloro, fluoro, C1-4alkyl, C2-4alkenyl, trifluoromethyl, trifluoromethoxy, and provided that no more than one substituent is
¾ is selected from the group consisting of phenylmethyl; thienyl;
pyrimidinyl; and phenyl; wherein the phenyl portion of phenylmethyl, and said thienyl and said phenyl of Rb are unsubstituted or substituted with one or two substituents each of which is independently selected from the group consisting of trifluoromethyl, chloro, and fluoro;
Ri is hydrogen or fluoro;
R2 is hydrogen;
and enantiomers, diastereomers, and pharmaceutically acceptable salt forms thereof.
18. A compound of Formula (I)
Figure imgf000153_0001
Formula (I)
selected from the group consisting of (3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3- amine,
(3 S)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3 -yl} - 1 -( 1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3 -yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} - 1 -(thiophen-3- ylcarbonyl)pyrrolidin-3-amine,
(3R)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3-amine,
(3R)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} -1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 - [(6-Bromo-3 ,4-dihydroisoquinolin-2( 1 H)-yl)carbonyl] azetidin-3 -yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(6-Phenyl-3,4-dihydroisoquinolin-2(lH)-yl)carbonyl]azetidin-3-yl}-l-
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Bromo- 1 ,3-dihydro-2H-isoindol-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Phenyl-l ,3-dihydro-2H-isoindol-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(4-Benzylphenyl)carbonyl]azetidin-3-yl} -N-methyl- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-Methy 1- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-1 -(Phenylcarbonyl)-N-( 1 - { [3 '-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine, (3S)-N- { 1 -[(3*,5*-Dichlorobiphenyl-4-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [5 -(trifluoromethoxy)- 1 -benzothiophen-2- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [5 -(trifluoromethyl)- 1 -benzothiophen-2- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [6-(trifluoromethyl)- 1 -benzothiophen-2- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(6-Bromo-3-chloro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Bromonaphthalen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N- { 1 -[(5-phenylnaphthalen-2-yl)carbonyl]azetidin-3- y 1} pyrrolidin-3 -amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[2-(trifluoromethyl)phenyl]naphthalen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[3-(trifluoromethyl)phenyl]naphthalen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[4-(trifluoromethoxy)phenyl]naphthalen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N-[l-(9H-Fluoren-2-ylcarbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-
3-amine,
(3S)-N-(1 - {[3-Chloro-6-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-
3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(3*-Chlorobiphenyl-4-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3',4*-Dichlorobiphenyl-4-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine, (3 S)-N- { 1 -[(3-Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[1 - ( {3-Chloro-6-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[1 - ( {3-Chloro-6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Bromonaphthalen-2-yl)carbonyl]azetidin-3-yl} -N-hydroxy- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-1 -(Phenylcarbonyl)-N-( 1 - { [4'-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [4'-(trifluoromethoxy)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 - [(3 -Methy 1-5 -phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 - ( {3 -Methy 1-5 - [4-(trif uoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 - ( {3 -Methy 1-5 - [3 -(trif uoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {6-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine, (3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-[(4- fluorophenyl)carbonyl]pyrrolidin-3-amine,
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-l-[(3- fluorophenyl)carbonyl]pyrrolidin-3-amine,
(3 S)- 1 -( 1 -Benzofuran-2-ylcarbonyl)-N-[ 1 -(biphenyl-4-ylcarbonyl)azetidin-3- yl]pyrrolidin-3 -amine,
(3 S)- 1 -( 1 -Benzothiophen-2-ylcarbonyl)-N-[ 1 -(biphenyl-4-ylcarbonyl)azetidin-3 - yl]pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(5-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5 -Phenyl- 1 -benzothiophen-2-y l)carbonyl] azetidin-3 -yl} -1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[3-(trif uoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {5-[4-(trif uoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)-N-Ethyl- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)-N-Hydroxy- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(3-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Chloro-6-fluoro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N- { 1 -[(3 -phenyl- 1 H-indol-6-yl)carbonyl] azetidin-3 - y 1} pyrrolidin-3 -amine,
N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-4-f uoro-l-(phenylcarbonyl)pyrrolidin-
3-amine, 4-Fluoro- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethy l)bipheny 1-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3R)-N-[ 1 -(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-4-fluoro-l -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-(Biphenyl-4-ylcarbonyl)azetidin-3-yl]-4-fluoro-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3R)-4-Fluoro-l-(phenylcarbonyl)-N-(l-{[3'-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3 S)-4-Fluoro- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethy l)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[( 1 -Methy 1-3 -phenyl- 1 H-indol-6-yl)carbonyl] azetidin-3 -y 1} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(3-Phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Cyclopropyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
{4-[(3-{[(3S)-l-(Phenylcarbonyl)pyrrolidin-3-yl]amino}azetidin-l- yl)carbonyl]phenyl} [4-(trifluoromethyl)phenyl]methanol,
(3 S)-N- { 1 -[(3-Methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
N- { 1 -[(4- {Fluoro[4-(trifluoromethyl)phenyl]methyl}phenyl)carbonyl]azetidin-3- yl} - 1 -(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(3-Cyclopropyl-6-fluoro-l-benzothiophen-2-yl)carbonyl]azetidin-3- yl} - 1 -(phenylcarbonyl)pyrrolidin-3-amine,
(3R,4R)-4-Methoxy- 1 -(phenylcarbonyl)-N-( 1 - { [3 '-(trifluoromethy l)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3R,4R)-l-(Phenylcarbonyl)-4-[(l-{[3'-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)amino]pyrrolidin-3-ol, (3S)-N-[l-({4-[Difluoro(phenyl)methyl]phenyl}carbonyl)azetidin-3-yl]-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(Phenylcarbonyl)-N-( 1 - { [3 -phenyl-6-(trifluoromethyl)- 1 -benzothiophen-2- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-Cyclopropyl-6-(trifluoromethyl)-l-benzothiophen-2- yl]carbonyl}azetidin-3-yl)-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-(l - { [3-(2-Methylprop- 1 -en- 1 -yl)-6-(trifluoromethyl) - 1 -benzothiophen-2- yljcarbonyl} azetidin-3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {4-[4-
(trifluoromethyl)benzyl]phenyl} carbonyl)azetidin-3 -yl]pyrrolidin-3 -amine, (3R,4R)-4- {[ 1 -(Biphenyl-4-ylcarbonyl)azetidin-3-yl] amino} - 1 -
(phenylcarbonyl)pyrrolidin-3-ol,
(3S)-N- { 1 -[(3-Cyclobutyl-6-fluoro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -Methyl-6-(trifluoromethyl)- 1 -benzothiophen-2-yl] carbonyl} azetidin-
3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
N- { 1 (5 -Chloro-3 -methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -N-[(3S)- l-(phenylcarbonyl)pyrrolidin-3-yl]formamide,
N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -N-[(3S)-
1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-yl]formamide,
N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -N-[(3S)-
1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-yl]formamide,
(3S)-N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(5-Chloro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Fluoro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine, (3 S)-N- { 1 -[(6-Fluoro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Fluoro-3-methyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-Fluoro-6-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-
3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N- [ 1 - ( {3 -Methy 1-5 - [3 -(trif uoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[l-({3-Methyl-5-[4-(trifluoromethyl)phenyl]-l-benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N- { 1 -[(3 -Methy 1-5 -phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-(3-Fluorophenyl)-3-methyl-l-benzothiophen-2-yl]carbonyl}azetidin-
3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 - { [5 -(4-Fluorophenyl)-3 -methyl- 1 -benzothiophen-2-yl]carbonyl} azetidin-
3- yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3-thiazol-
2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3-thiazol-
4- ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(5-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3-thiazol-
2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(5-Bromo- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3-thiazol-
4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-[l-({6-[3-(trif uoromethyl)phenyl]-l- benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-[l-({6-[3-(trif uoromethyl)phenyl]-l- benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine, (3S) - 1 -(Phenylcarbonyl)-N-[ 1 -( {3-[4-(trifluoromethyl)phenyl]- lH-indol-6- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 - ({6-[4-(trifluoromethyl)phenyl]-l - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S) - 1 -(Phenylcarbonyl)-N-[ 1 -( {3-[3-(trifluoromethyl)phenyl]- lH-indol-6- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-[l-({3-[4-(trifluoromethyl)phenyl]-lH-indol-
6-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-[l-({3-[3-(trifluoromethyl)phenyl]-lH-indol-
6-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-[l-({3-[3-(trifluoromethyl)phenyl]-lH-indol-
6- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3 S)-N- { 1 -[(5-Bromo- 1 -benzofuran-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N- { 1 -[(4-phenylquinazolin-7-yl)carbonyl] azetidin-3 - y 1} pyrrolidin-3 -amine,
(3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {4-[4-(trif uoromethyl)phenyl]quinazolin-7- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N- { 1 -[(4-Phenylquinazolin-7-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -({4-[4-(trif uoromethyl)phenyl]quinazolin-
7- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N- { 1 -[(4-Phenylquinazolin-7-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-(l-{[3'-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-(l-{[3'-(trif uoromethyl)biphenyl-4- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine, (3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-(l-{[4*-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-Fluoro-3'-(trifluoromethyl)biphenyl-4-yl]carbonyl}azetidin-3-yl)-l-
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-Methyl-3'-(trifluoromethyl)biphenyl-4-yl]carbonyl}azetidin-3-yl)-l-
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-2-ylcarbonyl)-N-[l-({l-[4-(trifluoromethyl)phenyl]-lH-indol-
5 -yl} carbonyl)azetidin-3 -yl]pyrrolidin-3 -amine,
(3S)-N- { 1 -[(1 -Pyrimidin-2-yl- lH-indol-5-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-{l-[(l-Phenyl-lH-indazol-5-yl)carbonyl]azetidin-3-yl}-l-(l,3-thiazol-2- ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(5-Phenyl- 1 -benzofuran-2-yl)carbonyl]azetidin-3-yl} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-(5-Chlorothiophen-2-yl)-l-benzofuran-2-yl]carbonyl}azetidin-3-yl)- l-(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 - [(3 -Methyl-5 -phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(6-Phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3-thiazol-
4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 - ( {3 -Methyl-5 - [3 -(trifluoromethyl)phenyl] - 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)- 1 -(Phenylcarbonyl)-N-[ 1 -( {4-[3-
(trifluoromethyl)benzyl]phenyl} carbonyl)azetidin-3 -yl]pyrrolidin-3 -amine, (3 S)- 1 -( 1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -( {4-[3-
(trifluoromethyl)benzyl]phenyl} carbonyl)azetidin-3 -yl]pyrrolidin-3 -amine, (3 S)- 1 -( 1 ,3 -Thiazol-4-ylcarbonyl)-N-[ 1 -( {6- [4-(trifluoromethyl)phenyl] - 1 - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine, (3S)-N-{l-[(5-Phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}-l-(l,3-thiazol-
2-ylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -({5-[3-(trifluoromethyl)phenyl]-l - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N-{l-[(5-Phenyl-l-benzothiophen-2-yl)carbonyl]azetidin-3-yl}-l-(l,3-thiazol-
4-ylcarbonyl)pyrrolidin-3-amine,
(3S)- 1 -(1 ,3-Thiazol-2-ylcarbonyl)-N-[ 1 -({5-[3-(trifluoromethyl)phenyl]-l - benzothiophen-2-yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)-N- { 1 -[(2 -Phenyl- 1 ,3-benzothiazol-6-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-
2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[2-(2-Fluorophenyl)-4-methyl-l,3-thiazol-5-yl]carbonyl}azetidin-3-yl)-
1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[2-(4-Fluorophenyl)-4-methyl-l,3-thiazol-5-yl]carbonyl}azetidin-3-yl)-
1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[2-(3-Chlorophenyl)-4-methyl-l,3-thiazol-5-yl]carbonyl}azetidin-3-yl)-
1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[2-(4-Chlorophenyl)-4-methyl-l,3-thiazol-5-yl]carbonyl}azetidin-3-yl)-
1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -( 1 ,3 -Thiazol-2-ylcarbonyl)-N-( 1 - { [6-(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3 S)- 1 -( 1 ,3 -Thiazol-4-ylcarbonyl)-N-( 1 - { [6-(trifluoromethyl)- 1 -benzothiophen-2- yl] carbonyl} azetidin-3 -yl)pyrrolidin-3 -amine,
(3S)-N- { 1 -[(6-Bromo-3-chloro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(6-Bromo-3-chloro- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-(l - { [3-Fluoro- 1 -(4-f uorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3 -yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine, (3 S)-N-(l - { [3-Fluoro- 1 -(4-fluorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3-yl)- 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)- 1 -(1 ,3-Thiazol-4-ylcarbonyl)-N-[ 1 -( {4-[4-
(trifluoromethyl)benzyl]phenyl} carbonyl)azetidin-3 -yl]pyrrolidin-3 -amine, (3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-(l-{[4*-(trifluoromethyl)biphenyl-4- yl]carbonyl}azetidin-3-yl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(3-Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[(3-Chloro-6-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} - 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({3-Chloro-6-[3-(trifluoromethyl)phenyl]-l-benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[1 - ( {3-Chloro-6-[3-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[1 - ( {3-Chloro-6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[1 - ( {3-Chloro-6-[4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-(l-{[3-Fluoro-3'-(trifluoromethyl)biphenyl-4-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-Methyl-3'-(trifluoromethyl)biphenyl-4-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S) - 1 -(Phenylcarbonyl)-N-[ 1 -( { 1 -[4-(trifluoromethyl)phenyl]- lH-indol-5- yl}carbonyl)azetidin-3-yl]pyrrolidin-3-amine,
(3S)- 1 -(Phenylcarbonyl)-N- { 1 -[(1 -pyrimidin-2-yl- lH-indol-5-yl)carbonyl]azetidin-
3 -yl} pyrrolidin-3 -amine,
(3 S)- 1 -(Phenylcarbonyl)-N- { 1 - [( 1 -phenyl- 1 H-indazol-5 -yl)carbonyl]azetidin-3 - yl} pyrrolidin-3 -amine, (3S)-N-{l-[(2-Phenyl-l,3-benzothiazol-6-yl)carbonyl]azetidin-3-yl}-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-l-(l,3-Thiazol-4-ylcarbonyl)-N-[l-({l-[4-(trifluoromethyl)phenyl]-lH-indol-
5 -y 1} carbonyl)azetidin-3 -yl]pyrrolidin-3 -amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-5-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-(l - { [ 1 -(4-Fluorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3-yl)- 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-[l-({l-Methyl-3-[3-(trifluoromethyl)phenyl]-lH-indol-6- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[l-({l-Methyl-3-[4-(trifluoromethyl)phenyl]-lH-indol-6- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[l-({l-Methyl-3-[3-(trifluoromethyl)phenyl]-lH-indol-6- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[l-({l-Methyl-3-[4-(trifluoromethyl)phenyl]-lH-indol-6- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-[l-({l-Methyl-3-[3-(trifluoromethyl)phenyl]-lH-indol-6- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -Chloro-6-(trifluoromethyl)- 1 -benzothiophen-2-yl] carbonyl} azetidin-
3-yl)- 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[3-Chloro-6-(trifluoromethyl)- 1 -benzothiophen-2-yl] carbonyl} azetidin-
3-yl)- 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[( 1 -Methyl-3-phenyl- 1 H-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 -[( 1 -Methyl-3-phenyl- 1 H-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -( 1 ,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)-N- { 1 -[(3-Fluoro-5-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Fluoro-5-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Fluoro-5-phenyl- 1 -benzothiophen-2-yl)carbonyl]azetidin-3-yl} -1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 -( { 3 -Fluoro-5 - [4-(trifluoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N- [ 1 -( { 3 -Fluoro-5 - [4-(trif uoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N- [ 1 -( { 3 -Fluoro-5 - [4-(trif uoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- [ 1 -( { 3 -Fluoro-6- [4-(trif uoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N- [ 1 -( { 3 -Fluoro-6- [4-(trif uoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3 S)-N- [ 1 -( { 3 -Fluoro-6- [4-(trif uoromethyl)phenyl]- 1 -benzothiophen-2- yl}carbonyl)azetidin-3-yl]-l-(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[5-Chloro-3-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-
3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(1 - {[5-Chloro-3-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-
3-yl)- 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[6-Chloro-3-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-
3-yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(1 - {[6-Chloro-3-(trifluoromethyl)- 1 -benzothiophen-2-yl]carbonyl} azetidin-
3-yl)- 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [5 -Methyl-3 -(trif uoromethyl)- 1 -benzothiophen-2-yl] carbonyl} azetidin-
3-yl)- 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-(l-{[6-Methyl-3-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-
3-yl)- 1 -(1 ,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[6-Methyl-3-(trifluoromethyl)-l-benzothiophen-2-yl]carbonyl}azetidin-
3-yl)- 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Phenyl- lH-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-2- ylcarbonyl)pyrrolidin-3-amine,
(3S)-N- { 1 -[(3-Phenyl- lH-indol-6-yl)carbonyl]azetidin-3-yl} - 1 -(1 ,3-thiazol-4- ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indol-6-y 1] carbonyl} azetidin-3 -y 1) - 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indol-6-y 1] carbonyl} azetidin-3 -y 1) - 1 -
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -(4-Fluorophenyl)- 1 -methyl- 1 H-indol-6-y 1] carbonyl} azetidin-3 -y 1) - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 - [( 1 -Methyl-3 -phenyl- 1 H-indazol-5 -yl)carbonyl]azetidin-3 -y 1} - 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 - [( 1 -Methyl-3 -phenyl- 1 H-indazol-5 -yl)carbonyl]azetidin-3 -y 1} - 1 -( 1 ,3 - thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N- { 1 - [( 1 -Methyl-3 -phenyl- 1 H-indazol-5 -yl)carbonyl]azetidin-3 -y 1} - 1 -
(phenylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [4-Fluoro- 1 -(4-f uorophenyl)- 1 H-indol-5 -yl]carbonyl} azetidin-3 -y 1)- 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3- yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3- yl)-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3- yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-
(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(3-Fluorophenyl)-l-methyl-lH-indol-6-yl]carbonyl}azetidin-3-yl)-l-
(phenylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[6-Phenyl-3-(trifluoromethyl)- 1 -benzothiophen-2-yl] carbonyl} azetidin-
3-yl)- 1 -(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3- yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3- yl)-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[3-(4-Fluorophenyl)-l-methyl-lH-indazol-5-yl]carbonyl}azetidin-3- yl)- 1 -(phenylcarbonyl)pyrrolidin-3 -amine,
(3 S)-N-( 1 - { [6-Fluoro- 1 -(4-f uorophenyl)- 1 H-indol-5 -yl]carbonyl} azetidin-3 -yl)- 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, (3R)-N-(1 - {[ 1 -(2,2-Difluoroethyl)- lH-indol-5-yl]carbonyl} azetidin-3 -yl)- 1 -(1 ,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [ 1 -(4-Fluorophenyl)- 1 H-indol-4-y 1] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [ 1 -(4-Fluorophenyl)- 1 H-indol-4-y 1] carbonyl} azetidin-3 -yl)- 1 -( 1 ,3 - thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[ 1 -(4-Fluorophenyl)-2,3-dihydro- lH-indol-4-yl]carbonyl} azetidin-3- yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[ 1 -(4-Fluorophenyl)-2,3-dihydro- lH-indol-4-yl]carbonyl} azetidin-3- yl)-l-(l,3-thiazol-4-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[l-(3-Fluorophenyl)-lH-indol-3-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(l-{[l-(4-Fluorophenyl)-lH-indol-3-yl]carbonyl}azetidin-3-yl)-l-(l,3- thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3S)-N-(1 - {[ 1 -(4-Fluorophenyl)-2,3-dihydro- lH-indol-5-yl]carbonyl} azetidin-3- yl)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-( 1 - { [3 -(4-Fluorobenzyl)- 1 -methyl- 1 H-indol-6-yl]carbonyl} azetidin-3 -yl)- 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
N-Methyl-N-phenyl-2-{5-[(3-{[(3S)-l-(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3- yl] amino } azetidin- 1 -yl)carbonyl] - 1 H-indol- 1 -yl} acetamide,
(3 S)-N-(l - { [4-Chloro- 1 -(4-fiuorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3 -yl)- 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
(3 S)-N-(l - { [ 1 -(4-Fluorophenyl)-6-methyl- 1 H-indol-5-yl]carbonyl} azetidin-3 -yl)- 1 -
(1 ,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine, and
(3 S)-N-(l - { [6-Chloro- 1 -(4-fiuorophenyl)- 1 H-indol-5-yl]carbonyl} azetidin-3 -yl)- 1 -
(l,3-thiazol-2-ylcarbonyl)pyrrolidin-3-amine,
and pharmaceutically acceptable salt forms thereof. A pharmaceutical composition comprising the compound of claim 1 or 18 and a member selected from the group consisting of a pharmaceutically acceptable carrier, a pharmaceutically acceptable excipient, and a pharmaceutically acceptable diluent.
A pharmaceutical composition of claim 19, wherein the composition is a solid oral dosage form.
A pharmaceutical composition of claim 19, wherein the composition is selected from the group consisting of a syrup, an elixir, and a suspension.
A method for treating inflammatory pain in a subject in need thereof comprising administering a therapeutically effective amount of the compound of claim 1 or 18 to the subject.
The method of claim 22 wherein the inflammatory pain is due to inflammatory bowel disease, visceral pain, migraine, post operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact
dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
PCT/US2011/057090 2010-10-22 2011-10-20 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors WO2012054721A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2013535087A JP2013540160A (en) 2010-10-22 2011-10-20 Amino-pyrrolidine-azetidine diamide as monoacylglycerol lipase inhibitor
EP11778748.1A EP2630139A1 (en) 2010-10-22 2011-10-20 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
RU2013123274/04A RU2013123274A (en) 2010-10-22 2011-10-20 AMINOPYRROLIDINAZETIDINDIAMIDES AS MONOACYLGLYCERINLIPASE INHIBITORS
BR112013009828A BR112013009828A2 (en) 2010-10-22 2011-10-20 amino pyrrolidine azetidine diamides as monoacylglycerol lipase inhibitors
CA2815353A CA2815353A1 (en) 2010-10-22 2011-10-20 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
CN201180061845.6A CN103261189B (en) 2010-10-22 2011-10-20 Amino-pyrrolidine-zetidine diamides as monoacylglycerol lipase inhibitors
KR1020137012916A KR20130140020A (en) 2010-10-22 2011-10-20 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
AU2011316975A AU2011316975A1 (en) 2010-10-22 2011-10-20 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
IL225815A IL225815A0 (en) 2010-10-22 2013-04-18 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40598410P 2010-10-22 2010-10-22
US61/405,984 2010-10-22

Publications (2)

Publication Number Publication Date
WO2012054721A1 true WO2012054721A1 (en) 2012-04-26
WO2012054721A8 WO2012054721A8 (en) 2013-05-16

Family

ID=44906426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/057090 WO2012054721A1 (en) 2010-10-22 2011-10-20 Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors

Country Status (13)

Country Link
US (2) US8575363B2 (en)
EP (1) EP2630139A1 (en)
JP (1) JP2013540160A (en)
KR (1) KR20130140020A (en)
CN (1) CN103261189B (en)
AR (1) AR083543A1 (en)
AU (1) AU2011316975A1 (en)
BR (1) BR112013009828A2 (en)
CA (1) CA2815353A1 (en)
IL (1) IL225815A0 (en)
RU (1) RU2013123274A (en)
TW (1) TW201305137A (en)
WO (1) WO2012054721A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2020007902A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
WO2020097389A1 (en) * 2018-11-09 2020-05-14 Vivace Therapeutics, Inc. Bicyclic compounds
WO2020179859A1 (en) 2019-03-06 2020-09-10 第一三共株式会社 Pyrrolopyrazole derivative
WO2021123051A1 (en) 2019-12-20 2021-06-24 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
US11420935B2 (en) 2019-04-16 2022-08-23 Vivace Therapeutics, Inc. Bicyclic compounds

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6640840B2 (en) 2014-09-22 2020-02-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Methods and pharmaceutical compositions for treating fibrosis
BR112018000041A2 (en) 2015-07-31 2018-09-04 Pfizer Inc. 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-ILA CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-ILA CARBAMATE DERIVATIVES AS MAGL INHIBITORS
WO2018134695A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
BR112019014099A2 (en) 2017-01-23 2020-02-11 Pfizer Inc. SPIRO-HETEROCYCLIC COMPOUNDS AS MAGL INHIBITORS
US11505546B2 (en) * 2020-03-26 2022-11-22 Janssen Pharmaceutica Nv Azaspirocycles as monoacylglycerol lipase modulators
CA3176113A1 (en) * 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Aminocyclobutanes as monoacylglycerol lipase modulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020314A1 (en) * 2001-08-29 2003-03-13 Aventis Pharma S.A. Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
US20030119810A1 (en) * 2000-03-03 2003-06-26 Daniel Achard Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
WO2008025736A1 (en) * 2006-08-26 2008-03-06 Abbott Gmbh & Co. Kg Substituted benzimidazolone derivatives, medicaments comprising them and their use
EP2180048A1 (en) * 2008-10-09 2010-04-28 Janssen Pharmaceutica, N.V. Alternative crystal form of monoacylglycerol lipase (MGLL)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6179998A (en) 1997-02-24 1998-09-09 Zymogenetics Inc. Calcitonin mimetics
AU1089599A (en) 1997-10-15 1999-05-03 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
WO2000063168A1 (en) 1999-04-16 2000-10-26 Coelacanth Chemical Corporation Synthesis of azetidine derivatives
FR2805810B1 (en) * 2000-03-03 2002-04-26 Aventis Pharma Sa PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION
AR033517A1 (en) 2000-04-08 2003-12-26 Astrazeneca Ab PIPERIDINE DERIVATIVES, PROCESS FOR THE PREPARATION AND USE OF THESE DERIVATIVES IN THE MANUFACTURE OF MEDICINES
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
ES2464157T3 (en) 2002-06-26 2014-05-30 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
US7435736B2 (en) 2002-12-23 2008-10-14 Janssen Pharmaceutica, N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
EP1702916A1 (en) 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
PE20071136A1 (en) 2005-12-21 2007-12-29 Schering Corp DERIVATIVES OF ANILINE SUBSTITUTED AS ANTAGONISTS OF HISTAMINE H3
FR2915199B1 (en) 2007-04-18 2010-01-22 Sanofi Aventis TRIAZOLOPYRIDINE-CARBOXAMIDE AND TRIAZOLOPYRIMIDINE-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2915198B1 (en) 2007-04-18 2009-12-18 Sanofi Aventis TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIDINE -CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
FR2915197B1 (en) 2007-04-18 2009-06-12 Sanofi Aventis Sa TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF.
WO2009117444A1 (en) 2008-03-17 2009-09-24 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
EP2283126A1 (en) 2008-04-25 2011-02-16 Janssen Pharmaceutica, N.V. Crystal structure of monoacylglycerol lipase (mgll)
EP2421848A1 (en) 2009-04-22 2012-02-29 Janssen Pharmaceutica N.V. Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2010124121A1 (en) 2009-04-22 2010-10-28 Jansen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119810A1 (en) * 2000-03-03 2003-06-26 Daniel Achard Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
WO2003020314A1 (en) * 2001-08-29 2003-03-13 Aventis Pharma S.A. Compositions for the treatment of parkinson's disease containing a cb1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain
WO2008025736A1 (en) * 2006-08-26 2008-03-06 Abbott Gmbh & Co. Kg Substituted benzimidazolone derivatives, medicaments comprising them and their use
EP2180048A1 (en) * 2008-10-09 2010-04-28 Janssen Pharmaceutica, N.V. Alternative crystal form of monoacylglycerol lipase (MGLL)

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs", 1985, ELSEVIER
BENITO ET AL., BRIT J PHARMACOL, vol. 153, 2008, pages 277 - 285
BEN-SHABAT ET AL., EUR J PHARMACOL, vol. 353, 1998, pages 23 - 31
CAVUOTO ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 364, 2007, pages 105 - 110
CB1 MATSUDA ET AL., NATURE, vol. 346, 1990, pages 561 - 4
CB2 MUNRO ET AL., NATURE, vol. 365, 1993, pages 61 - 5
COMELLI ET AL., BRIT J PHARMACOL, vol. 152, 2007, pages 787 - 794
CRAVATT ET AL., J NEUROBIOL, vol. 61, 2004, pages 149 - 60
DEVANE ET AL., SCIENCE, vol. 258, 1992, pages 1946 - 9
DI MARZO ET AL., CURR OPIN LIPIDOL, vol. 18, 2007, pages 129 - 140
DI MARZO ET AL., CURR PHARM DES, vol. 6, 2000, pages 1361 - 80
DOGRUL ET AL., PAIN, vol. 100, 2002, pages 203 - 9
GUINDON ET AL., BRIT J PHARMACOL, vol. 153, 2008, pages 319 - 334
HAJRASOULIHA ET AL., EURJ PHARMACOL, vol. 579, 2008, pages 246 - 252
J.F.W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS
JHAVERI ET AL., BRIT J PHARMACOL, vol. 152, 2007, pages 624 - 632
KATHURIA ET AL., NAT MED, vol. 9, 2003, pages 76 - 81
LICHTMAN ET AL., JPHARMACOL EXP THER, vol. 302, 2002, pages 73 - 9
LICHTMAN ET AL., PAIN, vol. 109, 2004, pages 319 - 27
MATULIS, D., KRANZ, J. K., SALEMME, F. R., TODD, M. J., BIOCHEMISTRY, vol. 44, 2005, pages 5258 - 66
MCCARBERG BILL ET AL., AMER J THER, vol. 14, 2007, pages 475 - 83
MECHOULAM ET AL., BIOCHEM PHARMACOL, vol. 50, 1995, pages 83 - 90
NJIE, YA FATOU, HE, FANG, QIAO, ZHUANHONG, SONG, ZHAO-HUI, EXP. EYE RES., vol. 87, no. 2, 2008, pages 106 - 14
PACHER ET AL., AMER JPHYSIOL, vol. 294, 2008, pages H1133 - H1134
PANTOLIANO, M. W., PETRELLA, E. C., KWASNOSKI, J. D., LOBANOV, V. S., MYSLIK, J., GRAF, E., CARVER, T., ASEL, E., SPRINGER, B. A.,, J BIOMOL SCREEN, vol. 6, 2001, pages 429 - 40
PERTWEE, BRIT J PHARMACOL, vol. 153, 2008, pages 199 - 215
PIOMELLI, NAT REV NEUROSCI, vol. 4, 2003, pages 873 - 884
SUGIURA ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 215, 1995, pages 89 - 97
T.W. GREENE, P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
T.W. GREENE, P.G.M. WUTS: "Protective Groups in Organic Synthesis", 1999, JOHN WILEY & SONS
WALKER ET AL., PROC NATL ACAD SCI USA, vol. 96, 1999, pages 12198 - 203

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9440948B2 (en) 2010-09-03 2016-09-13 University Of Florida Research Foundation, Inc. Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
WO2020007902A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
WO2020007905A1 (en) 2018-07-05 2020-01-09 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
US11884643B2 (en) 2018-07-05 2024-01-30 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
US11952359B2 (en) 2018-07-05 2024-04-09 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
WO2020097389A1 (en) * 2018-11-09 2020-05-14 Vivace Therapeutics, Inc. Bicyclic compounds
CN113302175A (en) * 2018-11-09 2021-08-24 维瓦斯治疗公司 Bicyclic compounds
US11866431B2 (en) 2018-11-09 2024-01-09 Vivace Therapeutics, Inc. Bicyclic compounds
WO2020179859A1 (en) 2019-03-06 2020-09-10 第一三共株式会社 Pyrrolopyrazole derivative
US11420935B2 (en) 2019-04-16 2022-08-23 Vivace Therapeutics, Inc. Bicyclic compounds
WO2021123051A1 (en) 2019-12-20 2021-06-24 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof

Also Published As

Publication number Publication date
TW201305137A (en) 2013-02-01
IL225815A0 (en) 2013-06-27
RU2013123274A (en) 2014-11-27
CN103261189A (en) 2013-08-21
JP2013540160A (en) 2013-10-31
BR112013009828A2 (en) 2016-07-26
WO2012054721A8 (en) 2013-05-16
AR083543A1 (en) 2013-03-06
CA2815353A1 (en) 2012-04-26
KR20130140020A (en) 2013-12-23
US20120101081A1 (en) 2012-04-26
CN103261189B (en) 2015-01-28
US20130196970A1 (en) 2013-08-01
US8575363B2 (en) 2013-11-05
EP2630139A1 (en) 2013-08-28
AU2011316975A1 (en) 2013-05-23
US8748417B2 (en) 2014-06-10

Similar Documents

Publication Publication Date Title
US8748417B2 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
EP2611774B1 (en) Di-azetidinyl diamide as monoacylglycerol lipase inhibitors
AU2011307252B2 (en) Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors
KR101705049B1 (en) Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2012054716A1 (en) Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
US8513423B2 (en) Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11778748

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 225815

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2815353

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013535087

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011778748

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137012916

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013123274

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2011316975

Country of ref document: AU

Date of ref document: 20111020

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013009828

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013009828

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130422